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Summary 
Essential or primary hypertension is a complex polygenic disease with genetic 
heritability averaging approximately 30% and with strong influence of 
environmental factors and gene-environment interaction. Heterogeneity in the 
general population and the polygenic complexities of the disease has meant that 
identification and functional validation of candidate genes has proved extremely 
difficult in humans. Several strategies have been developed to dissect genetic 
determinants of hypertension, one of which is the use of rodent models (1;2). 
Animal models of heritable hypertension offer more favourable investigative 
opportunities because of reduced genetic heterogeneity, the capacity for 
controlled breeding and environmental conditions, and the ability to produce 
genetic crosses and analyse large numbers of progeny. The stroke-prone 
spontaneously hypertensive rat (SHRSP) is a commonly used model of human 
essential hypertension. Previous studies conducted in our laboratory utilizing a 
combination of congenic strain construction and genome-wide microarray 
expression profiling in the SHRSP have allowed us to identify the positional 
candidate gene, glutathione S-transferase µ-type 1 (Gstm1), which is involved in 
the defence against oxidative stress and is significantly down-regulated in the 
SHRSP (3;4). Genomic DNA sequencing of Gstm1 in SHRSP and WKY identified 13 
single nucleotide polymorphisms (SNPs), an insertion and a deletion (5). 
Luciferase reporter gene assays implicated five SNPs to be responsible for 
significant reduction in luciferase activity measurements (6). In consideration of 
these previous studies, it is hypothesized that Gstm1 deficiency in the SHRSP 
plays a causative role in the development of oxidative stress and hypertension. 
To establish definitive proof that reduced Gstm1 expression affects blood 
pressure regulation and oxidative stress, two independent transgenic lines 
(referred to as Trans1 and Trans2) of SHRSP were created with the aim of 
rescuing Gstm1 deficiency by incorporation of a normal Gstm1 gene into the 
SHRSP genome. Generation of these transgenic SHRSP rats involved 
microinjection with a 2.7 kb linear construct encoding wild type (WKY) Gstm1 
under the control of the universal EF-1α promoter. They were generated using 
the same expression platform and microinjection fragment purification protocol 
employed in the successful production of the CD-36 transgenic, rat as previously 
described (7). The transgenic protocol was carried out in collaboration with Dr 
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Michal Pravenec (Prague), who is an expert in transgenic rat production, using 
male and female SHRSP rats from the University of Glasgow colony.  
Oxidative stress is an important pathogenic factor in the development of 
cardiovascular disease. Glutathione S-transferases protect against oxidative 
stress-induced injury through the detoxification of reactive oxygen species. It is 
hypothesised that Gstm1 deficiency in the SHRSP plays a causative role in the 
development of oxidative stress and hypertension. Thus the aims of this study 
were to establish definitive proof that reduced Gstm1 expression in the SHRSP 
plays a causative role in the development of hypertension and oxidative stress 
through utilizing a combinational approach of in vivo and ex vivo studies 
alongside molecular analysis to fully characterize the Gstm1 transgenic SHRSP 
rat. Additionally, information and insights gained from this investigation from the 
Gstm1 transgenic SHRSP will be applied to a translation aspect for the 
investigation of GSTM family in humans.  
Functional validation through hemodynamic and cardiac analysis included 
measurement of systolic, diastolic and mean arterial blood pressures, pulse 
pressure and heart rate using the Dataquest IV telemetry system (Data Sciences 
International) and transthoracic echocardiography was used to assess cardiac 
geometry and contractility. Telemetry data show that there is a significant 
reduction in systolic blood pressure, diastolic blood pressures, and pulse pressure 
in both of the transgenic lines when compared to the SHRSP suggesting that 
incorporation of a WKY type Gstm1 gene into the SHRSP genome does indeed 
reduce the hypertensive phenotype. Moreover, the observed reduction in systolic 
blood pressure is remarkably similar in magnitude to that demonstrated in the 
Chromosome 2 congenic strain, SP.WKYGla2c*, in which Gstm1 was identified as 
a candidate gene for hypertension. In order to investigate the potential role of 
Gstm1 deficiency in the salt-sensitivity phenotype in SHRSP rats, parental strain 
rats and Trans1 animals underwent 1% salt loading starting at 18 weeks of age. 
This resulted in Trans1 displaying a trend towards salt-sensitivity (i.e. 
exaggerated night-time daytime blood pressure variation) similar to that of the 
SHRSP, however, the Trans1 line still maintained a significant decrease in systolic 
and diastolic blood pressure compared to the SHRSP during salt loading.  
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In parallel with the significantly lower SBP, DBP and PP we also observe 
significantly improved cardiac function and reduced cardiac hypertrophy in the 
two independently generated transgenic lines. While there was no significant 
changes in both fractional shortening (FS) and ejection fraction (EF), between 
the four strains, relative wall thickness was significantly reduced in WKY, Trans1, 
and Trans2 rats when compared to the SHRSP with Trans1 and Trans2 rats 
showing an intermediate phenotype between the parental strains. 
Analysis of genetic and molecular changes resulting from the random insertion of 
Gstm1 into the SHRSP genome included assessment of transgene (WKY form) and 
total Gstm1 gene expression, protein quantification, immunohistochemistry 
(IHC), transgene insertion and copy number. Both transgenic lines demonstrated 
an increase in total and transgene specific expression of Gstm1 in kidneys at 5 
weeks of age as well as increased transgene expression in several other 
cardiovascular tissues. Protein expression was also similarly increased in the 
kidney at 5 weeks of age and showed a similar expression pattern to that of the 
WKY. Additionally, we saw increased total Gstm1 expression in a range of 
cardiovascular tissues at 21 weeks of age without changes of other Gstm family 
members (Gstm2 and Gstm3). Although it was not possible to identify the exact 
location of the transgene insertion site in both transgenic lines, data presented 
indicate that they are not identically inserted. Furthermore, sequencing data 
shows that each transgenic line contains multiple copies of the transgene across 
a number of generations. 
To assess renal function in the Gstm1 transgenic lines, rats from each line that 
were implanted with telemetry probes were assessed by 24-hr metabolic cage 
measurements which allowed for analysis of indirect glomerular filtration rate 
along with proteinuria and urinary electrolyte measurements. Histological 
analysis was used to assess renal morphology by examining haematoxylin and 
eosin (H&E) stained sections. Fibrosis was examined by staining with picrosirius 
red. At 21 weeks, we saw evidence of reduced renal pathology as indicated by 
the absence of renal vessel hyperplasia and reduced proteinuria in the WKY, 
Trans1, and Trans2 rats. H&E staining showed a more similar morphology to the 
WKY in the transgenic lines with no signs of accelerated hypertension. These 
improvements in renal pathology were also apparent in salt-loaded Trans1 rats.  
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Oxidative stress and myography measurements were also carried out in order to 
ascertain the impact of increased Gstm1 expression on the SHRSP genetic 
background. The data presented in this study clearly shows a reduction in renal 
oxidative stress in both transgenic lines. Furthermore, these improvements in 
oxidative stress were also apparent in salt-loaded Trans1 rats. Aortic and 
mesenteric artery wire myography data showed that there was no significant 
difference between SHRSP and transgenic lines for vascular function. Pressure 
myography in the mesenteric arteries, demonstrated that the transgenic lines 
were only significantly different from the SHRSP in terms of increased vessel 
cross sectional area (CSA), but did show trends of improved structure and 
mechanical alterations of these vessels.      
Additionally, we investigated the rodent GSTM family and applied them to a 
human cohort in order to assess translational aspects and expanded the study 
previously conducted by Delles et al. (8). The investigation included a larger 
number of subjects than that studied previously by Delles et al. and allowed for 
the elucidation of the relationship between other members of the GSTM family 
and human essential hypertension. While there was no significant difference in 
renal expression in GSTM5, GSTM3, GPx-1 and GPx-3 between normotensive and 
hypertensive patient, we found that GSTM2 expression was significantly 
increased in hypertensive patients when compared to normotensive patients. 
Moreover, we found there to be a borderline significance (p=0.054) between the 
rs11802 SNP genotype and GSTM5 expression. Further investigation between gene 
expression correlations showed there was a significant linear correlation 
between GSTM5 and GPx-1.  
In summary, multiple phenotypic and molecular techniques were applied in the 
analysis of the GSTM1 transgenic SHRSP. Transgenic SHRSP rats expressing the 
WKY form of the GSTM1 gene demonstrate significantly reduced blood pressure, 
oxidative stress and improved levels of renal GSTM1 expression. This data 
supports the hypothesis that significantly reduced renal GSTM1 plays a causative 
role in the development of hypertension in the SHRSP rat. 
  
 
 
 
 
 
 
 
 
1 Introduction 
  
 1.1 Cardiovascular Disease 
Approximately one third of adults in westernized countries have at least one 
form of cardiovascular disease (CVD) (9) and a substantial proportion (60%) of 
these adults are under 60 years old (9;10). This shift in demographics from the 
traditional 65+ years of age to that of 44+ years of age is a significant increase in 
premature CVD diagnosis. The early onset of CVD has been estimated to kill an 
average of 17.3 million people each year which represents 30% of all global 
deaths (11). Of these deaths an estimate 7.3 million were due to coronary heart 
disease and 6.2 million were due to stroke (10). By 2030 it is expected that 23.6 
million deaths will be caused by CVD (10). Consequentially, these statistics result 
in CVD being considered as the single largest risk for mortality in industrialized 
and more specifically in developing countries (12). The percentage of premature 
deaths from CVDs ranges from 4% in high-income countries to 42% in low-income 
countries (10). A major factor that contributes to this mortality rate is high blood 
pressure, or hypertension, which accounts for nearly two-thirds of all strokes and 
a half of all ischemic heart disease (13). The most recent estimate indicates that 
globally 7.6 million premature deaths (13.5% of total global mortality) and 92 
million disability-adjusted life years (6.0% of the global total) were attributable 
to high blood pressure (1). In addition to this, high blood pressure is a major risk 
for dementia, chronic kidney disease and heart failure (2;14). These statistics 
are similar in the UK where over 150,000 people died from cardiovascular disease 
in 2008, 300,000 people are living with moderate to severe disability as a result 
of stroke, and 10% of the population have significant kidney impairment. In 2006, 
the resulting health care cost of these diseases added up to approximately 14 
billion, of which 80.4% was spent on patient care and 19.6% spent on medication 
(15). Moreover, total economic costs for of CVD reached 30.6 billion in 2006 (15). 
For these reasons, the pressing need for increased awareness and for a 
comprehensive, more focused international research basis is needed to fully 
understand the complications and genetic aspects related to CVD.   
Cardiovascular disease is an umbrella classification of disease that includes all 
heart and circulation disorders. These classifications encompass ailments that 
directly affect the heart (i.e. arrhythmias, cardiomyopathies and congenital 
heart disease), from conditions that arise as a consequence of vascular disease 
(i.e. coronary heart disease, stroke, transient ischemic attack), as well as 
 conditions that can lead to, or result from, vascular disease including diabetes 
and chronic kidney disease (15), There are nine main risk factors for CVD, many 
of which are linked to each other. The major modifiable risk factors are; 
smoking, poor diet, high blood cholesterol, high blood pressure, lack of exercise, 
obesity, and diabetes (9). Other minor risk factors include medication, excess 
alcohol consumption, and psychosomatic stress.  Additionally, there are non-
modifiable risk factors that include ageing, family history, gender and ethnicity 
(9). Unfortunately, all or most of these risk factors affect health in Scotland, 
with hypertension being most prevalent, which illustrates a need for further 
research in CVD (16).    
1.2 Blood Pressure 
Blood pressure is considered one of the principal vital signs and is measured as 
the arterial pressure exerted by the systemic circulation of blood upon the walls 
of vessels. It is determined primarily by three factors: renal sodium excretion 
and resultant blood volume, cardiac performance, and vascular tone (17). With 
each beat of the heart blood pressure varies between maximum (systolic) and 
minimum (diastolic) pressure. Systolic blood pressure is the pressure that is 
exerted when the ventricles of the heart are contracting (beating); while 
diastolic blood pressure is the relaxed blood pressure where the heart refills with 
blood. Classification of blood pressure as adopted by the American Heart 
Association is generally, Hypotension, Desired, Pre-hypertensive, Stage 1 
Hypertension, Stage 2 Hypertension and Hypertensive Crisis (Table 1.1). In the 
UK blood pressure is usually categorized in to three groups; low, high and 
normal. While there are varying categories of blood pressure classifications, most 
authorities have defined elevated blood pressure (hypertension) as either a 
systolic blood pressure ≥ 140 mmHg or a diastolic blood pressure ≥ 90 mmHg. The 
hypertension cut off of 140/90 mmHg was selected in the early 20th century 
based on the fact that only 5−10% of the US population had blood pressures in 
that range (18).  
 
 
 
 
 Table 1-1: Classification of Hypertension 
    
Blood Pressure (BP) Category  
  
Systolic BP (mmHg) 
  
Diastolic BP (mmHg) 
Normal <120  <80 
High Normal  135-139  85-59 
Mild Hypertension (Grade 1)  140-159  90-99 
Moderate Hypertension (Grade 
2)  160-179  100-109 
Severe Hypertension (Grade 3)   ≥180   ≥110 
Values taken from (19) 
Both systolic and diastolic blood pressures increases progressively with age. 
While diastolic blood pressure is understood to continue increasing until 
approximately 50 years of age, systolic blood pressure has been known to 
increase with age until approximately 80 years old. Mean systolic blood pressure 
increases with age in both men and women, rising from 127 mmHg in men aged 
16-24 to 145 mmHg in men aged 75 and over, and from 119 mmHg to 149 mmHg 
in women (10). Adolescent blood pressure (15-19 yrs old) generally averages 
117/77 mmHg. According to the Scottish Health Survey, 33% of Scottish men and 
33% of Scottish women are hypertensive or are treated for hypertension (20).  
Epidemiological studies have documented multiple contributing factors, such as 
age, gender, body mass index, to the onset of essential hypertension (21). 
However, the specific underlying mechanisms involved in the development of 
hypertension are still not completely understood. A wide variety of physiological 
systems that have pleiotropic effects and interact in a complex manner have 
been found to influence BP (Figure 1.1). Sodium and fluid balance, and 
vasomotor tone are important in BP regulation. Both of these mechanisms are 
affected by numerous genetic and environmental factors, controlled by 
hormonal, non-sympathetic, paracrine and intracellular feedback loops.  
1.2.1 Blood Pressure Control and Regulation 
Blood pressure homeostasis is one of the most important and finely regulated 
systems of the body. Through this system, the body relies on the delivery of 
oxygen, nutrients and hormones at specific times and precise concentrations and 
to ensure the removal of metabolic waste products such as carbon dioxide. Many 
physiological mechanisms exist to ensure that both acute and long-term local and 
global blood flow is maintained at an appropriate level to supply individual 
organs in response to metabolic demands. Blood pressure, or mean arterial 
 pressure, is regulated through a complex physiological system involving the 
endocrine and nervous systems, in addition to the kidney heart and blood 
vessels. The definition of blood pressure is the rate of blood flow produced by 
the heart (cardiac output) multiplied by the resistance of the blood vessels to 
blood flow (vascular resistance). The resistance is produced mainly in the 
arterioles and is known as systemic (or peripheral) vascular resistance.  
There are various homeostatic mechanisms involved in blood pressure control 
that interact with one another in order to maintain appropriate feedback 
responses to environmental factors such as diet, exercise and stress that impact 
on blood pressure level. Both the nervous system and the renin angiotensin-
aldosterone system (RAAS) are intimately involved in regulating these parameters 
(22). The main organ involved in long-term regulation of blood pressure is the 
kidney, as it regulates blood volume by controlling salt and water levels within 
the body. Studies conducted by Guyton et al. showed that whenever blood 
pressure increases above an equilibrium level, the kidneys will excrete more 
sodium and water and thus decreases blood volume and cardiac output which 
then restores arterial pressure to normal (17). Bianchi et al. in 1974 then 
confirmed the importance of the role that the kidney plays in blood pressure 
regulation during his experiments where renal transplants between hypertensive 
and normotensive rats demonstrated a reduction of BP in hypertensive rats 
receiving normotensive kidneys and an increase in BP with normotensive rats 
receiving hypertensive kidneys, concluding that hypertension travels with the 
kidney (23).  
1.2.1.1 Renin Angiotensin System  
 Arterial pressure is regulated by a variety of endogenous factors, in particular 
the Renin-Angiotensin System (RAS) system (24). The renin-angiotensin system, is 
known as a physiological regulator and has been the subject of study for over a 
century (new insights RAS). The RAS is a hormonal cascade where the protein 
substrate angiotensinogen is successively metabolized by renin and angiotensin 
converting enzyme (ACE) to form  
  
 Figure 1-1: The complexity of BP regulation and the role of the kidneys and RAAS 
Angiotensinogen is released from the liver and cleaved by renin (released from 
the glanular cells of the juxtaglomerular complex) forming AngI. AngI is cleaved 
by ACE expressed on endothelial cells in the lung and is transformed into AngII. 
AngII is the main active peptide of the RAS and acts through binding to the AT1R 
or the AT2R. AngiotensinII stimulates the hypertrophy of renal tubule cells, 
leading to further sodium reabsorption. In the adrenal cortex, it acts to cause 
the release of aldosteron. Aldosterone acts on the tubules (e.g., the distal 
convoluted tubules and the cortical collecting ducts) in the kidneys, causing them 
to reabsorb more sodium and water from the urine. This increases blood volume 
and, therefore, increases blood pressure. In exchange for the reabsorbing of 
sodium to blood, potassium is secreted into the tubules, becomes part of urine 
and is excreted. Figure adapted from Schrier RW, ed. Renal and Electrolyte 
Disorders 5th ed. 1997. 
 
 
 
  
 
angiotensin (Ang) II, its major biologically-active peptide (24). Ang II interacts 
with multiple different vascular beds and organ systems that ultimately lead to 
elevated extra-cellular fluid (EFC) volume and thus resulting in raised arterial 
blood pressure (17). Ang II also causes vasoconstriction of the renal and systemic 
arterioles, which then increases total peripheral resistance and blood pressure. 
Furthermore, activation of Ang II receptors in the brain elevates blood pressure 
by increasing sympathetic output to the heart and vasculature, which increases 
cardiac output and total peripheral resistance. Ang II causes increase release of 
arginine vasopressin from the posterior pituitary gland which increases fluid 
retention in the renal collection duct in the kidneys (25). Additionally, Ang II 
stimulates thirst and the increased fluid ingestion expands blood volume thus 
elevating blood pressure through aldosterone secretion. Plasma Ang II increases 
aldosterone release from the adrenal gland and acts directily on the tubular 
receptors, which increases sodium chloride and fluid re-absorption in the distal 
nephron to increase ECF volume (26). Moreover, it stimulates sympathetic 
nervous activity which causes increased heart rate and blood vessel constriction 
(27).  
The classical actions of RAS, particularly its cardiovascular effects, are induced 
by activation of the angiotensin II type 1 (AT1) receptor. The efficacy of specific 
AT1 blockers (ARBs) in treating hypertension and reducing cardiovascular risk 
reflects the important role of this receptor in a variety of disorders (28). 
Similarly, targeted deletion of the major murine AT1 (AT1A) receptor cause a 
marked reduction of blood pressure and salt sensitivity in mice, confirming its 
importance in cardiovascular control (28). 
1.2.1.2 Other Mechanisms of Blood Pressure Regulation 
1.2.1.2.1 Autonomic Nervous Control 
In addition to the RAAS system, there are many other factors involved in blood 
pressure control. The most rapid in responding to the fall or rise in blood 
pressure is the autonomic nervous system as it receives information from the 
baroreceptors which relays to the vasomotor centre. The activation of the 
 baroreceptors in turn activates the sympathetic and parasympathetic nervous 
systems (29).  
The role of the arterial baroreflex is to maintain blood pressure homeostasis. 
This reflex mechanism counteracts deviations of blood pressure from a reference 
set point by modulating heart rate, peripheral vascular tone and other 
cardiovascular variables through autonomic paths. Blood pressure information is 
sensed by stretch receptors (baro receptors) located on the wall of the carotid 
arteries and aorta. When a change in blood pressure occurs, a modification in the 
dilation of arterial walls is sensed by these receptors and information is sent to 
control centers located in the brain stem through afferent neural fibres.  These 
centres process the baroreceptor inputs and modulate autonomic outflow so as 
to produce changes in the cardiovascular variables, i.e. heart rate, and 
vasoconstriction. Since the primary role of the baro-receptor is blood pressure 
regulation, an impairment of the baro-reflex will likely result in a significant 
deregulation of blood pressure. This is inclusive of sudden pressure drops on 
shifting positions as well as aberrant pressure rises with major risks of fatal 
events such as myocardial infarction and stroke. 
The sympathetic arm of the autonomic nervous system acts to stimulate the 
heart, constrict blood vessels, and stimulate the adrenal gland. Stimulation of 
the adrenal glands from increased impulses of the sympathetic system results in 
a release of norepeniphrine and epinephrine that increases heart rate and 
contractility. The parasympathetic system acts to depress cardiac function and 
dilatation of selected vascular beds.  
1.2.1.2.2 Endothelin  
ET has been shown to affect almost every blood pressure regulating system 
associated with sodium homeostasis (ET). The two primary receptors responsible 
for this are ETA and ETB. In general, activation of ETB reduces blood pressure and 
promotes urinary Na secretion through multiple cascades such as endothelial cell 
NO production with resultant vasodilation, inhibition of NA transport to the 
proximal tubule, reduced water re-absorption, and inhibition of renin release. 
 1.2.1.3 Hypertension  
Raised blood pressure or hypertension is estimated to cause approximately 7.5 
million deaths, ~12.8% of all annual deaths (30). According to the Global Health 
Risks Report by the World Health Organization, arterial hypertension remains the 
leading cause of morbidity and mortality world-wide (30). Hypertension is a 
considered a major risk factor for coronary heart disease and cerebrovascular 
disease (31). Blood pressure levels have been shown to be positively and 
progressively related to the risk of stroke and coronary heart disease. In some 
age groups, the risk of CVD doubles for each incremental increase of 20/10 
mmHg of blood pressure. In addition to coronary heart disease and 
cerebrovascular disease, uncontrolled blood pressure causes heart failure, renal 
impairment, peripheral vascular disease and damage to retinal blood vessels and 
visual impairment (31). Moreover, studies have shown that by achieving the 
target blood pressure of 140 mmHg there would be a 28-44% reduction in 
ischaemic heart disease, depending on the age (32).   
Hypertension is a multifactorial disorder that is most likely a result from the 
combination of various environmental determinants and genetic inheritance, and 
can be classified as either essential (primary) or secondary (33;34). Essential 
hypertension is described as a rise in blood pressure where there is no evident 
medical cause, and is the most prevalent type of hypertension that affects 90-
95% of hypertensive patients(33;34). Although no direct cause has been 
identified, there are many factors such as sedentary lifestyle (35), stress, 
hypokalemia (36), salt sensitivity (37), and obesity (38) with more than 85% of 
cases occur in those with a body mass index greater than 25 (39) that increase 
the risk of hypertension. Additionally, the risk of high blood pressure can also 
increase with age (40), by inherited genetic mutation, and/or family history (41). 
Existing evidence suggests that the genetic contribution for blood pressure 
variation in essential hypertension is about 30–50% (42). Secondary hypertension 
indicates that the increase in blood pressure is a result of (i.e. secondary to) 
another condition, such as renovascular hypertension caused by renal arterial 
stenosis as a result of hormonal changes, chronic renal failure, hyperthyroidism, 
neorogenic disorders that cause increased expression of adrenaline, or tumours 
(33;34).  
 1.2.1.4 Environmental Influences 
Hypertension is a disease of modern civilization and is greatly influenced by 
environmental factors and lifestyle choices. Blood pressure studies carried out on 
a population wide basis have shown that hypertension rates can differ greatly 
among population groups of similar genetic background due to environmental 
differences. For instance, the prevalence of hypertension differs between non 
westernized and westernized populations such as African and African-Americans 
(43;44). Furthermore, these rates can quickly increase within the same ethnic 
groups and when populations migrate from low to high-risk environment (I.e. 
dietary or exercise changes) (43;44). To contextualize environmental influences, 
mean placebo-subtracted SBP reduction for drug monotherapy is in the range of 
6.9–9.3 mmHg for four of the most common BP drug classes (45). Estimated SBP 
reductions for some of the major lifestyle modifications are in or near this range 
(46).  Major components such as smoking/tobacco use, obesity, poor diet, 
physical inactivity, and heavy alcohol consumption, as well as many of the minor 
components such as pollutants, have been extensively investigated in order to 
determine the cardiovascular risk level they present in today society (46).  
Risk factors such as alcohol and smoking are some of the more easily managed 
risk factors. Alcohol is considered a threshold risk factor where low to moderate 
alcohol consumptions results in only a low cardiovascular risk level, but high 
alcohol consumption, like that which is culturally present in the west of 
Scotland, results in a high CVD risk level (47). Consequently, reduction to 
moderate or complete alcoholic abstinence significantly reduces hypertension 
(15). Smoking, on the other hand, is considered one of the main avoidable risk 
factors contributing to hypertension and CVD. The immediate noxious effects of 
smoking are related to over-activity of the sympathetic nervous system, which 
increases myocardial oxygen consumption through a rise in blood pressure, heart 
rate and myocardial contractility (48). Chronic cigarette smoking induces arterial 
stiffness, a well know contributor to CVD, which can persist for up to a decade 
after smoking cessation. Additionally, the incidence of hypertension is increased 
with those who smoke more the 15 cigarettes per day (48).  
Another medical complication that is associated with hypertension that is heavily 
prevalent in today’s society is obesity. It is well known that there is an increase 
 of 3 mmHg (for systolic) and 2 mmHg (for diastolic) in blood pressure 
respectively, with every 10 kg increase in body weight (49). Studies have also 
shown that cerebrovascular disease, ischemic heart disease and congestive heart 
disease are also cardiovascular complications of obesity (49).   
Abundance or lack of vitamins and minerals, such sodium, and potassium, due to 
diet choices has also been shown to play a role in blood pressure regulation. 
Increased sodium consumption through processed foods has been shown to 
increase water retention. Conversely, too little potassium intake effects cell 
sodium levels which effects systemic sodium levels resulting in water retention 
and elevated blood pressure (50).    
Traditionally, studies investigating the correlation between hypertension and the 
environment have been based upon lifestyle choices such as diet, smoking and/or 
exercise. However, recent studies have elucidated that environmental exposure 
to pollutants and other harmful chemical also contribute to CVD risk (51;52).  
1.2.1.5 Genetic Influences 
Cardiovascular disease is a result of a complex interaction between genes and 
environment. In the past half century, impressive progress has been made in 
understanding its varied causes and manifestations (53); however, complete 
understanding of the initiating factors of essential hypertension are still elusive. 
Essential hypertension has been shown to run in families and evidence for 
genetic influence comes from multiple sources. Twin studies document a greater 
concordance of blood pressures in both maternal and fraternal twins (54), and 
population studies show a greater similarity of blood pressures within families 
than between families (55). Adoption studies confirm the latter observation 
because they demonstrate greater concordance of blood pressure among 
biological siblings than adoptive siblings living in the same household (56). 
Moreover, Lifton et al. demonstrates that single genes can impart large variance 
of blood pressure is demonstrated by rare the rare Mendelian forms of of hyper-
and hypo-tension (57).  
The investigation of rare forms of Mendelian forms of blood pressure variation 
where mutations in single genes produce large effects of blood pressure has 
 resulted in several genes being identified and characterized (58). The 
pathological variants in Mendelian or monogenic hypertension are known to 
follow the classic rules of Mendelian genetics and are often distinguishable 
specific genotype features (i.e. electrolyte and hormonal abnormalities) (59). 
Monogenic investigations have lead to the identification of mutations in 12 genes 
that lead to 8 different distinguishable Mendelian syndromes of hypertension and 
9 genes associated with Mendelian forms of hypotension. Furthermore, 8 of these 
genes in are associated with the alteration of salt re-absorption in the kidney 
(58;60). However the overall contribution of these conditions to blood pressure 
regulation in the general population is small.  
What is known as the candidate gene approach typically compares the 
prevalence of hypertension or the level of blood pressure among individuals of 
contrasting genotypes at candidate gene/loci in pathways known to be involved 
in blood pressure regulation. An example of this relates to genes of the renin–
angiotensin–aldosterone system, such as the M235T variant in the 
angiotensinogen gene (61). The M235T gene has been associated with increased 
circulating angiotensinogen levels and blood pressure in many distinct 
populations (61-63). A second example involves a common variant in the 
angiotensin-converting enzyme (ACE) gene that has been associated in some 
studies with blood pressure variation in men (64;65). However, most 
monogenetic variants only modestly affect blood pressure, and other candidate 
genes have not shown consistent and reproducible associations with blood 
pressure or hypertension in larger populations (58;66). Generally, monogenetic 
variants mutations account for only a small percentage of hypertension. A 
primary reason for this lies in the fact that numerous interacting genetic loci can 
influence the same phenotype, and studies have shown that multiple loci are 
involved in overall blood pressure variation (33).  
Large-scale meta-analyses of genome-wide association studies (GWAS) from the 
Global Blood Pressure Genetics (Global BPgen) and Cohorts for Heart and Aging 
Research in Genome Epidemiology (CHARGE) consortia identified a total of 43 
independent loci significantly associated with systolic blood pressure, diastolic 
blood pressure and hypertension (59;67;68). These genetic variations include 
single nucleotide polymorphisms (SNPs), variable number tandem repeats 
(VNTR), insertions, deletions and duplications. Many of these variants were found 
 to alter various systems, such as the renin-angiotensin system, renal sodium 
handling system, cholesterol metabolism pathways, inflammation, and oxidative 
stress (33). 
While identifying and understanding monogenic and polygenic forms of 
hypertension improve our comprehension of the genetic architecture of blood 
pressure and provide new biological insights in to blood pressure control, 
common genetic causes of hypertension in the general population remains 
elusive (63;69;70).  
 
1.2.1.6 Current prevention strategies 
Prevention of hypertension, although relatively unfashionable when compared to 
new drug and surgery related technologies, is the cheapest and simplest way to 
reduce the prevalence of hypertension.  Primordial prevention, which refers to a 
lifestyle that does not permit risk factor to appear, is used by the American 
Heart Association (AHA) to promote “ideal cardiovascular health” by 
incorporating Life’s simple 7 (www.mylifecheck.org). This ideal cardiovascular 
health incorporates sufficient exercise, a superior diet score, absence of 
smoking, a BMI less than 25 kg/m2, and ideal health factors, i.e. normal blood 
pressure, cholesterol, and fasting glucose. In addition to healthy life style 
choice, clinical prevention using drugs such as aspirin and statins are well known 
protectors of cardiovascular health. In general, primary prevention of both 
hypertension and cardiovascular events denotes delaying or limiting a first event 
in individuals who have not yet been formally diagnosed. This also includes 
individuals with risk factors where the risks themselves are often regarded as 
diseases and are targets for therapy.  
 
1.2.1.7 Current treatment strategies 
Considering that hypertension is a major public health concern and a primary 
cardiovascular risk that contributes significantly to cardiovascular mortality 
(71;72), its treatment is therefore important as a primary and secondary 
prevention strategy. Initial management of hypertension uses a multipronged 
approach, with emphasis lifestyle measures (non-pharmacological) and add-on 
 drug management (73). With recent studies providing increasing evidence that 
non-pharmacological therapies play important roles in both the prevention and 
reduction of hypertension, lifestyle medication can serve as an initial treatment 
to hypertension before the start of drug therapies (74). Furthermore, with 
hypertensive patients these therapies can facilitate a reduction of medication 
reliance for the hypertensive individual, provided that sustain in lifestyle 
change. Major lifestyle environmental factors which influence hypertension are 
dietary excess of sodium and fat Harp (75), a deficiency of fibre and potassium 
(76), lack of physical activity, psychosocial stress, and alcohol intake (77) 
Numerous short-term trials have documented that individuals can make these 
lifestyle changes which lower blood pressure (73). For example, the American 
Heart Association has originated the dietary approaches to stop hypertension 
program (DASH) as a crucial step to hypertension management. The DASH study 
showed that a diet full of fruits, vegetables and calcium while being low in 
sodium was beneficial to treating hypertension (77). The study also concludes 
that exercise is a critically important component, especially in children and 
young adults with hypertension from heightened sympathetic nervous system 
activity (77). 
When lifestyle changes need to be supplemented in order to obtain more ideal 
blood pressure levels, drug therapies are often prescribed. The main classes of 
blood-pressure-lowering drugs can be grouped into two categories. The first 
category consists of drugs that inhibit or block the renin-angiotensin-aldosterone 
system, namely angiotensin-converting enzyme (ACE) inhibitors and angiotensin 
receptor blockers, beta-blockers and aldosterone antagonists. The second 
category consists of drugs that lower blood pressure independently of the renin–
angiotensin system, and cause reflex activation of this system such as calcium 
antagonists and diuretics. Because of the variety of choice for drug mediated 
blood pressure reduction, deciding upon an initial drug management approach is 
a contentious issue. The JNC-1 report emphasized beta-blockers and thiazide 
diuretics as suitable drugs for first line management (74). On the other hand, 
recent studies that have evaluated newer drugs such as ACE inhibitors and CCB 
molecules report better outcomes as compared to the beta-blockers and 
thiazides. The British National Institute of Clinical Excellence (NICE) guidelines 
utilize ABCD algorithm for initial pharmacological management of hypertension 
 but has modified these to ACD algorithm in view of changing evidence (16). 
Current thinking is to start with an ACE inhibitor in young individuals and CCB in 
older individuals and step-up the drug therapy until blood pressure targets are 
reached (74). 
   
 
1.3 Animal Studies 
Given that hypertension is under polygenic control, and is due to a culmination 
of multiple gene-gene and gene-environment interactions, genetic studies 
involving genetic modification or dissection are not feasible in humans due to 
ethical implications. For this reason, an array of experimental models have been 
developed as a reductionist paradigm in order to study the determinants of 
essential hypertension (78). The most widely used experimental models are 
rodents models, specifically rats. Since rats have long been a favoured species 
for the study of hypertension, a variety of genetically hypertensive strains and 
non-genetic models have been developed and well characterized over the past 
35 years (79-82). The range of available models addresses both essential and 
secondary hypertension. Examples of non-genetic models include surgically 
induced hypertension (2 kidney 1 clip) where hypertension is induced by 
unilateral restriction of the renal artery, the deoxycorticosterone acetate 
(DOCA) –salt rat where hypertension is induced through the use of a 
mineralocoricoid, (DOCA), and diet-induced hypertension through increased salt 
intake (81). 
Genotype-driven genetic models, typically transgenic or knock-in/knock-out, 
have been extremely important in the study of Mendelian hypertension. 
Phenotypic-driven genetic models such as the spontaneously hypertensive rat 
(SHR) are used to identify underlying genes or mechanisms contributing to 
development of hypertension. Among these strains is the stroke-prone 
spontaneously hypertensive rat (SHRSP) (83;84) which is a model for essential 
hypertension, endothelial dysfunction and oxidative stress (79;80). The SHRSP 
develops a number of vascular complications, such as cardiac hypertrophy, 
cardiac failure and stroke (80;85;86). These animal models provide favourable 
investigative opportunities because of reduced genetic heterogeneity, controlled 
breeding, the ability to produce genetic crosses and analyse large numbers of 
 progeny (87). Although no species or model can consistently fulfil all the needs 
each study requires, it is important to work with the most appropriate model 
which most fully addresses the research question under investigation.   
1.3.1 SHRSP 
Spontaneously-hypertensive, stroke-prone rats are a unique genetic model of 
severe hypertension and cerebral stroke. They are of particular interest because 
their pathophysiology is very similar to that of stroke patients in the clinical 
setting (88). They were first developed in 1974 by Yamori et al. (89) as a 
substrain of the spontaneously hypertensive rat and were used as a genetic 
model for severe hypertension with alterations in their endocrine signaling 
systems (90). According to the National BioResource Project for the Rat 
database, the SHRSP is the strain showing the highest blood pressure among 179 
stains (91), indicating that the SHRSP has a distinct set of hypertension genes 
that make the SHRSP unique among the various rat strains. While there is likely 
to be significant overlap of disease related genes between the SHRSP and other 
hypertensive strains, the gene-gene interaction within the SHSRP is necessary for 
a full-blown effect on blood pressure. When compared with the SHR, the SHRSP 
has a high incidence of stroke (80 vs 10%) and severe hypertension (220-240 
mmHg vs 180-220 mmHg) (92). Furthermore, the incidence of stroke reaches 
100% in SHRSP rats with a high salt diet (89). The cerebral stroke observed in 
SHRSP rats is reported to be similar to brain oedema due to malignant 
hypertension or hyalinosis of small arteries due to severe hypertension rather 
than atherosclerosis based (91).   
1.3.1.1 Identifying QTL’s 
A major challenge in hypertension research is to identify the underlying 
causative factors responsible for the disease phenotype. One approach that has 
been used extensively is the genome wide scan and quantitative trait loci (QTL) 
mapping. QTL mapping is a phenotype driven approach that does not require a 
prior knowledge of either causative genes or their function, and can lead to the 
identification of novel genes involved in disease. QTL analysis involves at least 
two strains (generally rats or mice) that differ genetically with regard to the 
trait of interest and a genetic marker that distinguish between these parental 
 lines. Molecular markers, such as SNPs, simple sequence repeats (SSRs or 
microsatilites), restriction fragment lengths polymorphism (RFLPs) and 
transposable element positions are preferred because these markers are unlikely 
to affect the trait of interest (93).The parental strains are then crossed, 
resulting in heterozygous (F1) individuals. The F1 individuals are then crossed 
again using giving rise to F2 individuals where the phenotypes and genotypes are 
scored. Markers that are genetically linked to a QTL influencing the trait of 
interest will segregate more frequently with trait values whereas unlinked 
markers will not show a significant correlation.  
The principal goal of QTL analysis has been to answer the question of whether 
phenotypic differences are primarily due to a few loci with fairly large effects, 
or too many loci, each with small effects. It appears that a substantial 
proportion of the phenotypic variation in many quantitative traits can be 
explained with few loci of large effect, with the remainder due to numerous loci 
of small effect (94;95). Once QTL have been identified, molecular techniques 
can be employed to narrow the QTL down and to identify candidate genes. 
Indeed, the Rat Genome Database (http://rgd.mcw.edu/) has compiled more 
than 300 QTLs influencing rat blood pressure (91) with a considerable number of 
these QTLs being identified through experimental SHR/ SHRSP crosses with 
normotensive rat strains. Unfortunately, few causative genes have been 
identified thus far despite the large numbers of QTLs identified. This is primarily 
due to the fact that function analysis of candidate genes to confirm causality is 
extremely complex and requires a series of multiple investigations.   
1.3.1.1.1 QTL interaction in Complex diseases 
Genome-wide linkage studies performed on several rat crosses have been 
successful in identifying large chromosomal regions containing quantitative trait 
loci (QTLs) which are involved in blood pressure regulation (42;96). 
  
Figure 1-2:Geneological background of the Stroke Prone Spontaneously Hypertensive Rat 
(SHRSP) 
The SHRSP strain, maintained at Glasgow University (Gla), was obtained after filial 
generation 35-36. Personal communication & Ref. (89) 
 
  
   There have been numerous studies where the production of novel designer 
strains such as recombinant inbred strains or congenic strains, has allowed 
confirmation and genetic dissection of blood pressure QTLs (79;96-98).  
1.3.1.2 Recombinant inbred strains 
Recombinant inbred strains are derived from F2 individuals obtained by crossing 
of two highly inbred stains. Randomly chosen F2 pairs are brother-sister mated 
for more than 20 generations to become genetically fixed. Individual 
recombinant strains have unique combinations of loci derived by segregation and 
recombination of alleles present in the progenitor strains. An important feature 
of these strains is that because they are inbred, repeated assay can be carried 
out in order to precisely classify the phenotype of each strain from the average 
results obtained from the measurement of multiple rats from each strain.  This 
precise estimation of phenotype-genotype relationship is extremely important 
when studying highly variable traits such as blood pressure. Moreover, since data 
are cumulative across studies, accumulated data can be analyzed and trait 
relationships studied in a manner not possible with conventional, genetically 
segregated populations. This is a major advantage for the analysis of complex 
patho-physiological traits.    
1.3.1.3 Congenic Strains 
Congenic strains have been produced in order to confirm the existence of a QTL 
and to begin narrowing down the chromosomal region of interest for gene 
identification. A congenic strain is one in which the chromosomal region of 
interest has been selectively replaced by the homologous region from another 
stain. These strains are generated by mating two inbred strains and backcrossing 
the descendent to the original strains (known as the recipient strains) for at least 
5-10 generations. 
 Typically selection for the desired phenotype or genotype drives the strain’s 
generation. Through this either a desired phenotype, or a desired chromosomal 
region (assayed by genotype) is passed from the donor stain to the recipient 
strain. The congenic stain is then compared to a pure recipient strains to 
determine whether they are phenotypically different. If the quantitative trait of 
the congenic strain is significantly different from the former strain, it can be 
 concluded that a QTL that contributes to a phenotypic difference resides within 
this chromosome region. Upon completion of the congenic stain, brother-sister 
mating is ensures homozygosity for the congenic chromosome. Furthermore, 
construction of congenic sub-strains help to enable genetic dissection  
Since the early 1990’s, congenic stains have been an integral part in blood 
pressure and QTL–QTL interaction studies. However there are several limitations 
or difficulties that are involved when using congenic strains. Namely, that a 
single congenic strains does not necessarily resolve closely linked QTLs that act 
in the same direction, especially in the case of polygenic traits (99;100). 
Furthermore, there is also the chance that there is a lack of polymorphisms 
between the inbred strains used thus making it difficult to identify causative 
genes between the two strains (101;102). However, advances in technology mean 
that traditional genetic mapping techniques can now be complemented by high-
throughput methods, such as high-density arrays of synthetic oligonucleotides 
(103-105), cDNAs (106) for studying gene function and regulation, or identifying 
the genetic basis from an observed phenotype and deciphering the gene 
networks that contributed to increased susceptibility to metabolic disease 
processes in humans (68;107). Moreover these methods allow gene expression 
monitoring on a genome-wide scale and offer an opportunity to establish 
functional links between genotype and phenotype for complex diseases (68;108). 
Methods, such as microarray expression analysis have consistently been used as 
complimentary methods in order to generate genome-wide expression profiles in 
rodents (102) Flint (109) and has been routinely used in combination with 
traditional quantitative trait locus (QTL) mapping techniques (109).  
1.3.1.3.1 Microarray analysis 
Microarray profiling involves the hybridization of nucleic acid samples (or 
targets) to oligonucleotide probes that allow for the determination of a sequence 
or to detect variation in gene sequence or expression. Microarray has led to gene 
profiling that has played a key role in understanding drug side effects at the 
molecular level, and especially, novel molecular profiles for endocrine linked 
diseases such as hypertension (110). Since the premise of microarray profiling is 
that steady-state mRNA levels are altered in diseased samples, examining the 
 changes in mRNAs expressed in tissues and/or cells can elucidate unique 
expression patterns identifiable to a specific disease (110).  
1.3.1.4 Transgenic Strategies 
The first transgenic animals were generated around thirty years ago by injection 
of naked DNA into the pronuclei of mouse zygotes. This method of transgenic 
generation only allowed for random insertion into the genome (111). Even until 
recently, gene targeting involving homologous recombination (HR) in embryonic 
stem (ES) cells or cloning through nuclear transfer was limited to species where 
in which appropriate cells were available. While these techniques have been 
used for the generation of useful mutants in many different species (i.e. mouse, 
cow, pig), they are cumbersome and expensive and do not allow targeted 
modification of specific genes. Furthermore, while several of these strategies 
have been readily available for a number of years in the mouse, the same cannot 
be said of the rat because of the lack of appropriate technologies. Rat ES cells 
and induced pluripotent stems cells (iPS) have been available but the culture 
conditions for these cells and methodology for inducing HR were imperfect (112-
114). Furthermore, in vitro cultivation of rat spermatogonial stem cells and their 
ability to undergo HR has proven to be unsatisfactory (115;116). However, other 
methods based on the in vitro genetic engineering of pluripotent stem cells, 
transposon-mediated mutagenesis (117) and Nethyl- N-nitrosourea (ENU) 
mutagenesis (118;119) have been used with some success for producing 
mutations in the rat genome. 
Traditionally, the rat has been an important biomedical research model whose 
utility has led to significant advancements in modern medicine for humans. 
However, due to the difficulties mentioned above, the rat has been significantly 
hampered by a lack of technologies for targeted genome modification (120). An 
early example of successful transgenic rat production, which allowed 
confirmation of the importance of a gene for fatty acid metabolism and insulin 
resistance in the SHR model, is the transgenic rescue of Cd36 (121). Cd36 was 
first identified as a candidate gene by QTL analysis and confirmed by congenic 
strain production. The SHR rat was found to lack a functional Cd36 gene 
therefore; this gene was transgenically rescued by random insertion of the wild-
type version of the gene into the SHR genome. Two independent transgenic lines 
 were generated, and these lines were investigated in terms of insulin action in 
isolated muscle and glucose intolerance in order to measure insulin sensitivity. In 
both lines expression of wild-type Cd36 on the SHR genetic background induced 
improvements in glucose tolerance, insulin-stimulated glucose incorporation into 
muscle glycogen, and serum fatty-acid levels. Other factors, such as body 
weight, were not significantly different in the transgenic lines compared with the 
SHR progenitor strain (121). Further research into each of the independent lines 
identified differential expression patterns of Cd36 when the transgenic lines 
were compared showing unique characteristics for each line. However, in both 
lines, the Cd36 transgene substantially corrected (>70%) the SHR muscle defect 
in insulin action compared with normotensive control rats which supports their 
concept that primary genetic defects in fatty-acid metabolism contributes to the 
pathogenesis of insulin resistance (121).  
Despite over 195 transgenic or mutant rats that have been produced using either 
chemicals (118), transposons (117), nuclear transfer (122), rat ES cells (112;113), 
induced pluripotent stem cells (iPS) (114), or spermatogonial stem cells (SSC) 
(116), none,  of these methods until very recently were amenable to any form of 
targeted gene modification. 
However, several new approaches have enabled precise genome engineering in 
order to generate modifications, such as point mutations, accurate insertions and 
deletions, and conditional knockouts and knock-ins.  
1.3.1.4.1 Embryonic Stem cells 
Embryonic stem cells are pluripotent cells derived from the inner cells mass in 
very early stage embryos which can differentiate to any cell type in the embryo. 
When foreign DNA is introduced directly into ES cells, it may integrate randomly 
within the genome. However, if the introduced DNA is similar in sequence to part 
of the host genome, it may undergo “homologous recombination” and integrate 
as a single copy at a specific (123). Additionally, ES cells colonize the host 
embryo and often contribute to the germ line, resulting in the production of 
transgenic offspring are with the same newly introduced DNA. Thus providing a 
powerful developmental tool to generate experimental animals. Since stem cells 
 are easily accessible for genetic modification, they can be used to test transgene 
expression in both in vivo and in vitro environments (123).  
The strong activity in most cell lines and permissibility in most tissues make the 
cytomegalovirus (CMV) promoter, human polypeptide chain elongation factor 1α 
promoter (the EF-1α promoter) and mouse class I promoter (H-2K) some of the 
more popular choices for promoters (124;125). Unfortunately, in vivo the CMV 
promoter has shown to be silenced at the mRNA level in liver (126) and within 
several weeks in multiple organ systems as well (127;128). Other choices, like 
the EF-1α promoter have shown to be consistent in their gene expression in vivo 
(124).  
 
1.3.1.4.2 Zinc fingers nucleases 
Another method for creating knock-in and knock-out models is the use of zinc 
finger nucleases (ZNFs). ZFN allows for a directly targeted mutagenesis at the 1-
cell-stage embryo and thus making ES obsolete in this process. Without ES 
generation to consider, the ZFN process makes model generation much faster 
and avoids background strain limitations and is directly applicable to the rat. 
ZFNs have been used in recent years to successfully create numerous transgenic 
rat models on a variety of genetic backgrounds (129). 
 Zinc fingers were first discovered and used in 1985. They originated from 
biochemical studies arising from the interpretation of the interaction of the 
Xenopus protein transcription factor IIIA (TFIIIA) with 5S RNA (130). Subsequent 
studies investigating the structure revealed that zinc-fingers consisted of a 
three-dimensional structure that readily interacted with DNA (130), where each 
finger constitutes a self-contained domain stabilized by a zinc (Zn) ion ligated to 
a pair of cysteines and a pair of histidines and also by an inner structural 
hydrophobic core (130). Because of this three dimensional structure, zinc fingers 
can be linked linearly in tandem to recognize nucleic acid sequences of varying 
lengths. This modular design offers a large number of combinatorial possibilities 
for the specific recognition of DNA (or RNA).  
Application of this specific recognition lead to the use of zinc fingers being used 
to construct DNA-binding proteins for specific intervention in gene expression.  
 By fusing zinc fingers to nucleases to create hybrid molecules composed of 
tandem zinc finger-binding motifs to a non-specific cleavage domain of the 
restriction endonuclease, such as FokI, genes can be selectively altered by 
targeting the peptide to the desired gene target. One of the first examples of 
the power of the method was published in 1994 when a three-finger protein was 
constructed to block the expression of a human oncogene transformed into a 
mouse cell line (131). More specifically, zinc finger nucleases (ZFNs) have the 
ability to create site-specific double-stranded breaks which are repaired via non-
homologous end joining (NHEJ) which then results in the arbitrary addition or 
deletion of base pairs. The first successful example of ZFN technology in rats was 
by Geurts et al. (2009), where a single injection of DNA or messenger RNA that 
encodes specific ZFNs into one-cell transgenic rat embryos that express GFP lead 
to a high frequency of animals that do not express the transgenic marker as a 
consequence of homologous recombination at the GFP site (129). Specifically, 
ZFN reagents targeted a single-copy Green Fluorescent Protein (GFP) transgene 
inserted in a rat chromosome. Full knockout of the GFP transgene was achieved, 
as mutant animals lacked both GFPexpression and wild-type GFP sequence. 
Animals where then bred to wild-type animals with 1 out of 1 GFP offspring.  
There are two major platforms for generating polymeric zinc fingers with defined 
specificities. The first is a proprietary platform developed by Sangamo 
Biosciences and has partnered with Sigma to sell pre-assembled ZFN’s via the 
Compozr program (http://www.compozrzfn.com/). The second platform, an 
OPEN platform, was developed by the Zinc Finger Consortium 
(http://www.addgene.org/zfc; www.zincfingers. org/software-tools.htm) makes 
their modular assembly zinc finger pools and reagents freely available. Both 
platforms are available for transgenic animal research purposes.  
1.3.1.4.3 TALENs 
A more recent advancement in the production of knock-in or knock-out rats is 
the development of Transcription activator-like (TAL) effectors. TALs are a newly 
described class of specific DNA binding protein, so far unique in the simplicity 
and manipulability of their targeting mechanism. Produced by plant pathogenic 
bacteria in the genus Xanthomonas, the native function of these proteins is to 
directly modulate host gene expression (132). Upon delivery into host cells via 
 the bacterial type III secretion system, TAL effectors enter the nucleus, bind to 
effector-specific sequences in host gene promoters and activate transcription 
(132). Their targeting specificity is determined by a central domain of tandem, 
33–35 amino acid repeats, followed by a single truncated repeat of 20 amino 
acids. Of the naturally occurring TAL effectors that have been investigated, most 
have between 12 and 27 full repeats (133). Within the DNA binding domain, 
positions 12 and 13 of each repeat species the target nucleotide sequence and is 
referred to as the ‘repeat-variable di-residue’ (RVD). Furthermore, for TAL-
effector activity, all naturally occurring recognition sites are preceded by a T 
(134;135). Because of the straight forward sequence relationships and ease of 
designations through simple ‘protein=DNA code’ that relates modular DNA 
binding, Transcription activator-like effector nucleases (TALENs) have rapidly 
emerged as an alternative to ZFNs for genome editing.  
TALENs are similar to ZFNs and comprise a non-specific FokI nuclease domain 
fused to a customizable DNA-binding domain. Early investigations using TALENs 
were based on natural TALE scaffolds where FokI cleavage domain replaced the 
natural C-terminal activation domain, and resulted in modest targeted cleaveage 
properties (136). Research done by Mussolino et al. showed that TALENS with 
higher activity can be made by truncating the natural TALE scaffold on either 
side of the repeat units, retaining a minimum of 150 residues at the N-terminus 
and 20 amino acids at the C-terminus (136-138). These investigations resulted in 
tailored TALENs improving genome modification of up to 20% of target al.leles in 
transfected cells and having a comparable success rate of that of ZFNs (136-138). 
Additionally, the new optimized TALEN architecture has shown to be successful 
in the modification of human induced pluripotent stem cells (iPSCs) as well as in 
zebrafish and rat zygotes with similar knockout efficiencies as ZFNs (137-140).  
Furthermore, recent studies by SO and SO et al. using the CCR5 and the IL2RD 
loci in cultured human cells have shown that TALENs have significantly less 
cytotoxicity when compared to ZFNs (137). Furthermore, in vivo studies in the 
rat have not only showed less toxicity, but TALEN generated knockout animals 
resulted in an higher percentage of newborn animals compared to data obtained 
previously with ZFNs (129;141). A second advantage to using TALENs, is the 
increased specificity. Mussolino et al. showed that unlike the ZFN, the CCR5- 
 specific TALEN was able to discriminate between the CCR5 target locus and a 
highly similar site in CCR2(137).  
1.3.2 Oxidative Stress in Cardiovascular studies 
Oxidative stress is thought to result from an imbalance between the generation 
of reactive oxygen and nitrogen /species and the antioxidants that scavenge 
them. Under physiological conditions, several tightly controlled oxidative stress 
pathways contribute towards the production of reactive oxygen species (ROS), 
while several intra- and extra-cellular antioxidant enzymatic systems account for 
the reduction of ROS. In the past two decades, our concept of how oxidative 
stress contributes to chronic diseases has undergone considerable evolution. 
Traditionally, reactive oxygen species and their resultant oxidative stress have 
been examined in the context of damage to biologically important targets such 
as proteins, lipids, and DNA. Recently, these studies have led to clinical 
investigations implicating oxidative stress in human disease, including 
atherosclerosis and cardiovascular disease. For instance, oxidative stress in 
atherosclerotic cardiovascular disease is highlighted by the increase of 
biomarkers indicative of risk factors for coronary artery disease which have 
shown to have predicative values for cardiovascular risk in both primary and 
secondary prevention (142). End products such as serum lipid hydroperoxides 
(LOOH) which is generated from polyunsaturated fatty acids, Malondialdehyde 
(MDA) an end product of lipid peroxidation can be easily measured and have 
been shown to be elevated in association with cardiovascular risk factors 
(143;144).  
Although the mechanisms underlying cardiovascular disease are complex and 
multifactorial, there is growing evidence to suggest that an increased production 
of ROS, or oxidative stress, plays a critical role in the development of CVD (145).  
1.3.2.1 Reactive oxygen species and nitric oxide 
Reactive oxygen species (ROS) play a crucial role in human physiological and 
pathophysiological processes. They are ubiquitous reactive derivatives of O2 
metabolism found in the environment and in all biological systems. Reactive 
oxygen species (ROS) include free radicals, such as superoxide anion (O2-), 
 hydroxyl radical (OH-), nitric oxide (NO)and lipid radicals (LOO-), which possess 
unpaired electrons, or include molecules that possess oxidizing actions, such as 
hydrogen peroxide (H2O2), hypochlorous acid (HOCl) and peroxynitrite (ONOO-)  
(146).  
Physiologically, ROS are produced in a controlled manner at low concentrations 
intracellularly that can act as intracellular second messengers that modulate the 
function of biochemical pathways and regulation (147-149). An example of this 
cell signalling function is the role that ROS play in maintaining vascular integrity 
through regulating endothelial function and vascular contraction and relaxation 
(148;150). Under pathological conditions, increased ROS bioactivity leads to 
endothelial dysfunction, increase contractility, vascular smooth muscle cell 
growth, lipid peroxidation (increase MDA), and inflammation which are all 
important factors of vascular damage (148;150).  
Clinical studies have indicated that the inhibition of the RAAS is beneficial for 
hypertensive patients (151). Research by Matsuno et al. have shown that 
inhibition of the RAAS reduces up regulation of several NADPH oxidase isoforms 
which results in a reduction of oxidative stress. For instance, animals without the 
Nox1 protein develop less hypertension with angiotensin II infusion (or an 
increase in the RAAS) than animals with the Nox1 protein (152). Other ROS 
sources have been investigated in animal models with salt-induced hypertension 
where the up regulation of mitochondrial SOD2 demonstrated an 
antihypertensive effect (153). Furthermore, antioxidants either targeted to the 
mitochondria (eg, mitoTEMPO and MitoQ) or endogenously expressed in the 
mitochondria (SOD2 and thioredoxin 2) have all been shown to attenuate 
angiotensin II-induced hypertension (154;155).    
 Reactive nitrogen species, such as nitric oxide (NO) and peroxynitrite (ONOO-), 
are biologically important O2 derivatives that are recognized to be important in 
vascular biology through their oxidation/ reduction (redox) potential (147). Nitric 
oxide, also known as endothelium-derived relaxing factor (EDRF), is biosynthized 
endogenously from L-arginine, oxygen and NAPDH by various nitric oxide 
synthases (NOS) enzymes and is responsible for vasorelaxation by its effect on 
the vascular smooth muscle cells (VSMCs)  (156;157). Vascular NO relaxes blood 
vessels, prevents platelet aggregation and adhesion, limits oxidation of low 
 density lipoprotein (LDL) cholesterol, inhibits proliferation of vascular smooth 
muscle cells, and decreases the expression of pro-inflammatory genes that 
advance atherogenesis (157-159). An increased production and/or impaired 
inactivation of ROS (i.e. oxidative stress) leads to reduced bioactivity of NO. A 
dominant mechanism reducing bioavailability of vascular NO is rapid oxidative 
inactivation by the ROS superoxide (O2−). 
1.3.2.2 Oxidative stress 
Under normal physiological conditions, reactive oxygen species (ROS) produced in 
the course of normal metabolism are fully inactivated by an elaborate defensive 
cascade of cellular and extracellular antioxidants (160). However, certain 
pathological conditions increase the generation of ROS and/or the depletion of 
antioxidant capacity which leads to enhanced ROS activity and oxidative stress. 
Oxidative stress is often defined as an abnormal level of reactive oxygen species 
(ROS), such as free radical (e.g. nitric acid, hydroxyl group, superoxide) or non-
free radicals (e.g. hydrogen peroxide, lipid peroxide) that lead to oxidative 
damage and a biological system’s inability to readily detoxify the reactive 
intermediates (Figure 1-3). This imbalance often leads to consequential injury to 
cells or tissue.  
Compelling evidence has shown the oxidative stress to be associated with diverse 
physiological events, including cancer, the development of vasculopathies 
(hypertension, arthrosclerosis), renal disease and neuro-degeneration (148). 
Furthermore, increased production of ROS generally occurs as a result of 
inflammation, ageing, UV radiation, excessive alcohol consumption, cigarette 
smoking, and many other factors (161).  
1.3.2.3 The antioxidant system  
In order to protect against increased ROS levels, several different oxidases exist 
within vascular tissue, including superoxide dismutase (SOD), catalase, 
thioredoxin peroxidase, peroxiredoxin and glutathione peroxidase (GPx), which 
convert ROS into less noxious compounds. Superoxide dismutase (SOD) 
dismutates O2- at a rate of 2.4 x 109 mol.L-1.s-1 to the more stable hydrogen 
peroxide (H2O2), which is then converted to water by catalase or glutathione 
 peroxidase (GPx) (149;162;163). Collectively, these enzymes provide a first line 
of defence against superoxide and H202. Whilst such enzymes are of enormous 
importance in limiting ROS-mediated damage to intracellular macromolecules, 
there are additional anti-oxidants such as ascorbate which scavenges superoxide 
in order help maintain a normal homeostatic balance of ROS.  
However, in the case of the diseased states many of these antioxidant molecules 
may not be present at sufficient levels (164). Moreover, the expression of ROS-
producing enzymes have been shown to be altered by hormones such as 
angiotensin II (Ang II) or cytokines such as tumour necrosis factor (TNF) -α and 
interleukin (IL) -1β (149). 
1.3.2.3.1 Glutathione 
Glutathione (GSH) is found in the cytosol of cells where concentration ranges 
from 1–10 mM, with the majority of cells ranging between 1-2 mM and around 10 
mM in hepatocytes (165). GSH plays major roles in the different cellular 
compartments.In the mitochondria GSH regulates the balance between apoptosis 
versus necrosis (166), and in the nucleus, is found to be a key modulator of 
cellular division (167). GHS is considered a unique γ-glutamyl-lcysteinylglycine. 
This is largely due to the fact that it contains an unusual peptide linkage 
between the γ-carboxyl group of the Glu side-chain and the amino group of the 
cysteine (1,2). GSH synthesis involves the combination of cysteine with 
glutamate to produce c-glutamylcysteine. This reaction is catalyzed by the 
enzyme glutamate cysteine ligase (GCL), which is also called γ -glutamylcysteine 
synthetase. This enzyme requires coupled ATP hydrolysis to form an amide bond 
between the c-carboxyl group of glutamate and the amino group of cysteine 
(168). A secondary step involves the enzyme glutathione synthetase, responsible 
for adding glycine to the dipeptide to produce GSH (γ -glutamylcysteinylglycine) 
and also requires coupled ATP hydrolysis (169). GSH when reduced and results in 
the formation of glutathione disulfide (GSSG).  
  
  
Figure 1-3: Oxidative stress enzymes and their roles in maintaining the balance between O2-  
and NO. 
BH4 = tetrahydrobiopterin; eNOS = endothelial nitric oxide synthase; H2O = water; 
H2O2 = hydrogen peroxide; GPx = glutathione peroxidase; GSH = glutathione; 
GSSG = oxidized glutathione; GSTs = glutathione s-transferases; LO- or LOO- = lipid 
radicals; NAD(P)H = nicotinamide adenine dinucleotide (phosphate); NO = nitric 
oxide; O2 = molecular oxygen; O2 - = superoxide anion; ONOO- = peroxynitrite; ROS 
= reactive oxygen species; SOD = superoxide dismutase; VSMC = vascular smooth 
muscle cell. Adapted from Ref (146). 
 
  
  
The GSH–glutathione disulfide system is considered the most abundant redox 
system in eukaryotic cells (170). Qualitative and quantitative alterations of the 
GSH–GSSG redox system induced by reactive oxygen and nitrogen species has 
been implicated in the pathogenesis of certain chronic illnesses (such as sickle 
cell disease, asthma, and preeclampsia) are comprehensively reviewed by Dalle-
Donne et al. (171). 
The biologically active site of GSH is represented by the thiol group of the Cys 
residue. The high nucleophilicity of the thiol functionality facilitates the role of 
GSH as a free radical scavenger both under physiological conditions and in 
xenobiotic toxicity (172-174). GSH also helps in the regeneration of other 
antioxidants, e.g. vitamin E and ascorbic acid (ASC) (175-177). GSH is a cofactor 
for glutathione peroxidase in the decomposition of hydrogen peroxide or organic 
peroxides; for glyoxalase 1 in the detoxification of methylglyoxal and other _-
oxo-aldehydes; and for maleylacetoacetate isomerase in the conversion of 
maleylacetoacetate and maleylpyruvate to the corresponding fumaryl 
derivatives. GSH can also react with a number of endogenous moieties, resulting 
in the generation of bioactive endogenous GSH adducts. Although some adducts 
can be formed directly, glutathione- S-transferase (GST)-mediated reactions 
generally predominate (175). 
 
1.3.2.3.2 Glutathione peroxidises 
Glutathione peroxidises were the first selenoproteins to be identified in higher 
organisms (178). First discovered in 1973, over the past four decades they have 
been found in all higher organisms. The GPx family have been shown to play a 
role in the first line of defence for oxidative stress, by reducing H2O2 to water 
and second line of defence, by reducing organic peroxides such as lipid 
hydroperoxide to water and lipid alcohol, via conjugation of glutathione, forming 
GSSG (179;180). Moreover, the term “glutathione peroxidise” has been used to 
describe enzymes that may similarly catalyze the reduction of hydroperoxides by 
GSH, but are neither structurally nor phylogentically related to the family, such 
as GSH-S-transferases (24), selenoprotein P (181) or human peroxiredoxin VI  
 (182). The GPx, now known as GPx-1, that gave its name to the entire 
glutathione peroxidise family catalyzes the reduction of H2O2 and soluble organic 
hydroperoxides at the expense of GSH (183). GPx-1 is the most abundant GPx in 
mammals. It appears to be predominantly localized in the cytosol and the matrix 
space of mitochondria (184), and also protects the organism against oxidative 
damage (185). Its affinity for GSH comes from its structure of a lysine and four 
arginine residues which surrounds the active site selenium and serve to direct 
the two GSH molecules into an orientation that allows for the GSH sulphur to 
react with the selenium.  
Out of the 8 GPxs which are found in mammals, only half of them are known to 
contain selenocysteine, where selenocysteine (Sec) is at the catalytic centre and 
is a key component to the of the catalytic activity(180;186). GPx-1 and GPx-2 are 
homotetrameric proteins, GPx-3 is a homotetrameric glycoprotein while GPx-4 is 
a monomeric enzyme (180). GPx-1, also known as cytosolic GPx, can metabolize 
H2O2 and a variety of organic peroxides, including cholesterol and long-chain 
fatty acid peroxides with the aid of phospolipase A2 activity. GPx-2 found mainly 
in the epithelium of gastrointestinal tract (GSHPx-GI), displays a substrate 
specificity that appears largely identical to that of GPx-1 (187). GPx-3, a typical 
extracellular glycolated protein with a largely unknown function, and was first 
purified from plasma (188). GPx-3 mRNA is found to be expressed predominantly 
in kidney with the primary biosynthesis site in the proximal tubles (189). GPx-3 is 
also expressed in adipose tissure and lung epithelial cells (190;191). Its 
hydroperoxide specificity resembles that of GPx-1 (192), and can also reduce 
complex lipid hydroperoxides at a low rate (193). GPx-4 can react with 
phospholipid hydroperoxide (PHGPx). 
A GPx-1-/- knockout mouse shows increased susceptibility to ROS-induced 
oxidative stress (194). Studies focusing on the induction of GPx-1 have shown the 
GPx-1 to protect endothelial cells against oxidative stress, and transgenic studies 
with GPx-1 expression improved endothelial dysfunction (195). The cellular and 
tissue location of each of the GPxs have been shown to be critical for their 
biological functions (186). As mentioned earlier, GPx-3 has activity against 
phospholipid hydroperoxides (190). While GPx-4 is responsible for protection of 
membranes against oxidative damage and also control of cell function. While 
 GPxs are important, there are also other enzymes that have peroxidase activity, 
most notably the GSTs. 
1.3.2.3.3 Glutathione S-Transferases 
The glutathione S-transferases (GST) are a supergene family of soluble dimeric 
enzymes that catalyse the conjugation of glutathione (GSH) to a variety of 
electrophiles including arene oxides, unsaturated carbonyls, organic halides and 
other substrates (196). They play a key role in phase II of enzyme digestion 
(197), have a primary function of metabolizing a broad range of reactive oxygen 
species (ROS), and have been implicated in a number of diseases, including 
childhood asthma (198) and lung cancer (199). They also detoxify noxious 
electrophilic metabolites of xenobiotics which are produced intracellularly 
following exposure to air-borne products of combustion, from consumption of 
either over-cooked or mycotoxin-contaminated food, or from drinking polluted 
water (200). GSTs play a particular role in the protection against oxidative stress 
through their ability to catalyse the conjugation of GS with 4-hydroxynonenal 
(201;202), a major genotoxic and cytotoxic α,β-unsaturated aldehyde formed 
from n-6 polyunsaturated fatty acids during lipid peroxidation (203). 
Furthermore, GSTs can also conjugate GSH with adenine and thymine propenals, 
reactive purine and pyrimidine bases formed during DNA damage from oxidative 
stress (204). GST expression has been shown to be under the control of 
glucocorticoid response element (GRE), xenobiotics response element (XRE) or 
antioxidant response element (ARE) (197;200).  
There are two distinct, evolutionary separate multigene families with GST 
activities. The first superfamily consists of cytosolic proteins and the second 
consists of membrane-bound proteins (205;206). The cytosolic protein family is 
highly complex and in mammals at least 7 classes of transferase, designated 
Alpha, Mu, Pi, Sigma, Theta, Zeta and Kappa, have been characterized. While 
these enzymes are referred to as cytosolic GST, the Kappa class is located in the 
mitochondrion and are best referred to collectively as soluble GST (207). The 
cytosolic proteins are also considered the genuine GSTs, having both STs_N and 
GSTs_C domains (208). The second family, or the microsomal transferases family 
– recently called the MAPEG, Membrane Associated Proteins involved in 
Eicosanoid and Glutathione metabolism (206) has not been as thoroughly studied 
 as the soluble GST family. However, recent advances in molecular cloning have 
revealed that it contains significantly more members than was thought even just 
a couple of years ago (209;210). In addition to the structural differences 
between the two superfamilies, each family is functionally unique. The soluble 
transferases act primarily as detoxication enzymes to prevent cytotoxic and 
genotoxic damage cause by electrophiles generated as breakdown products of 
macromolecules. The MAPEG family serve to inhibit lipid peroxidation during 
oxidative stress (211). 
The soluble GSTs are dimeric proteins where each subunit is about 26 kDa and 
formed only from subunits within the same class (212). These GSTs are known as 
2-domain structures with the first structure made of structurally conserved 
nucleophilic glutathione binding sites (g-sties), and the second domain the 
diverse hydrophobic binding sites (H-sites) that determines the substrate 
specificities (213), with substrates being electrophillic compounds that react 
with the thiol moiety of glutathione (197). The G–sites mainly consist of 
interaction with N-terminal residues while the H–sites involve C-terminal residues 
and other parts of the protein. Through catalysis, GSTs bind a variety of 
electrophiles to the sulphydryl group of glutathione which results in more water-
soluble molecules (196). While GSTs are not unique in their function of 
protecting against phospholipid hydroperoxides and have been shown to have 
reduced activity towards phospholipid hydroperoxides than GPx-4, it should be 
recognized that their increased abundance in many tissues makes them 
physiologically important in reducing peroxidized lipids. Other roles that makes 
GST physioloigically important are their ability to remove ROS, regenerate S-
thiolated proteins, catalyze conjugations of endogenous ligands and catalysis of 
reactions in metabolic pathways not associated with detoxification (205). 
Furthermore, these biochemical data indicate the GSTs are not a first line of 
defence against free radicals. Generally, enzymes that are considered the first 
line of defence against oxidative stress are SOD, catalase and GPx. The GST 
family represents a second line of defence providers against oxidative stress that 
due to their broad range of substrate specificity are able to successfully reduce 
oxidative stress. While many studies on GSTs have focused mainly on the role of 
GST in cancer, new research has shown Gstm1 to play a role in genetic models of 
hypertension (78;214;215) 
 1.3.2.3.3.1 Mu Family of S-transferases 
 
As previously described, there are two distinct families of GST, the cytosolic 
proteins and the membrane-bound proteins (200;206). This thesis will focus only 
on the cytosolic (or soluble) enzymes. In mammals GSTs have eight cytosolic 
classes that have been identified—Alpha (A) located on chromosome 6, Mu (M) 
located on chromosome 1, Pi (P) located on chromosome 11, Theta (T) located 
on chromosome 22, Sigma (S) located on chromosome 4, Zeta (Z) located on 
chromosome 14, kappa (K) (chromosome location not know), and chi (O) (also 
called omega) on chromosome 10. Their classification was determined on the 
basis of a combination of criteria such as substrate inhibitor specificity, primary 
and tertiary structure similarities and immunological identity (216;216). Within 
these major classes, there are subclasses with different gene codes. For 
example, five different genes code for Mu class GSTs (GSTM1–M5) (198). The Mu 
class genes are situated in tandem (5-GSTM4-GSTM2-GSTM1-GSTM5-GSTM3-3`) in 
a 20 kb cluster on chromosome 1p13.3 (217). Each GSTM gene consists of 8 exons 
and 7 introns. The sequences of these genes and their encoded amino acid 
sequences are highly homologous, suggesting gene duplication in the evolution of 
the GSTM genes. Early investigative work with the GSTMs reported 
polymorphisms in the GSTM1 gene where single base changes   gave rise to the 
functionally identical GSTM1*A and the GSTM1*B alleles (204), a duplication of 
the GSTM1 gene (218), and the deletion of GSTM1 gene resulting in the null 
allele GSTM1*0 (219;220). The significance of the null GSTM1 genetic variation in 
human was first recognized in cancer studies demonstrating that patients 
carrying the GSTM*0 allele were at increased risks for colon and lung cancers 
(199). Allelism has also been identified in the GSTM3 with GSTM3*A and GSTM3*B 
where GSTM3*B differs from GSTM3*A by a 3bp deletion on intron 6. 
Furthermore, this difference creates a recognition motif for the YY1 
transcription factor in GSTM3*B and thus the possibility of differently regulated 
expression between alleles. Recent studies have shown many more 
polymorphisms in the GSTM family (221) however, the human polymorphism of 
GSTM and their pathological connections are not the main focus of this thesis.  
In the rat, a 155kb GSTM cluster locus is located on chromosome 2q34 in the in 
the order of M7-M1-M2-M4-M6b-M3-M6a, followed by M5 in an inverted 
orientation (Figure 1-4). In regards to the GST family in rodents, there is 
 extensive research on the biochemistry of GSTs as well as their roles as phase II 
detoxification enzymes during the early literature of rodent GSTs. However, new 
and recent studies have shown the GSTs, specifically GSTM1, to be correlated 
with the development of hypertension. Our group has indentified GSTM1 to be a 
positional and functional candidate gene for hypertension (96). There is also data 
on differential expression of this gene in other hypertensive rat strains as 
compared to normotensive reference strains (214;215). Further studies have 
shown that the difference in mRNA expression was reflected at the protein level 
in the kidney and was inversely correlated with renal ROS levels, suggesting that 
the pathophysiological roles of GSTM1 in hypertension involve the defence 
against oxidative stress (96). 
1.3.3 Identification of Gstm1 as a candidate gene for oxidative 
stress and its role in the development of hypertension in the 
SHRSP 
A genome-wide scan previously performed in the Glasgow laboratory by cross-
breeding the SHRSP and WKY inbred strains identified a QTL on rat chromosome 
2 encoding genes involved in blood pressure regulation (78). This QTL was 
confirmed and further refined by congenic breeding where genomic regions from 
the WKY were introgressed onto the background of the SHRSP. This strategy   
generated rats with significantly reduced blood pressure compared to the SHRSP 
(SP.WKYGla2c* congenic strain) (Figure 1-6) (78). Microarray expression profiling 
in the kidney at 16 weeks of age in the SHRSP, WKY and the SP.WKYGla2c*strain 
identified Gstm1 as a functional candidate gene. Additional studies were carried 
out in order to examine Gstm1 expression differences between SHRSP and WKY 
rats prior to the onset of hypertension. Microarray analysis assessed renal gene 
expression at 5 wks of age in the WKY, SHRSP, and the SP.WKYGla2c* rats. 
Results showed a significant reduction in the expression of Gstm1 in the SHRSP at 
this early time point (96).   
  
Figure 1-4: Organisation of the glutathione s-transferase mu genes in human and 
rat 
(A) Synteny between rat Gstm gene cluster on chromosome 2 and human GSTM 
gene cluster on chromosome 1. The names in brackets are the alternate names 
for the respective genes in earlier literature. AMPD2, adenosine monophosphate 
deaminase 2; EPS8L3, epidermal growth factor receptor pathway substrate 8-like 
protein 3; GSTs, glutathione S-transferase; (B) Organisation GSTM genes in 
individuals missing GSTM1 gene. Figure taken from (222) 
 
   
 In addition, it was shown that antihypertensive treatment was unable to impact 
on expression levels of Gstm1 in SHRSP rats (i.e. was unable to improve 
expression levels) indicating that this deficiency in Gstm1 expression appears to 
be a primary cause, rather than secondary to increase in blood pressure levels 
(87).  
Further investigation of this differential Gstm1 expression showed that the SHR 
and SHRSP genome contains 13 single-nucleotide polymorphisms (SNPs) within 
the promoter, a missense mutation and a 3’ untranslated region (UTR) 
polymorphism that was not found in the WKY or BN strains. Luciferase reporter 
constructs compared the transcriptional activities of Gstm1 between the SHRSP 
and WKY in addition to subcloning experiments were able to identify and isolate 
two SNP clusters that were responsible for the reduced expression in the SHRSP. 
Additional luciferase experiments suggested that an interaction between one or 
more SNP in each cluster contributed to reduced transcription. Other novel 
constructs were generated by site-directed mutagenesis in order to more fully 
investigate this interaction, however no consistent effects on expression were 
observed. The Transfac database was used to identify several potential 
transcription factor binding sites affected by the SHRSP mutations, the strongest 
candidate being peroxisome proliferator-activated receptor gamma (PPARγ), 
with binding sites affected in both implicated clusters.  
In order to investigate the physiological effects of reduced renal Gstm1 
expression in the SHRSP, renal GSH levels were measured at 5 and 16 weeks. 
Results showed lower expression levels in the SHRSP at both time points when 
compared to the WKY. Interestingly, GSH expression in the SP.WKY2GlaC* 
congenic strain was similar to that of the SHRSP at 5 weeks of age and similar to 
the WKY at 16 weeks of age. This data, when combined with the significant 
reduction of SBP in the SP.WKYGla2c* congenic strain leads to the hypothesis 
that renal oxidative stress caused by impaired GSH metabolism (reduced Gstm1 
expression) may contribute to the hypertensive profile of the SHRSP. 
   
Figure 1-5: Chromosome 2 congenic strain SP.WKYGla2c* 
A: The congenic strain contains a 22-cM segment, encompassing a quantitative 
trait locus (QTL), transferred from WKY (donor strain; blue) to the genetic 
background of SHRSP (recipient strain; orange) between the markers D2Wox9 and 
D2Mgh12. The congenic strain described is the SP.WKYGla2 (D2Wox9 – D2Mgh12) 
and is abbreviated to SP.WKYGla2c* and 2c* in figures. The Gstm family gene 
locus is encompassed within the congenic region, under the quantitative trait 
locus (QTL). Adapted from (78). 
 
 
 
 
  
 
Figure 1-6: Day-time and night-time average systolic and diastolic blood pressure 
Systolic (A) and Diastolic (B) blood pressure, measured by radio-telemetry over a 
three-week period for SHRSP, WKY and congenic strain SP.WKYGla2c*. n = 8-11 
per group. Adapted from (78). 
 
 
 
 
  
 Following on from these in vivo and ex vivo investigations, more specific in vitro 
and in vivo studies were conducted to examine the role of Gstm1 in the kidney. 
In order to elucidate the role of Gstm1 in rat kidney tubule epithelial cells (NRK-
52E), RNA interference (RNAi) was used to knockdown Gstm1 expression. Three 
different short interfering RNA (siRNA) sequences, targeted to Gstm1, were used 
and each significantly reduced expression of Gstm1 in both protein and mRNA 
levels. Off target effects were prevented through reduction of siRNA 
concentration. To assess the effect of Gstm1 knockdown in an in vivo setting, 
local delivery to the kidney via the renal artery was attempted. However, the 
delivery was shown to cause significantly renal damage. As an alternative route, 
plasmid vectors were generated that expressed Gstm1 specific short-hairpin RNA 
(shRNA) molecules based on the sequences that successfully knocked down 
Gstm1 expression in vitro. Unfortunately, transfection into the NRK-52E cells was 
poor and knock-down was not confirmed. 
The role of Gstm1 in the protection against cellular oxidative stress was 
evaluated in NRK-52E cells through Gstm1 knockdown and subsequent 
measurements of oxidative stress markers. Total GST activity was not reduced in 
cells transfected with Gstm1 specific siRNA, however, activity was increased 
following over expression of Gstm1. Additionally, knock down of Gstm1 did not 
show any change in glutathione levels. Oxidative stress was determined by 
measuring 8-isoprostane (a marker of lipid peroxidation), 8-hydroxy-2-
deoxyguanosine (8-OH-dG) (a marker of oxidative DNA damage) and by the comet 
assay (DNA damage). No significant difference in the levels of 8-isoprostane or 8-
OH-dG was observed in cells treated with Gstm1 specific siRNA compared to 
control siRNA, however significant DNA damage was demonstrated by comet 
assay.  
While the functional studies discussed above evaluated the effects of modulating 
Gstm1 expression in-vitro, the specific role for Gstm1 in protection against 
oxidative stress and hypertension remained to be fully determined and thus 
provided the strong imptetus to generate a transgenic model. In order to 
functionally validate Gstm1 and provide definitive evidence of the direct role 
played by the Gstm1 gene in hypertension, the transgenic strategy needed to be 
utilised. This is considered to be a gold standard method for functional validation 
of candidate genes. Therefore production of transgenic SHRSP rats in which the 
 Gstm1 had been ‘rescued’ was attempted. This involved the random insertion of 
wild-type Gstm1 into the SHRSP genome. More advanced methods of genetic 
modification such as ZFN or TALEN technology were not available in the rat at 
this time, since the SHRSP rat transgenic production procedure was started prior 
to 2009. After several unsuccessful attempts in-house, SHRSP rats were 
transferred to the laboratory of our collaborator Dr Michal Pravenec (University 
of Prague) who successfully generated two novel transgenic lines incorporating 
the wild-type Gsmt1 gene from the WKY into the SHRSP genome. The phenotypic 
and molecular analysis of these novel transgenic lines formed the basis of my 
PhD project. 
 
  
 1.4 Hypothesis 
Oxidative stress is an important pathogenic factor in the development of 
cardiovascular disease. Glutathione S-transferases protect against oxidative 
stress-induced injury through the detoxification of reactive oxygen species. It is 
hypothesised that Gstm1 deficiency in the SHRSP plays a causative role in the 
development of oxidative stress and hypertension.  
 
1.4.1.1 Aims 
 A combination of congenic breeding and microarray analysis has identified 
Gstm1 as a positional and functional candidate gene for hypertension in the 
strokeprone spontaneously hypertensive rat (SHRSP).  
This aims of this study were to establish definitive proof that reduced Gstm1 
expression in the SHRSP plays a causative role in the development of 
hypertension and oxidative stress. 
Specific aims: 
1. To functionally validate Gstm1 in an in vivo environment through 
assessment of hemodynamic and cardiac function 
2. To assess genetic and molecular changes from the incorporation of Gstm1 
into the SHRSP genome 
3. To assess renal function and oxidative stress parameters in the Gstm1 
transgenic lines.  
4. To investigate translational aspects of the GSTM family from rodent and 
apply them to a human cohort  
  
  
 
 
 
 
 
 
 
 
 
 
2 Materials and Methods 
  
 2.1 In vivo experimental procedures 
2.1.1 Experimental Animals  
2.1.1.1 Animal Strains 
The animal strains used in this thesis were SHRSPGla, WKYGla and Gstm1 
transgenic SHRSPGla.  Animal housing conditions consisted of controlled 
environmental conditions, where temperature was maintained at 21°C with 12 
hour light/dark cycles starting 7am to 7pm. Rats where fed a standard rat chow 
(rat and mouse No. 1 maintenance diet, Special Diet Services) and water 
provided ad libidum. Weaning of offspring took placed at 3 weeks of age when 
they were sexed, ear-tagged (National Band and Tag. Co.) and caged, with a 
maximum of 3 animals per cage, according to sibling group and sex.    
All work with experimental animals was in accordance to the Animals Scientific 
Procedures Act 1986 under the project license of Dr. Delyth Graham (60/4286) 
and Prof Anna F Dominiczak (60/3618). Inbred colonies of SHRSP and WKY have 
been maintained at the University of Glasgow since 1991 by brother-sister 
breeding. The colony started in 1991 when Dr. D.F. Bohr, from the Department 
of Physiology at the University of Michigan (USA), gifted 6 males and 7 females of 
each strain to the University of Glasgow. These colonies originated from the 
National Institute of Health, Bethesda, Maryland, USA, and were subsequently 
maintained at the University of Michigan as inbred colonies for 15 years. Integrity 
of the colonies was maintained, as well as the distinction between normotensive 
and hypertensive phenotypes, by selection of SHRSP adult breeders with blood 
pressures 170-190mmHg (males) and 140-170mmHg (females), and WKY adult 
breeders of 120-140mmHg (males) and 100-130mmHg (females). In order to 
confirm homozygosity of all loci, animals were selected at random and screened 
by microsatellite markers.    
2.1.1.2  Transgenic Animals 
Two independent transgenic lines of Gstm1 SHRSP rats were created through 
incorporation, by microinjection, of a normal Gstm1 gene into the SHRSP 
genome. The transgenic strains used in this study were derived by the same 
expression platform and microinjection fragment purification protocol as was 
employed in CD-36 rat transgenesis previously described by Pravenec et al. 2001 
 (7). In brief, the Gstm1 cDNA sequence was cloned into pEF1/Myc-HisA 
(invitrogen), an expression construct including the constitutive human elongation 
factor 1 α subunit (EF1 α) promoter and bovine growth hormone (BGH) 
polyadenylation signal separated by a multiple cloning site (223). The cloned 
cDNA ligation insertion was verified by direct sequencing with pEF1 T7F and BGH 
PolyAR primers. The resulting expression plasmid, named pEF1 WKY Gstm1 was 
amplified and purified using the Qiagen Maxi kit (Qiagen, Hilden, Germany). The 
construct was linearized by digesting the pEF1 WKY Gtsm1 plasmid with the 
enzymes PvuII and AatII in order to have a final isolated fragment for transgene 
injection of 2.725kb fragment that encompassed the EF-1a promorter, Gstm1 
cDNA and BGH polyedenlyation sequences. Gstm1 protein expression from pEF1 
WKY Gstm1 was confirmed by tranfection into HeLa cells and Western blotting as 
previously described (223). Generation of the transgenic rats was carried out in 
Prague (in collaboration with Dr Michal Pravenec) using male and female SHRSP 
from the University of Glasgow. The transgenic production process involved 
superovulation of female SHRSP which were then timed mated with SHRSP stud 
males to generate embryos. On day one embryos were harvested and 
microinjected with the DNA linear construct into the pronuclei. The embryos 
were then transferred into the oviducts of psuedopregnant female recipient rats, 
followed by natural pregnancy and pup rearing. This process was repeated a 
several times in order to generate an additional independent transgenic line in 
order to confirm assessment of phenotypic and genotypic changes.  
To assess transgene expression, genomic DNA was isolated from 4-mm tail tips, 
and screened for transgene sequences by polymerase chain reaction (PCR) with 
primers amplifying across the EF1α promoter sequences (primers pEF1F + pEF1R), 
and with two primer pairs that spanned EF1α promoter and Gstm1 cDNA 
sequence (pEF2F + pEF2R and pEF3F + pEF3R). Transgene positive pups from each 
of the independent transgenic lines were weaned and transported to the 
University of Glasgow for full phenotypic and molecular analysis. Additional PCR 
primers were created to confirm transgene insertion (pEF5F + pEF5R). 
Additionally, throughout the course of the study, genomic DNA was again isolated 
from the ear notch or tail tips of the transgenic animals to confirm the genetic 
background and to assure that the transgene was not lost in subsequent 
generations. Screening of polymorphic microsatellite markers located on 
 chromosome 2, 3, and 14, verified the SHRSP lineage of each of the transgenic 
animals. These markers are used for routine screening of SHRSP, WKY and 
congenic strains at the BHF GCRC (See appendix). 
 
Due to mandatory quarantine period and health status issues (mycoplasma 
infection), transgenic founders were held within a Category III suite at the 
University of Glasgow and mated with SHRSP females from the Glasgow colony. 
All offspring were screened and transgenic positive males and females were 
mated to ‘fix’ the two independent transgenic lines (Trans1 and Trans2). 
Transgenic lines underwent caesarean re-derivation to ‘clean’ the health status 
(i.e. remove all mycoplasma infection) by fostering caesarean derived transgenic 
pups onto clean Sprague Dawley foster mothers who had just littered down. 
These ‘clean’ transgenic pups subsequently were interbred within each line for 
the establishment of the transgenic lines.  
 
Trans2 animals, while showing a strong positive screening for the transgene, 
showed reduced fertility. This infertility led to difficulties with acquiring enough 
Trans2 animals to sustain the line, and generating enough stock animals to 
incorporate into the study. Because of this, it was not possible to include Trans2 
animals into every experiment carried out within the project.    
 
2.1.2 Hemodynamic Profile 
2.1.2.1 Blood Pressure measurements by Tail Cuff Plethsymography 
Measurement of systolic blood pressure was carried out using the well 
established method of tail cuff plethysmography as described previously (224). 
Rats were preheated at 30°C for 20 minutes in an insulated box to insure 
vasodilatation of the tail artery. Rats were then manually restrained by being 
wrapped in a soft cloth and an inflatable cuff placed on their tail along with a 
piezoceramic transducer (Hartmann &Braun type 2) for pulse detection. The 
pressure in the cuff is controlled in 1mmHg steps over a 300 mmHg range by 
pressure control unit (designed and built “in house” by DCBP Electronics, 
(Southern General Hospital, Glasgow). Multiple cuff inflation and deflation steps 
were carried out through the duration of each tail cuff session and the resulting 
pulsatile signal detected by the transducer was visualized as a function of 
 pressure and displayed on computer using Microsoft Windows compatible 
software. At least 8 of 10 readings were recorded, with the highest and lowest 
readings being discarded, and the remaining readings averaged for a single 
session value.  
2.1.2.2 Blood Pressure measurements Telemetry  
 At 12 weeks of age, radiotelemetry probes were surgically implanted under 
sterile conditions into the abdominal aorta as previously described in (225;226) 7 
days after implantation before baseline blood pressure measurements were 
recorded. Systolic blood pressure (SBP), Diastolic blood pressure (DPB), Mean 
arterial blood pressure (MAP), pulse pressure (PP), heart rate (HR) and motor 
activity were measured using The Dataquest IV telemetry system (Data Sciences 
International) as previously described in (227). Briefly, Heart rate, blood 
pressures, pulse pressure, and activity were recorded for 10 seconds every 5 min 
throughout the day and night. The results from each rat were averaged to weekly 
day and night averages using an excel spreadsheet macro. The telemetry 
recording equipment includes a transmitter (radio frequency transducer model 
TA11PA), receiver panel, consolidation matrix 4650, and a dedicated computer 
with accompanying software. All radio transmitter devices (probes) were 
calibrated and confirmed to be accurate within ±3 mm Hg before being 
implanted.  
Implantation of radio-telemetry probes was carried out while rats were 
anesthetized with 2.5% Isofluorane in 1.5 L/min 02 for the duration of the 
surgical implantation process. After anesthetization, but before the start of the 
surgery, Carprofen (5 mg/kg) a non-steroidal anti-inflammatory analgesic was 
administered for pain control. The radio-telemetry probe was then inserted into 
the descending abdominal aorta pointing towards the proximal end of the animal 
(i.e. towards the heart), against the flow of blood, and was sutured to the 
abdominal wall in order to reduce movement of the probe while implanted. 
Following surgery, rats where housed in individual cages that were placed upon 
the receiver panel and monitored daily. The rats were free to roam about the 
cages and to feed and drink ad libitum.        
 
 2.1.3 Echocardiography  
Transthoracic echocardiography was used to assess cardiac geometry and 
contractility, as previously described (228;229). Echocardiography was performed 
prior to sacrifice at 21 weeks of age. Animals were sedated and short axis 2-
dimensional B-mode and M-mode images were taken through the left parasternal 
window at the papillary muscle levels using ACUSON Sequoia C512 
Echocardiograph, which is capable of both 2-D and 3-D multiple frequency 
imaging. Averaged data from six consecutive cardiac cycles from each M-mode 
tracing were used in the following equation for the calculation of left ventricular 
mass (ASE-cube formula with Devereux correction factor) (LV mass =0.8 
[1.04[(EDD + PWT + AWT)3 – EDD3]]+0.6). Where PWT = Posterior wall thickness 
(mm), AWT = Anterior wall thickness (mm), EDD = End diastolic dimension (mm). 
LV end-systolic volume (ESV) and LV end-diastolic volume (EDV) can be 
calculated from two-dimensional images according to a modified Simpson’s rule. 
LV ejection fraction (LVEF) is then determined from EDV and ESV. Cardiac index 
is estimated as cardiac output adjusted for tibia length 
 
2.1.4 Metabolic Cages 
Metabolic cages were used for housing individual rats for the collection of urine 
and the monitoring of water in-take for baseline and salt-loading studies. 
Telemetered rats were housed in metabolic cages at 16 (baseline) and 21 weeks 
for a 24 hour time period. For acclimation purposes, 15 week old rats were 
housed in metabolic cages for a 4 hour period prior to baseline measurements. 
Metabolic cages differ from standard cages by an upper chamber with a support 
grid that allows to rat to stand while allowing urine and feces to pass through the 
grid and into a funnel which separates and collects the feces and urine. A small 
feeder and marked water bottle on the outside of the cage allows access to 
standard rat chow and regular or salt-loaded water. Urine that was collected was 
kept on ice and stored at -80° C, until required for biochemical analysis.  
 
 2.2 Ex vivo Experimental Procedure      
2.2.1 Tissue Preparation        
At sacrifice animals were terminally anesthetized by isoflurane. The thoracic 
cavity was opened to expose the heart and blood samples were collected by 
cardiac puncture with a 23 gauge needle. Tissues, such as: kidneys, spleen, liver, 
aorta, heart, carotid arteries, fat, brain, adrenals and skeletal muscle,  were 
harvested and snap-frozen in liquid nitrogen and stored at -70°C for RNA, DNA or 
protein extraction. 
For histological assessment, tissues were blotted on tissue paper to remove 
excess blood and any additional surrounding connective tissues were separated 
from the vascular tissue immediately after harvest. Tissues were then fixed in a 
10% formalin solution overnight at room temperature and subsequently 
transferred into PBS. The fixed samples were later embedded in paraffin blocks 
by trained technical staff in the laboratory. Paraffin section of 3-6 µm thickness 
were cut and baked onto silanized slides at 60°C for 3 hours followed by 40°C 
overnight. Both the paraffin blocks and sections were kept at room temperature 
and stored in appropriate boxes. Transverse cross sections of kidney and aorta 
were used. 
Thoracic aortas and mesenteric resistance arteries were harvested and taken to 
determine endothelial function by wire and vessel morphology by pressure 
myography (see section 5.2.4-5.2.5). Blood samples collected in heparin and/or 
EDTA lined tubes during sacrifice were kept on ice until centrifugation at 2400 
RPM for 20 mins at 4°C. Plasma was then extracted and stored at 80° C for renal 
function experiments.  
 
2.2.2 Organ Mass index     
Organ mass indices for whole heart, left ventricle plus septum, and kidneys were 
measured at time of tissue collection. At sacrifice organs were removed, blotted 
to remove excess blood and weighed. Organ weights were corrected for body 
weight or tibia length. After sacrifice a scalpel was used to expose the knee and 
ankle joint on an extended hind limb, the tibia length was determined using a 
 double-pointed drawing compass and was subsequently measured with a ruler. 
Both body weight and tibia length were used to assess organ mass indices, and 
both methods of measurements showed similar trends and significance for 
results.  
 
2.2.3 Histology  
2.2.3.1 Histological Assessment of Gross Pathological Changes  
Histological analysis was used to assess cardiac and renal pathological changes by 
examining haematoxylin and eosin (H&E) stained sections. Fibrosis was examined 
by staining with picrosirius red where microscopic analysis and a colour threshold 
application were used to measure the average intensity of picrosirius red stain of 
fibrotic tissue. 
2.2.3.2 Immunohistochemistry       
Sections cut to 6 µm thickness were de-parafinised and hydrated by 2x7 minute 
washes in Histoclear before going down an ethanol gradient of 100%, 95% and 75% 
for 7 minutes at each stage. Sections were then washed in water for 7 minutes. 
Endogenous peroxide was then quenched by incubating slides for 30 minutes in 
0.3% H2O2 (10ml 30% to 1L) in methanol at room temperature. Sections were then 
rinsed in 2 x 10 minute water washes. Sections were blocked for 60 minutes with 
2% normal serum in PBS (2 drops of ABC kit blocking serum in 5ml PBS or 100µl 
appropriate serum in 5ml PBS). Slides where placed in humidified trays in order 
to prevent slides from drying out. Excess blocking reagent was removed and 
replaced with 1°Ab/antiserum or negative control diluted in blocking serum for 
overnight at room temperature. The following day, sections underwent 3x5 
minutes washes in PBS. A  biotinylated 2°Ab antibody, diluted in blocking 
reagent (ABC universal kit, 2 drops blocking serum + 2 drops supplied vectastain 
biotinylated antibody + 5ml PBS) was added for a 30 minute room temperature 
incubation. This was followed by 3x5 minute PBS washes. If the ABC 2°Ab 
antibody was used, and ABC complex was added to the sections and incubated 
for 30 minutes at room temperature. This was followed by 3x5 minute PBS 
washes. DAB chromogen (DAB substrate kit) for universal and peroxiase 2°Ab 
antibody was prepared following manufacturer’s instructions. Sections were 
 incubated for 5 minutes at room temperature in a humidified chamber and then 
washed for 5 minutes in water. Sections were counterstained with Haematoxylin 
for 90-120 seconds and placed under a running tap for 5 minutes. Sections were 
then dehydrated through a reverse ethanol gradient of 70%, 95% and 100% for 7 
minutes at each stage. Immediately following, sections then washed 2x’s in 
Histoclear for 7 minutes and mounted using Histomount (National Diagnostics, 
GA, USA). 
   
2.2.3.3 Heamatoxylin and Eosin Staining – cardiac and renal remodelling 
Kidney sections from WKY, SHRSP, Trans1 and Trans2 were stained with Harris 
haematoxylin for 2 minutes, washed under a running tap for 5 minutes and 
transferred to eosin for 1 minute before final 5 minute water wash. Sections 
were then dehydrated through a reverse ethanol gradient of 70%, 95% and 100% 
for 7 minutes at each stage. Immediately following, sections then washed 2x’s in 
Histoclear for 7 minutes and mounted using Histomount (National Diagnostics, 
GA, USA). Examination and analysis was performed under a microscope where 
nuclei appeared purple and cytoplasm pink.   
2.2.3.4 Fibrosis staining and measurement 
Fibrosis was assessed in renal sections from WKY, SHRSP, Trans1 and Trans2 rats 
using picrosirius red (Sigma-Aldrich, UK) which stains collagen type I and type III 
fibres bright red. After the removal of paraffin, sections were incubated under 
dark conditions in 0.1% picrosirius red solution for 90 minutes at room 
temperature, followed by 2 x 5 minutes washes in 0.01 N HCl and 1 x 5 minute 
wash under a running tap. Sections were then dehydrated through a reverse 
ethanol gradient of 70%, 95% and 100% for 7 minutes at each stage. Immediately 
following, sections then washed 2x’s in Histoclear for 7 minutes and mounted 
using Histomount (National Diagnostics, GA, USA) and cured overnight on the 
bench top. Collagen was stained various shades of red, with the cytoplasm 
yellow. 
 
 
 2.2.4 GFR 
 Indirect glomerular filtration rates (GFR) were determined by measurement of 
urine and plasma ceatinine concentrations. The equation (urinary creatinine 
concentration   X urine flow rate) / plasma creatinine concentration was used to 
calculated GFR. All measurements were determined by a clinically validated 
automated analyzer (c311, Roche Diagnostics, Burgess Hill UK), using the 
manufacturers calibrators and quality control material for Isotope dilution-mass 
spectrometry (IDMS). All calculations were normalized to kidney weight.  
 
2.2.5 Oxidative Stress Measurements    
2.2.5.1 Lipid Peroxidation (Malondialdehyde) Assay   
Samples were homgenized by polytron in 1ml of freshly prepared homogenisation 
buffer (10µl 0.5M BHT/acetonitrile per ml PBS) for every 100mg of tissue. 
Samples were immediately placed on ice until they were transferred into a 2ml 
Eppendorf tube and centrifuged at 3000g at 4°C for 10 minutes. If the samples 
were still turbid, supernatant was placed in a new eppendorf tube and 
centrifuged again. Standards and samples were transferred into a deep 96 well 
plate where 325µL of MDA cocktail was added to standards & samples. Plate was 
then sealed and placed in an oven for 1 hour at 45°C. Samples were then 
centrifuged at 2450g in 15 minutes at 4°C. 200µl of supernatant was transferred 
to a flat-bottom 96-well plate and absorbance was read at 586nm using a 
SpectraMax. 
 
2.2.5.2 Glutathione Assay  
 Glutathione levels were measured according to Cayman Glutathione Assay Kit 
(#703002) manufacturer’s instructions. Briefly, liver, heart, brain, kidney, and 
aorta tissue was homogenized in 1x MES buffer provided in kit in a bijou contain 
using a polytron (1ml for every 0.2g tissue). Homogenates were transferred to 
2ml Eppendorf tubes and centrifuge at 10,000g for 15min at 4°C. Supernatant 
was transferred to a new 2ml Eppendorf and kept on ice. A 25 µL aliquot was 
reserved for protein measurement by BCA assay (see section 2.6.2). Fresh MPA 
reagent (5g MPA in 50ml H2O) was prepared and used within 4hrs at 25°C. Equal 
 volumes of MPA were added to each sample. Samples were immediately vortexed, 
allowed to rest for 5 minutes at room temperature and then centrifuged 
at >2000g for 3 minutes. Supernatants were then transferred to a 2ml Eppendorf. 
300 mls of each sample was transferred to a new 1.5 Eppindorf and 15 µL of 4M 
TEAM reagent (531µl triethanolamine + 469µl H2O) was added to each sample 
and vortexed. Standards for measurements were set up according to 
manufacturer’s instructions.  
For measuring GSSG, a 100µL aliquot of standards and samples was removed to 
new tubes. 1µl of 1M 2-vinylpyridine solution (108µl 2-vinylpyridine + 892µl EtOH) 
was added to each of the 100µl aliquots. Samples were then vortexed and 
incubated at room temperature for 60 minutes.  
Once GSSG samples were ready, 50µl of all samples (Total GSH and GSSG) were 
added to a clear 96-welled plate. Fresh Assay Cocktail was prepared (MES buffer, 
Cofactor Mixture, reconstituted Enzyme mixture, water, and reconstituted DTNB) 
according to protocol. The cocktail was added to the entire plate within 2 
minutes using a multi-channel pipette. The plate was then covered and 
incubated in the dark on an orbital shaker for 25 minutes. Absorbance was read 
at 405nm on a SpectraMax. 
 
2.2.5.3 Hydrogen Peroxide Assay  
 Hydrogen Peroxide levels were measured using Invitrogen’s Amplex® Red 
Hydrogen Peroxide/Peroxidase Assay Kit Amplex Red (Invitrogen) according to 
manufactures instructions for tissues. The Amplex Red Assay uses 10-acetyl-3,7-
dihydroxyphenoxazine (Amplex® Red Reagent) to detect hydrogen peroxide 
(H2O2) or peroxidase activity. In the presence of peroxidase, the Amplex® Red 
reagent reacts with H2O2 in a 1:1 stoichiometry to produce the red-fluorescent 
oxidation product, resorufin, where absorbance can be measured at 560 nm using 
a microplate reader.  
2.2.5.4 Lucigenin Chemiluminescence   
Protein was extracted from frozen tissue in a ROS protease inhibitor cocktail 
buffer (aprotinin, leupeptin, and pepstatin) using a pellet pestle in 1.5mL 
 Eppendorf on ice. Protein concentration was measured by BCA (see section 2.6.2) 
assay for analysis purposes. Basal levels of reactive oxygen species were 
measured using a luminometer by adding 175 µl of ROS buffer, 1.25µl of 
lucigenin and 50µl of sample. Immediately following basal activity, 25µl NADPH 
(1mM) was added to each sample and fluorescence was measured again. The 
average of 30 readings for each samples from both the basal and NAPDH 
recordings were used to calculate the change in lucigenin activity using the 
formula (NAPDH-BASAL) RLU/µg protein. RLU stands for relative lights unit in the 
Berthold Detection Systems MPL2 Luminometers. The intensity of the emitting 
light is proportional to the amount of enzyme present and is directly related to 
the amount of HGH antigen in the sample. By reference to a series of HGH 
standards assayed in the same way, the concentration of HGH in the unknown 
sample is quantified 
2.2.5.5 Griess Assay 
Total nitrate and nitrite concentrations were measured using the Cayman 
Biochemical Nitrate/Nitrite Colorimetric Assay Kit. All steps were followed using 
the manufacturer’s instructions and recommendations. In short, the assay kit 
uses a simple two-step method for measuring the nitrite to nitrate ratio. The 
first step consists of converting nitrate to nitrite utilizing a nitrate reductase 
(Sulfanilamide/ Greiss Reagent 1). The second step is the addition of 
ethylenediamine/ Greiss Reagent 2 which turns nitrite into a deep purple azo 
compound. This azo chromophore conversion allows for a photometric 
measurement of the absorbance at 540 nm for an accurate quantification of NO2- 
concentration. In order to measure nitrite alone (to attain the nitrite and nitrate 
ratio), the assay was performed a second time on the tissue samples without the 
addition of Griess reagents. Standards and samples for each assay were 
transferred into a flat bottom 96 well plate and absorbance was read at 540 nm. 
Determination of Nitrite and Nitrate samples was according to manufacturer’s 
instructions.  
 
 
 2.2.6 Wire Myography   
For examination of functional response and vascular reactivity, small (3rd order) 
mesenteric arteries (MRA) and thoracic aortas were harvested at 21 weeks of 
age. The vessels were dissected from connected tissue and stored in Krebs buffer 
overnight at 4 °C before use. For mesenteric arteries, a 2 mm (approximately) 
length of artery was mounted onto two stainless steel wires on a four channel 
small vessel myograph (Danish Myotechnology, Denmark). Changes in force were 
measured by connecting the force transducer to a myo-interface and were then 
recorded using a data acquisition package (ADI Instruments Powelab systems). 
The vessels were maintained in Krebs buffer (0.25 M NACl; 0.001 M KCL; 2 
mMMgSO4; 50 mMNaHCO3; 2 mMKH2PO4; 2 nM CaCl2) warmed to 37̊ °C and 
bubbled with 95% O2 and 5% CO2 (pH 7.4). Following a 30 minute equilibrium 
period, vessels were set to a normalized internal diameter in order to achieve 
optimal contraction. Internal diameter was calculated using the following 
equation, L1 = 0.0*L100. L100 was determined using the LaPlace equation where 
effective pressure (P) equals wall tension (T) divided by the internal rediau (P = 
T/r). After 1 hour, contractile response of the vessel was tested by a pre-
treatment of KCL (10 uM) to determine the maximum active tension development 
that allowed for standardization of initial experimental conditions. Vessels were 
then washed 4 or more time with Krebs buffer and were allowed to rest for at 
least 30 minutes. A cumulative concentration curve of noradrenalin, 10 mM to 
30mM, was performed. Immediately following the noradrenalin addition, a 
carbachol dose response curve, 10 nM to 10µM, was performed in order to 
ascertain the % relaxation in response to the stimulated contraction. The dose 
response curves were followed by a Krebs buffer wash out to baseline. The 
noradrenalin curve was then repeated in the presence of L-NAME (100µm). The 
resulting increase of tension caused by L-NAME provided a measure for the effect 
of nitric oxide on basal tone. The percentage of maximum contraction was 
calculated in response to the noradrenalin without L-NAME.  
For aortic measurements, a ring of 4 mm (approximately) length was mounted on 
a large wire myograph (Danish Myotechnology, Denmark). Aortic rings were 
stretched to 1.5 newtons over a period of 40 minutes in order to equilibrate. 
Changes in force were measured by connecting the force transducer to a myo-
interface and were then recorded using a data acquisition package 
 (DanishMyoTech p100 pressure system, Denmark). All procedures steps are as 
explained in the previous paragraph with the exception that noradrenaline was 
replaced with phenylephrine.   
 
2.2.7 Pressure Myography        
In order to assess the pressure-diameter relationship differences between SHRSP, 
WKY and transgenic lines, pressure-diameter relationships were constructed to 
examine the structural and mechanical differences in mesenteric resistance 
arteries (DanishMyoTech p100 pressure system, Denmark) 
Third order mesenteric arteries without side branches were dissected out of the 
surrounding connective tissues, cleaned, and placed in a calcium free Krebs (0.25 
M NACl; 0.001 M KCL; 2 mMMgSO4; 50 mMNaHCO3; 2 mMKH2PO4; 1mM EDTA) 
solution overnight at 4̊ °C. The following morning the MRA was attached to the 
glass canulae within the myograph with nylon threads. During the attachment 
process, MRA were maintained in 10 ml cold Ca2+ free Krebs solution while one 
end was attached and the vessel lumen was gently flushed to remove any 
remaining blood before the second end was attached to the canulae. Krebs 
solution temperature within the canulae was raised to 37°C and was bubbled 
gently with 95% O2 and 5% CO2. To equilibrate the MRA, a prolonged intraluminal 
pressure at 70 mmHg for 60 minutes was maintained. Immediately following, the 
intraluminal pressure was reduced to 10 mmHg and incremental pressure 
increases of 20 mmHg until 120 mmHg over a period of 60 mins. Measurements of 
internal (Di) and external (De) were measured and used to calculate structural 
parameters cross sectional areas (CSA) and wall to lumen ration using the 
following equations: CSA = (π/4) x (De
2-Di
2). Wall/lumen = (De
2-Di
2)/2Di. The 
following mechanical parameters were calculated according to the method of 
(Baumbach and Heistad, 1989). Circumferential wall strain, where D0 is the 
diameter at the lowest intraluminal pressure of 10 mmHg and Di is the observed 
internal diameter for a given pressure, equals (Di-D0)D0. Circumferential wall 
stress = (PxDi)/De-Di where P is the intraluminal pressure.            
    
 2.3 General Molecular Biology 
Any experiments involving RNA used autoclaved DEPC-treated dH20 or RNase-free 
water (Qiagen). All plastic-ware used for RNA work was pre-treated and RNase-
free (Life Technologies). Filtered RNase-free tips were used in all RNA work. 
Water used in any molecular was distilled water that was been autoclaved and 
referred to as sterile dH20.    
2.4  RNA Extraction 
2.4.1.1 Total RNA Extraction 
Total RNA samples were extracted using Qiagen RNeasy kits (Qiagen, Hilden, 
Germany) according to manufactures recommended instructions for fibrous 
tissues (Appendix C of RNeasy Handbooks). The resulting elute was then 
quantified by measuring 1.5 µL of RNA sample using the NanoDop DN-1000 
spectrophotometer spectrophotometer (NanoDrop Technologies LLC, Wilmington, 
Delaware USA) under the software program ND-1000 v3.2). Integrity of the 
extracted RNA was checked by Agilent. In brief, absorbance at 260 nm was used 
for quantification of nucleic acids with an optical density of 1 corresponding to 
40ng/µL RNA. Ratios of absorbance (260 nm/280 nm) of approximately 2.0 for 
RNA indicated that the nucleic acid preparations were sufficiently free from 
protein contamination which could compromise downstream experiments. In 
order to determine the most accurate quantification, averages of duplicates or 
triplicates readings were taken.   
 
2.4.2 DNase Treatment of Extracted Total RNA 
The RNA samples were extracted on DNase treated columns by electing to take 
the optional DNase-treatment step in the RNeasy handbook. This was done by 
following manufacturer’s recommended instructions where 80µL of DNase 
treatment (10µL DNAse 1 stock +70µL RDD buffer) was added to each sample and 
incubated at room temperature for at least 15 mins.  
 
 2.4.3 Reverse Transcription (RT)-PCR    
Reverse transcription was performed using the Applied Biosystems High Capacity 
cDNA Archive Kit (Applied Biosystems). All steps were performed according to 
manufacturer’s instructions. 1 µg of DNAse treated RNA samples were reverse 
transcribed into cDNA in a 100 µL reaction containing a final concentration of 1X 
RT buffer, 5mM MgCL2, 1mM dNTP mixture,1u/µL RNAsin (RNase inhibitor), 0.5 µg 
of random heximers, 15 u of AMV reverse transcriptase (Multiscribe) on a 96-well 
plate. For negative controls, additional reactions without reverse transcriptase 
were included.   The reaction was then placed on a thermocycler and underwent 
the following two-step reaction conditions: 25°C for 10 min, 37°C for 120 mins. 
The samples were then stored at -20°C until use.  
2.4.4 Real-Time Polymerase Chain Reaction  
Relative real-time RT-PCR quantitation of the samples was carried out in a two-
step RT-PCR assay using the Taqman Gene Expression Assays from Applied 
Biosystems in a multiplex reaction (if the gene of interest and β-actin reacts with 
the same efficiency). Each reaction consisted of 2.5 µL Taqman Expression PCR 
Master Mix, 1x VIC labelled β-actin or GapDH probe (housekeeper), 1X FAM-
labelled probe for the gene of interest, and 2 µL of cDNA in a final volume of 5 
µL in a 384-well plate. The comparative eeCT method was used for relative 
quantification of expression, normalized to β-actin or Gapdh (for heart tissue) in 
each sample and then expressed relative to SHRSP ABI PRISM 7700 Sequence 
Detection System User Bulletin #2). 
In order to use the eeCT, it was imperative to experimentally confirm that the 
amplification of efficiencies of the target and control gene PCRs were the same 
(i.e. that EX=ER). Therefore the amplification efficiencies of each gene 
expression assay were measured in duplex PCRs with either GapDH or β-actin 
assays using a serial dilution of template. This process was performed for all 
gene expression assays and custom gene expression assays for each cDNA 
template (e.g. for cDNA from heart, kidney, aorta, liver and brain). Each assay 
was assessed according to the Applied Biosystems guidelines. Each gene 
expression assay for mRNA from each tissue that was used in this study amplified 
efficiently        
 2.4.4.1 Real-Time Polymerasase Chain Reaction using SYBR Green: 
Real-time RT-PCR quantititation of the samples was carried out in a two-step RT-
PCR assay. The reactions were prepared using Applied Biosystems Power SYBR 
Green Master Mix. All reactions were completed in duplicate, including minus RT 
controls. Each reaction consisted of 2.5µL of cDNA sample (section2.4.3), 3.65µL 
of RNAse-free H2O, 100µM sense primer, 100µM antisense primer, and 6.25 µL of 
master mix in a 12.5 µL reaction.  
The following cycling parameters were used: 50ºC for 10 minutes, then 95ºC for 
10 minutes. This was followed by 40 cycles of 95ºC for 10 seconds and a 
combined annealing/extension temperature of 60ºC for 2 minutes. During each 
cycle of the PCR the fluorescence emitted by the binding of SYBR-Green to the 
dsDNA produced in the reaction was measured. To confirm the specificity of the 
reactions dissociation curves were constructed for each primer pair at 0.1ºC 
intervals between the temperatures of 60 ºC and 95ºC.  
  
2.5 Genomic DNA Preparation  
2.5.1 DNA Extraction 
Genomic DNA from SHRSP, transgenic, and WKY animals was extracted using 
Qiagen DNeasy kits (Qiagen, Hilden Germany) according to manufacturer’s 
instructions.    
2.5.2 Sequencing 
1-3 µg of genomic DNA, that was extracted as stated in 2.5.1, was digested 
separately with either HindIII or PstI restriction enzymes for 1.5 hours at 37° C in 
0.5 µL epindorf tubes. Resulting fragments were then ligated overnight at 16 °C 
with T4 ligase. Primers designed specifically for HindIII (GstmFragA) and PstI 
(GstmFragB) restriction sites were used as primers with the ligated templates for 
the first round of PCR amplification. First round PCR was performed using the 
primer sets GstmFragA (1+2) and GstmFragB (1+2):  
 GstmFragA 1- ATT GCA TGA AGA ATC TGC TTA GG 
GstmFragA 2- ACA AGC AGG GAG CAG ATA CTG GC 
GstmFragB 1- AAA GGA GTG GGA ATT GGC TCC GG 
GstmFragB 2- CAA CGC GTA TAT CTG GCC CGT AC 
Product from the first round PCR was utilized as a template for a second nested 
PCR reaction using nested Gstm1FragA (3+4) and nested Gstm1FragB (3+4) primer 
sets: 
GstmFragA 3- TGT ACG GGC CAG ATA TAC GCG TTG 
GstmFragA 4- GAG CAG ATT GTA CTG AGA GTG CAC 
GstmFragB 3- GGT AAA CTG GGA AAG TGA TGT CG 
GstmFragB 4- GAG CAG ATT GTA CTG AGA GTG CAC    
For a schematic view of this process pre refer to figure 4-11.  
The PCR reactions were run on the Pelteri Thermal Cycler (PTC-225) under the 
conditions 95 °C for 4 mins, 96 °C for 30s and 58 °C for 30s and 72 °C for 60s for 
35 cycles, then held at 72 °C for 7 min. In order to separated the amplified 
fragments, 15-20 µL of PCR reaction was electrophoresed with 3µL of 6X loading 
dye in a 1% agarose gel at 100V for 1.5 hours, alongside a 1Kb DNA ladder.  
DNA fragments that were considered the correct sizes were then isolated from 
the aragose gels by Qiaquick gel desolving kt (Qiaquick handbook pg 25) 
according to handbook instructions (Qiagen). Extracted DNA eluate was then 
quantified by measuring 1.5 uL of RNA sample using the NanoDop DN-1000 
spectrophotometer spectrophotometer (NanoDrop Technologies LLC, Wilmington, 
Delaware USA) under the software program ND-1000 v3.2, in which absorbance 
ratios of 260 nm/280 nm equalled approximately 1.8 for DNA. This indicated that 
the DNA preparations were sufficiently free from protein contamination. Like 
RNA samples, averages of either duplicate or triplicate measurements were 
taken for samples requiring precise quantification. 
Eluted DNA was then placed into a plasmid cloning kit (Stratoclone) and cloned 
according to manufacturer’s instructions (Stratoclone). Positive colonies were 
then screened and verified by 2% X-gal. Plasmid DNA was then prepped for DNA 
 sequencing using Qiagen Plasmid mini prep kit (Qiagen) according to 
manufacturer’s instructions. 
Plasmid DNA was sequenced by using Applied Biosystems  BigDye Terminater n3.1 
Cycle Sequencing kits. All reaction were performed on a 96 well plate and 
included included 3.5µl 5X sequencing buffer; 0.5µl Ready Reaction; 8µl 
template (100-200ng of plasmid DNA); ~3.2µl primer (2.0 µM Final); ~4.8µl H2O. 
The temperature program cycle was: 96°C for 45 secs, 50°C for 25 secs, 60°C for 
4 mins. Steps 1-2 repeated 25 times.  
Sequencing was initially analyzed on Applied Biosystems SeqScape software 
version 2.1 to see if fragments aligned to the genome. Fragments that were 
aligned were then analyzed without the use of computer software and each 
nucleic acid was examined in order to verify that the connecting sequences were 
novel and not erroneous transgene fragments. Experimental sequences were then 
aligned with known sequences derived from bioinformatic databases such as 
UCSC genome browser or ENSEMBL.  
2.5.3 Copy Number Variation  
Identification of the Gstm1 transgene across generations was determined in each 
transgenic line through Taq-man analysis. Copy number variation Taqman probes, 
SNP Genotyping Assay (Applied Biostystems) and SNP Gene Expression Assay 
(Applied Biosystems), were custom synthesized to a unique portion of the 
transgene construct.  The SNP Genotyping Assay was analyzed by Taqman 
Genotyper, a specifically designed analysis package developed by Applied 
Biostand for this assay. The SNP Gene Expression Assay was compared to a unique 
single copy gene (RNase P 30) that was custom designed for the genetic 
background of rats. Using the comparative (∆∆CT) method with additional steps 
as calculated by Applied Biosystems Copy Caller Software, copy number variation 
analysis was performed on the Taqman 7900. 
 2.6 Protein Extraction 
2.6.1 Protein Extraction 
Protein from tissues was extracted using a Hepes lysis buffer (50mM Hepes, 1mM 
DTT, 0.5% Tween, ph 7.4). On the night before extraction, one tablet of Roche 
EDTA-free protease inhibitor cocktail tablet was added for every 10 mls of Hepes 
lysis buffer used. The samples were homogenized in cold Hepes lysis buffer (1ml 
of Hepes buffer for up to 0.3g of tissue). The homagenates were kept on ice until 
centrifuged at 14,000 rmp for 10 mins at 4°C and the supernatant contain the 
protein was transferred to a new tube and kept on ice. 5µL of supernatant was 
removed to determine protein concentration by nanodrop. The rest of the 
protein was stored at -80 °C until needed.   
2.6.2 Protein Quantification 
The protein concentration of each sample was determined using a Peirce BCA 
(bicinchoninic acid) protein assay kit according to the manufacturer’s 
instructions. The bovine serum albumin (BSA) standards were diluted to 
appropriate concentrations for the standard curve while the protein samples 
were diluted accordingly to fit within the standards spectrum. Briefly, a standard 
curve was generated using the following BSA dilutions: 2000 µg/mL, 1500 µg/mL, 
1000 µg/mL, 750 µg/mL, 500 µg/mL, 250 µg/mL, 125 µg/mL and 25 µg/mL. 200 
µL of working reagent was added to 25 µL of sample or standard in duplicate in a 
96 well plate, and incubated for 30 minutes at 37ºC in the dark. The plate was 
then analysed on a Wallac Victor2 plate reader (Wallac, Turku, Finland) with 
absorbance at 570 nm. Results were then calculated according to the linear 
equation based on the standard curve generated. 
For measurement of proteinuria in urine samples, the Peirce 660 Protein Assay 
from Thermo Scientific was used. Pre-diluted samples were used and purchased 
from Thermo Scientific. Urine samples were diluted with water in order to fall 
within the working range of the pre-dilute samples.  10µL of each replicate of 
standard, unknown sample and the appropriate blank sample were added into a 
microplate well. 150µL of the Protein Assay Reagent was added to each well. 
Plate was then covered and placed on a plate shaker at medium speed for 1 
 minute and then left to incubate for 5 minutes at room temperature. The plate 
was then analysed on a Wallac Victor2 plate reader (Wallac, Turku, Finland) with 
absorbance at 570 nm. A standard curve was calculated by plotting the average 
Blank-corrected 660nm measurement for each BSA standard (see above for 
concentrations) vs. its concentration in µg/mL and then used to determine the 
protein concentration of each unknown sample.  
 
2.6.3 Gel Electrophoresis 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
western immunoblotting was used to detect the Gstm1 protein. First, samples 
were prepared at the appropriate concentration with 6x loading buffer 
containing: 10% weight/volume (w/v) SDS, 30% (v/v) glycerol, 10% (v/v) Tris-HCl 
pH 6.8, 0.01% (w/v) bromophenol blue and 2% (v/v) β-mercaptoethanol. Samples 
were heated at 95ºC for 5 minutes to denature the protein, mildly cooled and 
loaded into the well.  
The polyacrylamide (PA) gel consisted of a 4% stacking gel containing 13.3% (v/v) 
N,N’-methylene-bis-acrylamide (polyacrylamide 30%), 25% (v/v) Tris pH 6.8 (3.75 
mM), 0.1% (v/v) SDS, 1% (v/v) ammonium persulphate (APS) and 0.1% (v/v) of 
N,N,N’,N’-Tetramethylethylenediamine (TEMED). Since the molecular mass for 
Gstm1 was 26 kDa, a 12% resolving gel which contained 40% (v/v) of PA (30%), 
25% (v/v) of Tris pH 8.8 (11.25 mM), 0.1% (v/v) SDS, 1% (v/v) APS and 0.1% (v/v) 
TEMED was used.  
Following sample loading, gels were electrophoresed at 100 V through the 
stacking gel, then switched to 200 V for electrophoresis through the resolving gel 
in running buffer (0.025 M Tris-HCl, 0.2 M glycine, 0.001 M SDS) for 
approximately 2 hours. Protein was then transferred to Hybond-P polyvinylidene 
difluoride membrane (Amersham Bioscience UK Limited, Buckingham, UK), to 
enable antibody binding and detection. Protein transfer was performed using an 
electric current which promotes protein migration from the gel to the 
membrane. Protein transfer was performed using the semi-dry method at 75 mV 
for 45 mins. 
 2.6.4 Western Immunoblotting 
Once proteins were transferred to the membrane, antibody detection was 
performed. The membranes were first blocked in TBS-T [150 mM NaCl, 50 mM 
Tris, 0.1% (v/v) Tween-20] + 10% (w/v) fat-free milk powder (blocking buffer) for 
8 hours at 4ºC. Membranes were incubated with rabbit anti-rat Gstm1 polyclonal 
antibody (gift from Prof. John Hayes, University of Dundee)diluted in blocking 
buffer at the 1:5000 dilution overnight at 4ºC with shaking.  
Following overnight incubation the membrane was washed twice in blocking 
solution for five minutes each at room temperature, followed by incubation with 
an 1:2000 dilution of the appropriate secondary antibody, goat anti-rabbit IgG 
secondary antibody conjugated to horseradish peroxidase (HRP) (Neomarkers, 
Fremont, CA, USA) for 1 hour at room temperature with shaking. The membrane 
was then washed six times for 15 minutes each at room temperature with 
shaking, four times with blocking solution and two times with tris buffered 
saline-tween (TBS-T). Proteins were visualized using Enhanced Chemiluminescent 
(ECL) Detection System (Amersham Biosciences UK Limited, Buckingham, UK) 
following the manufacturer’s instructions. Films were exposed for various lengths 
of time, ranging from 10 seconds to 35 mins. 
 
2.7 Statistical Analysis 
In vivo phenotypic measurements were performed with 6 to 8 rats per group. 
Results are expressed as mean +/- standard error of the mean (SEM) unless 
otherwise stated. Repeated measures ANOVA was used to compare 
radiotelemetry data between groups, as described previously (Davidson et al., 
1995). Briefly this was a general linear model ANOVA using a Tukey pair-wise 
comparison. Statistical significance was considered with p values of < 0.05. Other 
comparisons between groups for the in vivo measurements  were performed by 
one way ANOVA with Tukey’s multiple comparison test, unless stated otherwise, 
and statistical significance was considered with p values of <0.05. Statistical 
analyses were performed using GraphPad Prism 4. *, **, *** represents p<0.05, 
p<0.01 and p<0.001 versus SHRSP, respectively. 
 Ex vivo experiments were performed with 4 to 8 rats per group as described in 
each figure’s legend. Results are expressed as mean +/- standard error of the 
mean (SEM), unless otherwise stated. Statistical significance was considered with 
p values of < 0.05. Comparisons between groups were performed by one way 
ANOVA with Tukey’s multiple comparison test, unless stated otherwise. Area 
under the curve was calculated from organ bath and myography response curves 
with one way ANOVA and Tukey’s multiple comparison test used to determine 
significance between the 4 strains of animals. Statistical analyses were 
performed using GraphPad Prism 4. *, **, *** represents p<0.05, p<0.01 and 
p<0.001 versus control. 
Molecular experiments were performed with 3 to 8 rats per group as described in 
each figure’s legend. Results are expressed as mean +/- standard error of the 
mean (SEM), unless otherwise stated. Statistical significance was considered with 
p values of < 0.05. Comparisons between groups were performed by one way 
ANOVA with Tukey’s multiple comparison test, unless stated otherwise. Tukey’s 
multiple comparison test used to determine significance between the 4 strains of 
animals. Statistical analyses were performed using GraphPad Prism 4. *, **, *** 
represents p<0.05, p<0.01 and p<0.001 versus control. 
Human translational experiments for gene expression were analyzed using Prism 
graph pad using student’s t-test or 1-way ANOVA as appropriate. Initial SNP 
quality checking included estimation of allele frequencies using the Hardy-
Weinberg equilibrium.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
3 In vivo Phenotypic Characterization of the 
Gstm1 transgenic SHRSP rat 
 
  
  
3.1 Introduction 
Studies in human and experimental medicine have shown that increased 
oxidative stress is associated with increased blood pressure (230;231). In 2000, 
Vaziri et al. reported that oxidative stress and arterial hypertension were 
produced in normal Sprague-Dawley rats through glutathione depletion by oral 
administration of buthione sulfoximine (BSO) (160). These findings are supported 
by other studies where the induction of chronic oxidative stress by glutathione 
depletion has been shown to cause severe hypertension in normotensive rats  
(230-232). Additionally, studies by McBride et al. have implicated that decreased 
renal Gstm1 levels contribute to the development of oxidative stress and 
hypertension in the stroke-prone spontaneously hypertensive rat (SHRSP) rat via 
reduced antioxidant defences (96).  
The SHRSP is a well characterized experimental model for human essential 
hypertension and stroke. Some of the characteristics in common between the 
SHRSP and human essential hypertension are; adult onset of hypertension and 
the continued increase of blood pressure with age, sexually dimorphic blood 
pressure levels, and proneness to stroke (227). The hypertensive phenotype in 
the SHRSP results in an increased cardiac workload and an impaired mechanical 
performance that contributes to cardiac hypertrophy (233). These similarities 
with human essential hypertension make the SHRSP one of the best existing 
models of human cardiovascular disease (36;37;84). The SHRSP model 
demonstrates an imbalance between nitric oxide (NO) and superoxide (O2
-) levels 
leading to oxidative stress (78).This oxidative stress has been implicated in the 
development of vascular endothelial dysfunction and renal pathology (234;235). 
Oxidative stress is an important pathogenic factor in the development of 
cardiovascular diseases and increased production of reactive oxygen species 
(ROS) and/or reduced defences against ROS not only leads to endothelial 
dysfunction, but also causes structural damage to tissue and organs, and is 
considered a major contributor to cardiac pathologies (231;236;237). Studies 
demonstrating that reduced Gstm1 protein expression in the SHRSP is associated 
with increased oxidative stress (96) implicate Gstm1 as an important functional 
candidate for development of endothelial dysfunction and hypertension. In 
 addition, pharmacological intervention studies and mRNA expression data in the 
SHRSP provide evidence to support a causal role for Gstm1 in the development of 
hypertension (13). For example, significantly reduced renal Gstm1 expression 
levels are already evident in 5-week old SHRSP before the onset of hypertension 
(238). Moreover, reduced expression of Gstm1 in the SHRSP could not be 
improved by antihypertensive treatment (i.e. the angiotensin II type 1 receptor 
blocker, losartan) during either reversal studies (i.e. established hypertension) or 
prevention studies (i.e. development of hypertension). These data suggest that 
altered Gstm1 expression may contribute directly to the pathogenesis of 
hypertension and is not an adaptive response caused by long-term differences in 
blood pressure. 
It is generally accepted that the gold standard for proving causality of a 
functional candidate gene is to perform a transgenic knockdown or rescue 
experiment (Include a REF). Accordingly, in this project we aimed to 'rescue' the 
deficiency of Gstm1 in the SHRSP by incorporation of a normal Gstm1 gene from 
WKY into the SHRSP genome under the control of the universal EF-1α promoter. 
As detailed in the Materials & Methods section (Chapter 2), two novel and 
independent SHRSP transgenic lines have been generated through a joint 
collaboration between Glasgow University and Prague’s Academy of Sciences 
(Drs. Michal Pravenec and Vladimir Landa). SHRSP males and females were sent 
to Prague where the transgenic procedure was performed. This consisted of 
female SHRSP rats being super-ovulated and time-mated with male SHRSP rats. 
On day one of ovulation, embryos were harvested and injected with a linear 
construct that consisted of the EF-1α promoter and Gstm1 WKY gene. The 
embryos were then transferred into recipient females and normal gestation 
allowed to progress. Offspring were screened for insertion of the transgene and 
positive 'founder' animals were transferred to the University of Glasgow. This 
process generated two independent transgenic lines (Trans1 and Trans2). 
The understanding of cardiovascular changes that are related to oxidative stress 
in the SHRSP rat will be important for the elucidation of mechanisms underlying 
human essential hypertension. The aim of this chapter was to phenotypically 
characterize the two independently generated transgenic rat lines, and establish 
definitive proof that defective Gstm1 expression plays a functional role in blood 
pressure elevation and cardiovascular dysfunction. This was carried out though 
 examination of the effects of transgenic expression of wild type Gstm1 on (1) 
hemodynamic parameters in the SHRSP, (2) examination of the cardiac function 
and mass through echocardiography. 
3.2 Materials and Methods 
3.2.1 Hemodynamic Measurements 
3.2.1.1 Tail cuff Plethysmography 
Measurement of systolic blood pressure was carried as described in the main 
methods section (Section 2.1.2.1). Male rats starting from the age of 5-8 weeks 
old, depending upon size, were tail cuffed every week in order to measure SBP 
until the implantation of telemetry probes at 12 weeks of age. Multiple cuff 
inflation/deflation values were obtained through the duration of each tail-cuff 
session and an average was taken for each animal. For SHRSP, WKY and Trans1, 
n=3 or more for each weekly reading; however, for Trans2 we n numbers were 
generally low (i.e. n=2) due to poor breeding performance. 
3.2.1.2 Telemetry 
3.2.1.2.1 Base line and salt loading 
Baseline blood pressure characteristics were investigated by implantation of 
radio-telemetry probes (TA11PAC40) at 12 weeks of age and data was 
continuously recorded until 21 weeks of age in male WKY, SHRSP, Trans1, and 
Trans2 rats (n=7-8). In salt-loaded rats blood pressure characteristics were 
investigated in male WKY, SHRSP and Trans1 given 1% NaCl in the drinking water 
ad libidum for 3 weeks, starting at the beginning of week 18.  Radiotelemetry 
measured systolic blood pressure (SBP, mmHg), diastolic blood pressure (DBP, 
mmHg), pulse pressure (PP, mmHg), heart rate (beats per minute, BPM) and 
motor activity (arbitrary units, AU). All hemodynamic measurements were 
carried out as described in section 2.1.2.2.   
 
 3.2.2 Echocardiography 
Transthoracic echocardiography was performed on lightly anesthetized rats 
(1.25%-1.5 % isoflourane in 1.5 Liters/min O2) placed in the left lateral decubitus 
position. Left ventricular motion mode (M-mode) measurements at the level of 
the papillary muscles were used to delineate wall thicknesses and internal 
diameters at systole (s) and diastole (d). Images were captured using an Acuson 
Sequoia C512 ultrasound system and then used to assess cardiac geometry and 
contractility, as previously described (228;239). Echocardiography was performed 
prior to sacrifice at 21 weeks. Cardiac index was estimated as cardiac output 
adjusted for tibia length. A typical echocardiogram examination lasts for 
approximately 5-10 minutes, from induction of anaesthesia. For further 
information please see section 2.1.3. 
3.2.3 Tissue Collection 
Animals were sacrificed at 21 weeks of aged. Tissues were excised and any 
excess blood removed before weighing kidneys, whole heart and left ventricular 
plus septum after dissection. This was corrected to tibia length. Further detail as 
described in section 2.2.2. 
 
3.2.4 Statistics 
Telemetry data was analyzed using a repeated measures ANOVA followed by a 
Tucky’s post-hoc correction for multiple comparisons. Week one of the 
hemodynamic measurement period is a recovery period and has not been 
included in the statistical analysis. Pulse pressure diurnal variation and 
echocardiography data was analyzed using a one way ANOVA followed by a 
Tukey’s corrections, unless stated otherwise. All data is displayed as mean with 
standard error of the mean. 
  
 3.3 Results 
3.3.1 Hemodynamic Measurements 
3.3.1.1 Tail Cuff data 
Rats were tail cuffed starting between 5 and 8 weeks of age. The variable start 
date was dependent upon rat size since the tail cuff transducer has a lower size 
limit, and appropriate fit is necessary to ensure accuracy of BP measurement. 
Baseline systolic blood pressure was significantly reduced in both transgenic lines 
and WKY (F = 8.35, p< 0.01) when compared to SHRSP (Table 3-1).  
3.3.1.2 Radio Telemetry Measurements – Baseline 
3.3.1.2.1 Systolic blood pressure 
At 12 weeks of age, rats underwent radio telemetry implantation and systolic 
blood pressure was measured by automated scheduled sampling every 5 mins. 
Raw data files were hourly averaged prior to exportation into an Excel 
spreadsheet where the data underwent analysis by a specifically designed Excel 
macro and were averaged into weekly daytime (7am-7pm) and night-time (7pm-
7am) data sets (Figure 3-1). SBP rises continuously over the full hemodynamic 
measurement period (between 12 – 21 weeks of age) for both SHRSP and WKY 
parental strains and the two transgenic lines. However, the rate of increase is 
greater in the SHRSP strain. Baseline systolic blood pressure was significantly 
reduced in both transgenic lines (F = 52.46, p< 0.001) where SBP averaged 175.6 
±6.22 mmHg for Trans1 rats and 174.2 ±6.36 mmHg for Trans2 rats, when 
compared to SHRSP 198.1 ±1.5 mmHg. While SBP in Trans1 and Trans2 rats was 
significantly higher than WKY (systolic 150 ± 4.7 mmHg, F=56.24, p<0.001), they 
were not significantly different from one another (F = 52.46, p> 0.05). 
3.3.1.2.2 Diastolic Blood Pressure 
DBP also shows a continuous rise over the full measurement period for SHRSP, 
WKY and Trans1 rats. However, this trend was less pronounced in Trans2 rats. 
Baseline diastolic blood pressure for Trans1 and Trans2 rats averaged 124.3 ± 
5.89 mmHg and 131.7 ±1.33 mmHg, respectively, while DPB for the parental 
strains were 137.8 ±9.3 mmHg and 107.1 ± 3.5 mmHg, for SHRSP and WKY 
 respectively. Repeated measure ANOVA determined that DBP for Trans1 and 
Trans2 lines were significantly different from both SHRSP and WKY (SHRSP: 
F=107.1, p< 0.001; WKY: F=107.1, p<0.001) (Figure 3-2). Additionally, while 
diastolic blood pressure in not significantly different 9 F=107.1, p>0.05), their 
slopes of lines are different.      
3.3.1.2.3 Pulse Pressure 
Pulse pressure between the parental strains, WKY (40.72 ± 0.65 mmHg) and 
SHRSP (59.68±0.308 mmHg) was significantly different (F=364.4, p<0.001). Pulse 
pressure in Trans 1 rats (51.79±0.411 mmHg) was significantly reduced when 
compared to the SHRSP (F=364.4, p<0.001) (Figure 3-3). While there is a large 
margin of error between animals for pulse pressure in Trans2 rats, the strain 
showed a significant reduction in pulse pressure (40.75±0.53 mmHg) when 
compared to the SHRSP and Trans1 rats (F=364.4, p<0.01). Additionally, pulse 
pressure in Trans2 was not significantly different to WKY rats (F = 364.4, p >0.05) 
(Figure 3-3).  
3.3.1.2.4 Heart rate and Locomotor Activity 
Heart rate and activity are illustrated in Figures 3-4 and 3-5. There were no 
significant differences in heart rates across the measurement period between 
the four strains (WKY: 334.4±6.0 BPM; SHRSP: 335.6±4.39 BPM; Trans1: 
324.7±5.29 BPM; Trans2: 323.0±5.59 BPM). Additionally, there was no significant 
difference in motor activity between the four strains (WKY: 2.965±0.33 AU; 
SHRSP: 2.965±0.30 AU; Trans1: 2.99±0.31 AU; Trans2: 3.1±0.27 AU).  
 
  
Table 3-1: Systolic blood pressure measured by tail cuff plethsmography measurements from 5-12 weeks   
                                           SHRSP                       WKY                       Trans1                      Trans2 
5 weeks 124 ±5.5 107.5 ± 5.38* ND ND 
6 weeks 113.9 ± 5.18 127.5 ± 4.98* ND ND 
7 weeks 152.8 ± 4.68 127.6 ±7.44* 126.5 ± 0.25* 100.3 ± 1.58* 
8 weeks 164.9 ± 5.76 136.2 ±4.97* 135.5 ± 0.85* 124 ± 0.25* 
9 weeks 188.2 ± 10.27 136.8 ±7.2* 142.3 ± 5.1* ND 
10 weeks 191.6 ± 8.3 139.7 ±8.38* 158.3 ±6.67* 88.93 ± 6.48* 
11 weeks 205.9 ±3.87 134.7 ±8.03* 168.3 ± 0.399* 172.5* 
12 weeks 197.9 ± 11.37 146.7 ± 5.74* 164.8 ± 7.23* 161.7 ± 5.55* 
Systolic blood pressure is significantly reduced in both transgenic lines and WKY rats compared to SHRSP *(p<0.001). Statistical analysis was 
done by repeated measures ANOVA. Values are presented as mean ± SEM. ND = not determined  
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Figure 3-1: Systolic Blood Pressure in Trans1, Trans2 and Parental Strains.  
Hemodynamic profile for Trans1 and Trans2 rats implanted at 12 weeks of age. 
Weekly average daytime and night-time values for male WKY (n=6), SHRSP (n=6), 
transgenic 1 (n=8), and transgenic 2 (n=6) rats. Systolic blood pressure is 
significantly reduced in both transgenic lines and WKY rats compared to SHRSP 
***(p<0.001). Statistical analysis was done by repeated measures ANOVA. Values 
are presented as mean ± SEM.  
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Figure3-2: Diastolic Blood Pressure in Trans1, Trans2 and Parental Strains.  
Hemodynamic profile for Trans1 and Trans2 rats implanted at 12 weeks of age. 
Weekly average daytime and night-time values for male WKY (n=6), SHRSP (n=6), 
transgenic 1 (n=8), and transgenic 2 (n=6) rats. Systolic blood pressure is 
significantly reduced in both transgenic lines and WKY rats compared to SHRSP 
***(p<0.001) *(p<0.05). Statistical analysis was done by repeated measures 
ANOVA. Values are presented as mean ± SEM.   
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Figure3-3: Pulse Pressure in Trans1, Trans2 and Parental Strains. 
Average weekly pulse pressure represented at night-time and day-time averages 
male WKY (n=6), SHRSP (n=6), Tran1 (n=8), and Trans2 (n=6) rats. Pulse pressure 
of transgenic animals was significantly lower than SHRSP. Pulse pressure in 
Trans1 rats was significantly increased from that of WKY; however, pulse 
pressure in Trans2 rats was not significantly different from WKY ***p<0.001 versus 
SHRSP. Statistical analysis was done by repeated measures ANOVA. Values are 
presented as mean ± SEM  
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Figure3-4: Heart Rate in Trans1, Trans2 and Parental Strains. 
Heart rate measured by radio telemetry, calculated as night-time and day-time 
averages, in male SHRSP (n=6), WKY (n=6), Trans1 (n=8) and Trans2 (n=6) rats 
from 12 to 21 weeks of age. There was no significant difference in heart rate 
between the different strains. Statistical analysis was done by repeated 
measures ANOVA. Values are presented as mean ± SEM.  
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Figure 3-5: Locomotor Activity in Trans1, Trans2 and Parental Strains. 
Motor activity measured by radiotelemetry in SHRSP (n=6), WKY (n=6), Trans1 
(n=8), and Trans2 (n=6) males rats from 12-21 weeks of age. Data calculated as 
day-time and night-time averages. There was no significant difference in motor 
activity between the different strains. Statistical analysis was done by repeated 
measures ANOVA. Values are presented as mean ± SEM. 
  
  
3.3.1.3 Radio Telemetry Measurements – 1% Salt Loading 
3.3.1.3.1 Systolic blood pressure 
Salt-loading with 1% NaCl from weeks 18-21 significantly elevated SBP in the 
SHRSP and Trans1 animals (SHRSP: Baseline 214.51 ± 5.12 vs. Salt 234.41 ± 5.79; 
Trans1: Baseline 183.13 ± 2.79 ± 5.12 vs. Salt 205.91 ± 4.56, p<0.05) as analyzed 
by t-test. There was no effect of salt loading on the WKY strain (Table 3-2). 
Salt-loaded systolic blood pressure measured from 18-21 weeks of age (Figure 3-
6) was significantly reduced in Trans1 rats (184.8±4.14 mmHg) when compared to 
SHRSP (205.2±5.58 mmHg) (F = 14.6, p< 0.001). Additionally, SBP in Trans1 rats 
and SHRSP was significantly higher than WKY (systolic 150.4 ± 1.39 mmHg, 
F=4.41, p<0.001). Due to breeding limitations, Trans2 rats were not included in 
the salt-loading protocol. 
3.3.1.3.2 Diastolic Blood Pressure 
Diastolic blood pressure was significantly elevated in the SHRSP and Trans1 
animals (SHRSP: Baseline 147.81 ± 5.66 vs. Salt 170.75 ± 5.21; Trans1: Baseline 
130.85 ± 2.79 ± 1.99 vs. Salt 150.49 ± 6.61, p<0.05) as analyzed by t-test. There 
was no effect of salt loading on the WKY strain (Table 3-2). 
Salt-loaded diastolic blood pressure (Figure 3-7) for Trans1 averaged 124.3 ± 5.89 
mmHg, while DPB for the parental strains SHRSP and WKY were 137.8 ±9.3 mmHg 
and 107.1 ± 3.5 mmHg, respectively. Repeated measures ANOVA determined that 
DBP for Trans1 rats was significantly different from both SHRSP and WKY (F 
=20.21, p< 0.001). 
3.3.1.3.3 Pulse Pressure 
Pulse pressure between salt-loaded WKY (39.45 ± 3.7 mmHg) was significantly 
reduced when compared to the SHRSP (58.41 ±3.1 mmHg) (Figure 3-8). Previous 
studies that investigated pulse pressure differences between salt-loaded SHRSP 
and WKY and congenic rats have identified an exaggerated diurnal variation in 
the SHRSP (240). Pulse Pressure for Trans1 was significantly different from both 
SHRSP and WKY (F = 11.80, p >0.0005). (Figure 3-8). Furthermore, diurnal 
 variation, the maximum difference between daytime and night-time pulse 
pressure, was significantly greater in the SHRSP (p < 0.0001) (Figure 3-8 Panel B) 
when compared to the WKY. Salt-loaded Trans1 rats displayed an intermediate 
phenotype where diurnal variation not significantly different from either the 
SHRSP or WKY (p>0.05). While there was an exaggerated diurnal difference in 
pulse pressure between the SHRSP and Trans1 strains during salt loading, there 
was no significant difference in pulse pressure between baseline and salt loading 
conditions for any of the strains (Table 3-2).  
3.3.1.3.4  Heart Rate and Locomotor Activity 
Salt loading conditions did not significantly change locomotor activity for any of 
the three strains when compared to baseline conditions. While there was no 
significant change in heart rate for parental strains during salt loading conditions 
when compared to baseline conditions, Trans1 HR was significantly increased 
(Baseline 311.96 ± 1.97 vs. Salt 327.35 ± 3.81, p<0.05) as measured by t-test. 
Heart rate and motor activity measured by radiotelemetry in salt-loaded rats are 
illustrated in Figures 3-9 and 3-10. Similar to baseline measurements, there was 
no significant difference in activity between WKY (3.14±0.33 AU), SHRSP 
(3.21±0.27 AU) and Trans1 rats (2.92±0.29 AU) (p>0.05). However, after the 
addition of 1% NaCl at 18 weeks, a repeated measures ANOVA determined that 
day-time heart rate for SHRSP (340.4±5.6 BPM) was significantly increased 
compared to the WKY (318.3±10.23 BPM) and Trans1 rats (324.2±8.2 BPM) (F = 
15.57. p<0.001) (Figure 3-10).   
 
  
   
Table 3-2: Baseline vs. Salt Loading Strain Comparison 
                                                                           SHRSP                          WKY                              Trans1 
SBP Baseline 214.51 ±5.12 154.49 ± 1.72** 183.13 ± 2.79* 
SBP 1% Salt 234.41 ± 5.79* 156.72 ± 3.10** 205.91 ± 4.56* 
DBP Baseline 147.81 ± 5.66* 110.25 ±3.25** 130.85 ±1.99* 
DBP 1% Salt 170.75 ± 5.21 109.72 ± 2.19** 150.49 ± 6.61* 
PP Baseline 61.67 ±1.56 42.96 ±1.89* 52.94 ± 2.15* 
PP 1% Salt 62.89 ± 2.62 38.51 ± 2.33**   52.46 ± 4.51 
Activity Baseline 2.92 ±0.18 2.75 ± 0.23 3.04 ±0.211 
Activity  1% Salt 3.19 ± 0.29 3.02  ± 0.12 2.91 ± 0.14 
Heart Rate Baseline 329.84 ±5.08 334.18 ±4.86 311.96 ±1.97+ 
Heart Rate 1% Salt 340.15 ±  7.36 321.68 ± 3.58 327.35 ±3.81 
Baseline = averages of daytime + nighttime data over a 5 week baseline period. 1% salt = averages of daytime + nighttime data over a 3 
week salt-loading period.  Significantly different when compared to SHRSP *(p<0.05). Significantly different when compared to SHRSP and 
Trans1 **(p<0.05). Significantly different when compared to SHRSP and WKY +(p<0.05). Values are presented as mean ± SEM 
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Figure 3-6: Systolic Blood Pressure for salt-loaded SHRSP, WKY and Trans1 rats.  
Hemodynamic profile for Trans1 rats implanted at 12 weeks of age and Salt 
loading at 18 weeks of age. Weekly average daytime and night-time values for 
WKY (n=8), SHRSP (n=8) and Trans1 (n=8) rats. Systolic blood pressure is 
significantly reduced in both Trans1 and WKY rats compared to SHRSP *(p<0.001), 
repeated measures ANOVA. Values are presented as mean ± SEM 
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Figure 3-7: Diastolic Blood Pressure for salt-loaded SHRSP, WKY and Trans1 rats.  
Hemodynamic profile for Trans1 rats implanted at 12 weeks of age and Salt 
loading at 18 weeks of age. Weekly average daytime and night-time values for 
WKY (n=8), SHRSP (n=8) and Trans1 (n=8) rats. Diastolic blood pressure is 
significantly reduced in both Trans1 and WKY rats compared to SHRSP *(p<0.001), 
repeated measures ANOVA. Values are presented as mean ± SEM 
     
Figure 3-8: Pulse Pressure for salt-loaded SHRSP, WKY and Trans1 rats.  
Hemodynamic profile for Trans1 rats implanted at 12 weeks of age and salt-
loaded at 18 weeks of age. Weekly average daytime and night-time values for 
WKY (n=8), SHRSP (n=8) and Trans1 (n=8) rats. (A)Pulse pressure is significantly 
reduced in both Trans1 and WKY rats compared to SHRSP *(p<0.001), repeated 
measures ANOVA. (B) WKY diurnal variation is significantly different from SHRSP 
(p < 0.05) as determined by one way ANOVA. Values are presented as mean ± 
SEM. 
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Figure 3-9: Locomotor Activity for salt-loaded SHRSP, WKY and Trans1 rats. 
Telemetry measured data from 12 to 21 week olds. There was no significant 
difference in locomotor activity between the different strains as measured by 
telemetry and calculated as night-time and day-time averages. Values are 
presented as mean ± SEM 
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Figure 3-10: Heart Rate for salt-loaded SHRSP, WKY and Trans1 rats 
Telemetry measured data from 12 to 21 week olds. Average heart rate in beats 
per minute (bps) as measured by radiotelemetry and calculated as night-time 
and day-time averages. In WKY and Trans1 rats salt-loaded heart rate was 
significantly lower than SHRSP *(p<0.05), repeated measures ANOVA. Values are 
presented as mean ± SEM 
  
 3.3.2 Echocardiography - Baseline  
3.3.2.1 LVMI mass assessed by Echocardiography 
Left ventricular mass index (LVMI) were assessed in 21 week old WKY, SHSRP, 
Trans1 and Trans2 rats by echocardiography immediately prior to sacrifice. When 
compared to the normotensive WKY, SHRSP rats had a significantly increased 
LVMI at 21 weeks of age (SHRSP: 3.435±0.29 mg/g; WKY: 2.41±0.06 mg/g, 
p<0.05). LVMI in Trans1 and Trans 2 rats was not significantly different from WKY 
at 21 weeks of age (Trans1: 2.61±0.31 mg/g; Trans2: 2.75±0.14 mg/g. p>0.05). 
Additionally, LVMI in Trans2 rats was significantly reduced compared to that of 
the SHRSP (p<0.05), however, the trend towards reduced LVMI in Trans1 rats did 
not reach statistical significance (Figure 3-12). Statistical analysis was performed 
by a student’s t-test. 
3.3.2.2 Relative Wall Thickness 
Left ventricle wall thickness was measured by echocardiography. When 
compared to WKY rats, SHRSP had a significantly increased relative wall 
thickness (RWT) at 21 weeks of age (SHRSP: 0.8±0.11 mm; WKY: 0.49±0.12 mm, F 
=7.9, p<0.001). RWT in Trans1 and Trans 2 rats were not significantly different 
from WKY at (Trans1: 0.64±0.07 mm; Trans2: 0.62±0.11 mm, p>0.05). 
Additionally, RWT in Trans1 and Trans2 rats was significantly reduced compared 
to that of the SHRSP (F =7.9, p<0.05) (Figure 3-12).    
3.3.2.3 Fractional Shortening 
Fractional shortening was measured by echocardiography in order to help 
ascertain myocardial contractility parameters. There were no significant 
differences in left ventricular ejection fraction between WKY, SHRSP, Trans1 and 
Trans2 rats (SHRSP: 42.15±10.14%; WKY: 36.5±7.53%; Tran1: 46.72±11.85%; 
Trans2: 42.72±6.99%, F=2.25, p>0.05) (Figure 3-13). 
3.3.2.4 Stroke Volume 
In order to determine blood/volume delivery by the heart per beat, stroke 
volume was measured by echocardiography. Stroke volume for SHRSP rats was 
significantly decreased when compared to WKY, Trans1 and Trans2 rats (SHRSP: 
 0.2282±0.034 mL; WKY: 0.43±0.032 mL; Trans1: 0.32±0.086ml; Trans2: 
0.34±0.045mL, f=8.87, p<0.05, p<0.001) (Figure 3-14). Stroke volume in Trans1 
and Trans2 rats was not significantly different from WKY (Figure 3-14) 
3.3.2.5 Cardiac Output  
Cardiac output was measured to assess the effectiveness of the heart to deliver 
blood to the rest of the body. Normotensive WKY cardiac output was measured 
at 126.2±32.39 mls/min. Cardiac output for Trans1 and Tran2 rats was not 
significantly different from that of the WKY (Trans1: 100.5±14.94 L/min; Trans2: 
106.7±16.28 L/min, F=6.42, p>0.05). However, SHRSP cardiac output was 
significantly decreased when compared to WKY, Trans1 and Trans2 rats (SHRSP: 
72.86±15.23 L/min, F=6.42, p<0.05) (Figure 3-15)  
3.3.2.6 Ejection Fraction 
Ejection fraction was also measured by echocardiography in order to determine 
heart function. There were no significant differences observed in left ventricular 
ejection fraction between WKY, SHRSP, Trans1 and Trans2 rats (SHRSP: 
79.19±10.2%; WKY: 79.36±8.03%; Trans1; 84.95±6.55%; Trans2 80.48±6.39%, F = 
2.25, p>0.05) (Figure 3-16).  
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Figure 3-11: Left Ventricular Mass Index for SHRSP, WKY Trans1 and Trans2 rats 
LVMI data as measured by echocardiography at 21 weeks of age, SHRSP (n=6), 
WKY (n=6), Trans1 (n=8), Trans2 (n=8) rats. LVMI in WKY and Trans2 rats was 
significantly less than that of the SHRSP *(p<0.05), as compared by T-test. Values 
are presented as mean ± SEM.  
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Figure 3-12: Relative wall thickness in SHRSP, WKY, Trans1 and Trans2 rats 
Relative wall thickness as measured by echocardiography at 21 weeks of age, 
SHRSP (n=6), WKY (n=6), Trans1 (n=8), Trans2 (n=8) rats. RWT in WKY, Trans1 
and Trans2 rats were significantly less than that of the SHRSP, p<0.05) Values are 
presented as mean ± SEM.  
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Figure 3-13: Fractional Shortening in SHRSP, WKY, Trans1 and Trans2 rats 
Fractional Shortening as measured by echocardiography from 21 weeks of age, 
SHRSP (n=6), WKY (n=6), Trans1 (n=8), Trans2 (n=8) rats. There were no 
significantly differences between the four strains. Values are presented as mean 
± SEM.  
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Figure 3-14: Stroke Volume in SHRSP, WKY, Trans1 and Trans2 rats 
Stroke Volume as measured by echocardiography at 21 weeks of age, SHRSP 
(n=6), WKY (n=6), Trans1 (n=8), Trans2 (n=8) rats. Stroke volume in WKY, Trans1 
and Trans2 rats was significantly greater compared to that of the SHRSP 
***(p<0.001) *(p<0.05). Values are presented as mean ± SEM.  
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Figure 3-15: Cardiac Output in SHRSP, WKY, Trans1 and Trans2 rats 
Cardiac Output as measured by echocardiography from 21 weeks of age, SHRSP 
(n=6), WKY (n=6), Trans1 (n=8), Trans2 (n=8) rats. Cardiac output in WKY, Trans1 
and Trans2 rats was significantly different than that of the SHRSP **(p<0.001) 
*(p<0.05). Values are presented as mean ± SEM.  
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Figure 3-16: Ejection Fraction in SHRSP, WKY, Trans1 and Trans2 rats 
Ejection Fraction as measured by echocardiography at 21 weeks of age, SHRSP 
(n=6), WKY (n=6), Trans1 (n=8), Trans2 (n=8) rats. There were no significantly 
differences between the four strains. Values are presented as mean ± SEM.  
  
  
3.3.3 Cardiac and Left ventricular Hypertrophy assessed at 
sacrifice. 
Cardiac (whole heart) mass index and left ventricular (left ventricle + septum) 
mass index were measured to determine cardiac and left ventricular hypertrophy 
respectively at sacrifice (21 weeks of age). SHRSP (3.24±0.04 mg/g), Trans1 
(3.04±0.11mg/g) and Trans2 (3.16±0.16mg/g) rats demonstrated left ventricular 
hypertrophy when compared to the WKY (2.47±0.06 mg/g) (F = 32.13; p<0.001) 
(Figure 3-17). There was no significant different between the two transgenic 
strains (p>0.05). For whole heart normalized to body weight, SHRSP (4.24±0.04 
mg/g), Trans1 (4.35±0.36 mg/g) and Trans2 (4.12±0.14 mg/g) rats demonstrated 
cardiac hypertrophy when compared to the WKY (3.34±0.04 mg/g) (F = 30.88; 
p<0.001). There was no significant difference between the two transgenic lines 
(p>0.05) (Figure 3-18).   
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Figure 3-17: LVMI in SHRSP, WKY Trans1 and Trans2 rats 
Left Ventricular mass index normalized to body weight  at 21 weeks of age, 
SHRSP (n=6), WKY (n=6), Trans1 (n=8), Trans2 (n=8) rats at sacrifice. LVMI in WKY 
was significantly less than that of the SHRSP, Trans1 and Trans2 rats *(p<0.05), 
one-way ANOVA. Values are presented as mean ± SEM.  
  
  
 
Figure 3-18: Cardiac mass index in SHRSP, WKY Trans1 and Trans2 rats 
Whole heart weight normalized to body weight at 21 weeks of age, SHRSP (n=6), 
WKY (n=6), Trans1 (n=8), Trans2 (n=8) rats at sacrifice. Cardiac mass index in 
WKY rats was significantly less than that of the SHRSP, Trans1 and Trans2 rats 
*(p<0.05). Values are presented as mean ± SEM.  
  
 3.4 Discussion 
In this Chapter significant reduction in hemodynamic parameters measured by 
radiotelemetry in Gstm1 transgenic SHRSP rats provides convincing evidence that 
Gstm1 plays an important role in blood pressure regulation in the SHRSP rat. In 
parallel with the significantly lower SBP, DBP and PP we also observe 
significantly improved cardiac function and reduced cardiac hypertrophy in the 
two independently generated transgenic lines. Moreover, the observed reduction 
in systolic blood pressure is remarkably similar in magnitude to that 
demonstrated in the Chromosome 2 congenic strain, SP.WKYGla2c*, in which 
Gstm1 was identified as a candidate gene for hypertension (78). Importantly, 
these findings demonstrate that significant improvements in hemodynamic and 
cardiac parameters occur in two independently generated transgenic lines. These 
findings support the hypothesis that Gstm1 plays a central role in blood pressure 
regulation, since random insertion of the transgene into two distinct genomic 
locations leads to similar levels of functional cardiovascular improvement.  
Whilst the overall outcome of random Gstm1 transgene insertion in the SHRSP is 
a significant reduction in the hypertensive phenotype, there are some subtle 
differences between the two independently generated transgenic lines. For 
example while diastolic blood pressure for both Trans1 and Trans2 rats is 
significantly lower than that of the SHRSP, the diastolic pressure profiles differ in 
the rate of increase over time between the two transgenic lines (Figure 3-2). 
Diastolic blood pressure in Trans1 rats originates lower than that of the SHRSP 
and remains significantly lower throughout the measurement period. On the 
other hand, diastolic blood pressure in Trans2 rats starts at a similar level to that 
of the SHRSP, but remains constant over time. These diastolic profile differences 
between the two independent transgenic lines could be a result of a number of 
factors. These factors include transgene insertion site effects, line specific mRNA 
or protein level differences, and/or variability due to small numbers in the 
Trans2 line resulting from breeding difficulties. 
When transgenic lines are generated by microinjection of a transgene into a 
fertilized embryo there is the potential for the transgene to insert anywhere 
within the genome. Independently generated lines are highly unlikely to have the 
transgene inserted into the same genomic position, and thus have the same 
 effect. Furthermore, there is also a possibility that the transgene will insert into 
a region containing a gene that contributes to blood pressure regulation, and 
thereby, blood pressure control may be impacted by the insertion site. One 
example to illustrate the potential diversity in phenotypes between two 
independently generated transgenic rat lines with the same inserted transgene is 
the CD-36 transgenic SHR rat generated by Pravenec et al. (121). In this 
example, while two independent transgenic lines were produced using the same 
EF1-α promoter, there are unique differences between the transgenic lines. 
While incorporation of cd-36 ameliorated insulin resistance in both lines, one line 
had an additional effect of a modest decrease in blood pressure (121). 
Additionally, when developing transgenic lines, it is often difficult to ascertain 
what impact the insertion site will have on a particular phenotype. The 
generation of more than one transgenic line (using the same transgene and 
promoter) is therefore important in order to confirm that the phenotypic 
differences are the result of the transgene itself and not the insertion site. If the 
phenotypic changes are similar between two independently generated lines then 
this provides confidence that the phenotype differences are due to transgene 
functional effects (rather than insertion site effects).  
Other factors that could contribute to line specific differences are mRNA or 
protein expression level differences within each independent line. Since each 
line was derived separately, Trans1 and Trans2 will most likely have a unique 
expression patterns with a distinct copy number profiles. Furthermore, transgene 
insertion by microinjection has the potential to insert multiple copies of the 
gene into the recipient genome (7;121). In other transgenic animals, studies have 
shown that gene expression is associated with copy number which resulted in 
varying effects on each transgenic line (241;242). Differences like copy number 
and expression patterns between Trans1 and Trans2 may be responsible for the 
line specific differences in diastolic BP profile. However without further 
investigation, it is difficult to reconcile the impact of copy number variation 
specifically on the rate of diastolic BP increase over time observed in the two rat 
lines. 
An alternative explanation for the diastolic BP differences between the two 
transgenic lines could simply be due to breeding issues experienced with the 
Trans2 line. Trans2 rats were difficult to breed; showing low fertility throughout 
 the length of the project. Due to limited numbers of male stock animals, Trans2 
rats underwent the radiotelemetry BP monitoring and echocardiography 
protocols at a later stage compared to Trans1 rats and parental strains. Some 
phenotypic drift is not uncommon in inbred rat colonies and may contribute in 
part to the DBP differences observed here.  
In order to investigate the potential role of Gstm1 deficiency in the salt-
sensitivity phenotype in SHRSP rats, parental strain rats and Trans1animals 
underwent 1% salt loading starting at 18 weeks of age, i.e. after the onset of 
adult hypertension.  While some salt-sensitivity was evident in the Trans1 
animals (i.e. exaggerated night-time daytime blood pressure variation) similar to 
the SHRSP, there was still a significant decrease in systolic and diastolic blood 
pressure compared to the SHRSP. This reduced hemodynamic profile during salt-
loading is in contrast to the profile observed in the chromosome 2 congenic 
strain (SP.WKYGla2c*), which showed no significant difference in blood pressure 
profile compared to the SHRSP during salt-loading(78). However, there are many 
differences between the SP.WKYGla2c* strain and the Gstm1 transgenic rats, such 
as the insertion of a single gene (in the transgenic) in contrast to a relatively 
large introgressed genomic region (in the congenic, approximately 59Mbp with 
boundary markers D2Wox9-D2Mgh12), that that could potentially affect response 
to salt. The Trans1 line demonstrates similar blood pressure reduction during 
both baseline and salt-loading periods; therefore, we can conclude that the 
WKY-form of the Gstm1 gene may play an important role in the preventative 
effects on salt-sensitivity in our transgenic animals.  
Multiple publications suggest that pulse pressure is a better predictor of 
cardiovascular risk than isolated systolic or diastolic blood pressures (243;244). 
Figure 3-3 shows that pulse pressure is significantly reduced in both transgenic 
lines. While pulse pressure levels in Trans2 rats is more similar to that of the 
WKY than Trans1 rats, both lines show a reduction of cardiovascular risk when 
compared to the SHRSP. Elevated pulse pressures are thought to be associated 
with increased artery stiffness (245). Franklin et al. states that a high pulse 
pressure may reflect already diseased arterial walls in addition to several other 
adverse cardiac implications of potential prognostic value (245;246). 
Furthermore, several studies state that there is an association between pulse 
 pressure and a risk of morbid cardiovascular events which is independent of 
systolic and diastolic blood pressure (243).  
When investigating the effects of salt loading on pressure, our data show that 
diurnal variation is exaggerated in SHRSP compared to WKY and Trans1 rats 
(Figure 3-7) which is in agreement with previously published data in salt-loaded 
parental strains (240). Koh-Tan et al. explains the importance of pulse pressure 
variability and its effects on end organ damage (240). In particular, the lack of 
blood pressure regulation has been shown to be correlated with the development 
and severity of renal damage (240;247;248). This damage is a result of altered 
microcirculation within the glomerular arterioles where a high pulsatile 
glomerular filtration rates may expose the glomerular capillaries to potentially 
damaging effects that lead to vascular damage in the kidneys (247). 
Measurement of vascular function and end organ damage are therefore pertinent 
considerations in this study and will be discussed in further chapters. 
Echocardiography measurements allowed investigation of cardiac function and 
cardiac hypertrophy in the SHRSP, WKY and transgenic rats. Both fractional 
shortening (FS) and ejection fraction (EF), which are the most commonly used 
indexes of global left-ventricular systolic function, showed that there was no 
significant differences between the four strains. This data confirms previous 
findings at 16 weeks of age in the parental strains, and thus allows us to 
conclude that the insertion of the transgene did not have any adverse effects on 
cardiac function (239). Relative wall thickness, another commonly used 
parameter to describe the degree of left ventricular hypertrophy, was 
significantly reduced in WKY, Trans1, and Trans2 rats when compared to the 
SHRSP. While RWT in Trans1 and Trans2 rats was not reduced to WKY levels, they 
were not significantly different and thus showing an intermediate phenotype. 
Previous studies done in our lab have shown that in the SHRSP at 16 weeks of 
age, cardiac fibrosis (interstitial and perivascular) is observed (249;250). While 
cardiac fibrosis was not measured at 21 weeks in this study, we would 
hypothesize that there is a reduction of cardiac fibrosis in Trans1 and Trans2. 
However, while there is an improved cardiac function in the Tran1 and Trans2 
lines, we cannot determine if this change is due to increased Gstm1 expression 
or if this reduction is a secondary effect of the significantly lowered blood 
pressure in the transgenic animals. There is a lack of literature regarding a role 
 for Gstm1 in cardiac disease. A fairly recent review by Conklin (251) on 
cardiovascular studies in humans states that little is known about how much 
Gstm1 contributes to GST activity in cardiovascular tissues. These conclusions, in 
relationship to our findings, indicate that further investigation is required to 
determine the role that Gstm1 plays in the healthy and diseased heart.  
In conclusion, the production of two independent Gstm1 transgenic lines 
generated on the SHRSP genetic background has provided a unique opportunity 
to investigate causality of Gstm1 deficiency on the development of hypertension 
and cardiac hypertrophy. In this Chapter we have demonstrated a significant 
reduction in blood pressure in both transgenic rat lines, and improved cardiac 
function. This data supports the hypothesis that reduced renal Gstm1 plays a 
causative role in oxidative stress mechanisms underlying the development of 
hypertension in the SHRSP. 
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4.1 Introduction 
In the previous chapter it was demonstrated that Gstm1 transgenic SHRSP rats 
have a significant decrease in systolic blood pressure and cardiovascular 
hypertrophy when compared to the parental SHRSP strain. The next stage of our 
study was designed to investigate the molecular changes occurring as a result of 
transgenic rescue of Gstm1. As previously mentioned, Gstm1 was identified as a 
positional and functional candidate gene through a series of experiments 
involving the generation of chromosome 2 congenic rat strains and microarray 
expression profiling(78;87). These studies demonstrated that expression of 
Gstm1 in the kidney was significantly reduced at 16 weeks of age in SHRSP 
compared to the chromosome 2 congenic strain (SP.WKYGla2c*) and normotensive 
WKY strains (40;85). Furthermore, additional microarray expression profiling and 
qRT-PCR validation demonstrated that Gstm1 expression in 5 weeks old SHRSP 
rats was significantly reduced when compared to WKY and SP.WKYGla2c* rats 
(252). Taken together with the findings in the 2c* congenic strain, this reduction 
in expression prior to the onset of hypertension in this model is consistent with 
the hypothesis that reduced Gstm1 expression is likely to be a causative factor in 
increased blood pressure and not a secondary event. In line with these early 
expression differences in the SHRSP, evidence in the literature also demonstrates 
that Gstm1 expression in the SHR is reduced at 3 weeks of age when compared to 
the WKY (253).     
In addition to the differences in Gstm1 expression profile, previous DNA 
sequencing of the upstream regulatory region of Gstm1 identified 13 single-
nucleotide polymorphisms (SNPs), a missense mutation and a SNP in the 3’ un-
translated region (UTR) of the SHRSP and SHR that were not identified in the 
WKY or BN (254;255). Additionally, luciferase promoter assays implicated five 
SNPs to be responsible for significant reduction in Gstm1 expression in the SHRSP 
(223). However, establishing definitive proof that a gene affects blood pressure 
requires evidence that changing the expression of the candidate gene in 
isolation, alters blood pressure. Depending on the direction of change of the 
implicated gene, this can be achieved by generating knockout, knock-in 
(targeted) or untargeted over-expression transgenic rat models. However, prior 
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to 2009 the ability to generate transgenic rats was severely limited due to the 
fact that, unlike the mouse, it was not possible to generate and maintain rat 
embryonic stem (ES) cells.  
Despite these previous ES cell restrictions, technology did allow for 'transgenic 
rescue' in the rat, whereby normally functioning genes were microinjected into 
embryos of disease models in order to provide definitive proof of causality. An 
example of this gold standard method is the derivation of the CD-36 transgenic 
rat, whereby the CD-36 candidate gene was originally identified by QTL analysis 
and congenic strain construction and then confirmed by transgenic rescue (CD-36 
overexpression) (121;256). Other examples included generation of transgenic 
animals expressing an antisense sequence to reduce expression of target genes 
(257), dominant negative mutants in order to induce dwarfism (258), or siRNA-
expressing constructs (259). Since these early studies many transgenic rats, 
whether over-expression or knockout, have been produced for the advancement 
of cardiovascular studies (260-262). The generation of transgenic rats are 
fundamentally similar to that of a transgenic mouse where microinjection of the 
construct into the pronucleus of a single-cell embryo is followed by implantation 
into recipient females and resultant pups are screened for positive markers. 
However, these techniques are more successful in mice, typically generating 3%-
5% transgene-positive offspring per injected embryo (263), compared to 0.2%-2% 
in rats (264;264).   
Based on these successful transgenic investigations, and specifically the CD-36 
study (121), the SHRSP Gstm1 transgenic rat was produced using the WKY variant 
of Gstm1 gene under the direction of the EF-1α promoter. The EF-1α promoter is 
a commonly used mammalian ubiquitous or “house-keeping” promoter. This gene 
has a housekeeping function in all cells and is expressed to high levels. 
Importantly, due to its indispensable housekeeping function in all cells, EF-1α 
promoter expression is consistent from a temporal viewpoint, relatively insulated 
from changes in cell physiology and is cell type independent (265;266). There are 
several potential drawbacks associated with the production of transgenic lines 
using untargeted over-expression methods. These include random insertion sites, 
expression incompatibilities that could result in disrupted expression of vital 
genes, possible lethal transgene over-expression, insertion site discordance, and 
copy number variation (267-270).  
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  It is hypothesized that incorporation of wild type Gstm1 into the SHRSP genetic 
background will result in significantly increased Gstm1 mRNA and protein 
expression in the kidney and other organs. Moreover, a better understanding of 
the transgene expression profile within the SHRSP Gstm1 transgenic rat will help 
to elucidate whether the changes in both cardiac mass and cardiac function (as 
demonstrated in the previous Chapter) are simply secondary effects to the lower 
blood pressure or if Gstm1 is having a direct effect on the heart.  
The aims of the chapter were (1) to determine whether incorporation of WKY 
(wild-type) Gstm1 within the SHRSP genome results in increased expression of 
Gstm1 in cardiovascular relevant tissues (i.e. kidney, brain, heart, aorta, liver). 
(2) To determine if changes in mRNA expression leads to significant differences 
in protein expression and determine where expression is localized. (3) To 
identify the transgene insertion site in both transgenic lines and to determine if 
there are multiple copies.  
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4.2 Materials and Methods 
4.2.1 Animal Strains 
Male SHRSP, WKY, Trans1 and Trans2 rats (n=6-8) were sacrificed at 5 weeks of 
age (before onset of hypertension) and at 21 weeks of age (established 
hypertension). Kidney, heart, liver, thoracic aorta, and brain were taken during 
tissue harvest under deep terminal anaesthesia. Tissues were snap frozen in 
liquid nitrogen and stored at -80°C for analysis of DNA, mRNA or protein 
expression or fixed in 10% formalin for IHC.  
4.2.2 mRNA Expression 
4.2.2.1 qRT-PCR  
RNA was extracted, quantified, DNAse treated and reverse transcribed as 
described in section 2.4 in tissues from 5-week-old and 21-week-old male rats. 
Total mRNA expression of Gstm1 and other Gstm family members were assessed 
by Applied Biosystems Gene Expression Assays and Custom Gene Expression 
Assays were used for all qRT-PCRs. The reaction constituents and temperature 
cycling parameters were as follows:  
Table 4-1:Taqman Reagent List  
Reaction Mixture Volume 
Master Mix 2.5 
20x Gene Expression Assay 0.25 
20X GapDH or β-Actin Assay 0.25 
cDNA 2.0 
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Table4-2: Temperature Cycling for Taqman 
Temperature Time 
50°C 2 min 
95°C 10 Min 
95°C 15 sec 
60°C 1 min 
Repeat steps 3 & 4 35x’s 
 
All samples were amplified in triplicate with at least three treatment replicates 
included per experiment. Fluorescence of FAM and VIC dyes was measured for all 
reactions during temperature cycling. For all tissues, except heart, β-Actin was 
used as the housekeeping gene. For heart, GAPdH was used as the housekeeping 
gene. Data was analyzed as detailed in section 2.4.4. 
4.2.2.2 SYBR Green 
For transgene or WKY (wild-type) gene expression, Exiqon custom locked-nucleic 
acid SYBR Green probes were used, see section 2.4.4.1 for further details. The 
exact primer sequence for the LNA-SYBR green probes is copyrighted by Exiqon 
and is unknown outside of the company. However, it was assured that the 
primers overlap the SNPs specific to the WKY and transgene sequence of the 
Gstm1 gene.  
  
4.2.3 Protein Expression and Localization (IHC)  
4.2.3.1 Protein expression 
Protein was extracted from tissues using a Hepes lysis buffer (50mM Hepes, 1mM 
DTT, 0.5% Tween, ph 7.4). On the night before extraction, one tablet of Roche 
EDTA-free protease inhibitor cocktail tablet was added for every 10 mls of Hepes 
lysis buffer used. The samples were homogenized in cold Hepes lysis buffer (1ml 
of Hepes buffer for up to 0.3g of tissue). The homagenates were kept on ice until 
centrifuged at 14,000 rmp for 10 mins at 4°C and the supernatant containing the 
protein was transferred to a new tube and kept on ice. 5µL of supernatant was 
129 
 
removed to determine protein concentration by nanodrop method. The rest of 
the protein was stored at -80 °C until required.  
4.2.3.2 Western Blot 
Protein samples were prepared and quantified as described in sections 2.6.1 and 
2.6.2. Gel electrophoresis and blotting were carried out on these samples as 
described in section 2.6.3. Into each lane, 30µg of protein sample prepared in an 
equal volume of 2x sample reducing buffer was loaded and a low range rainbow 
marker was used to determine band size. For immunodetection the membrane 
was incubated at 4°C overnight with a rabbit anti-rat Gstm1 polyclonal antibody 
(gift from Prof. John Hayes, University of Dundee) used at a dilution of 1:5000 
followed by a goat anti-rabbit IgG secondary antibody conjugated to horseradish 
peroxidase (Dako) at 1:2000 for one hour at room temperature. Bands were 
visualised using enhanced chemiluminescence, as described in section 2.6.4   
4.2.3.3 Protein Expression and Quantification 
The antisera used to assess the protein expression and localization of the Gstm1 
by immunohistochemistry were gifts from Prof. John D. Hayes. The protein 
concentration of each sample was determined using a Peirce BCA (bicinchoninic 
acid) protein assay kit according to the manufacturer’s instructions. The bovine 
serum albumin (BSA) standards were diluted to appropriate concentrations for 
the standard curve while the protein samples were diluted accordingly to fit 
within the standards spectrum 
4.2.3.3.1 IHC 
Sections cut to 6 µm thickness were de-parrifinised and hydrated by 2x7 minute 
washes in Histoclear before going down an ethanol gradient of 100%, 95% and 75% 
for 7 minutes at each stage. Sections were then washed in water for 7 minutes. 
Endogenous peroxide was then quenched by incubating slides for 30 minutes in 
0.3% H2O2 (10ml 30% to 1L) in methanol at room temperature. Sections were then 
rinsed in 2 x 10 minute water washes. Sections were blocked for 60 minutes with 
2% normal serum in PBS (2 drops of ABC kit blocking serum in 5ml PBS or 100µl 
appropriate serum in 5ml PBS). Slides where placed in humidified trays in order 
to prevent slides from drying out. Excess blocking reagent was removed and 
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replaced with 1°Ab/antiserum or negative control diluted in blocking serum for 
overnight at room temperature. The following day, sections underwent 3x5 
minutes washes in PBS. A  biotinylated 2°Ab antibody, diluted in blocking 
reagent (ABC universal kit, 2 drops blocking serum + 2 drops supplied vectastain 
biotinylated antibody + 5ml PBS) was added for a 30 minute room temperature 
incubation. This was followed by 3x5 minute PBS washes. If the ABC 2°Ab 
antibody was used, and ABC complex was added to the sections and incubated 
for 30 minutes at room temperature. This was followed by 3x5 minute PBS 
washes. DAB chromogen (DAB substrate kit) for universal and peroxiase 2°Ab 
antibody was prepared following manufacturer’s instructions. Sections were 
incubated for 5 minutes at room temperature in a humidified chamber and then 
washed for 5 minutes in water. Sections were counterstained with Haematoxylin 
for 90-120 seconds and placed under a running tap for 5 minutes. Sections were 
then dehydrated through a reverse ethanol gradient of 70%, 95% and 100% for 7 
minutes at each stage. Immediately following, sections then washed 2x’s in 
Histoclear for 7 minutes and mounted using Histomount (National Diagnostics, 
GA, USA). 
4.2.4 Localization of the Transgene Insertion Site 
1-3 µg of genomic DNA, that was extracted as stated in 2.5.1, was digested 
separately with either HindIII or PstI restriction enzymes for 1.5 hours at 37° C in 
0.5 µL epindorf tubes. Resulting fragments were then ligated overnight at 16 °C 
with T4 ligase. Primers designed specifically for HindIII (GstmFragA) and PstI 
(GstmFragB) restriction sites were used as primers with the ligated templates for 
the first round of PCR amplification. First round PCR was performed using the 
primer sets GstmFragA (1+2) and GstmFragB (1+2):  
GstmFragA 1- ATT GCA TGA AGA ATC TGC TTA GG 
GstmFragA 2- ACA AGC AGG GAG CAG ATA CTG GC 
GstmFragB 1- AAA GGA GTG GGA ATT GGC TCC GG 
GstmFragB 2- CAA CGC GTA TAT CTG GCC CGT AC 
Product from the first round PCR was utilized as a template for a second nested 
PCR reaction using nested Gstm1FragA (3+4) and nested Gstm1FragB (3+4) primer 
sets: 
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GstmFragA 3- TGT ACG GGC CAG ATA TAC GCG TTG 
GstmFragA 4- GAG CAG ATT GTA CTG AGA GTG CAC 
GstmFragB 3- GGT AAA CTG GGA AAG TGA TGT CG 
GstmFragB 4- GAG CAG ATT GTA CTG AGA GTG CAC    
For a schematic view of this process please refer to Figure 4-1.  
The PCR reactions were run on the Pelteri Thermal Cycler (PTC-225) under the 
conditions 95°C for 4 mins, 96 °C for 30s and 58 °C for 30s and 72 °C for 60s for 
35 cycles, then held at 72 °C for 7 min. In order to separate the amplified 
fragments,  
15-20 µL of PCR reaction was electrophoresed with 3µL of 6X loading dye in a 1% 
agarose gel at 100V for 1.5 hours, alongside a 1Kb DNA ladder.  
DNA fragments that were considered the correct sizes were then isolated from 
the aragose gels by Qiaquick gel desolving kt (Qiaquick handbook) according to 
handbook instructions (Qiagen). Extracted DNA eluate was then quantified by 
measuring 1.5 uL of RNA sample using the NanoDop DN-1000 spectrophotometer 
spectrophotometer (NanoDrop Technologies LLC, Wilmington, Delaware USA) 
under the software program ND-1000 v3.2, in which absorbance ratios of 260 
nm/280 nm equalled approximately 1.8 for DNA. This indicated that the DNA 
preparations were sufficiently free from protein contamination. Like RNA 
samples, averages of either duplicate or triplicate measurements were taken for 
samples requiring precise quantification. 
Eluted DNA was then placed into a plasmid cloning kit (Stratoclone) and cloned 
according to manufacturer’s instructions (Stratoclone). Positive colonies were 
then screened and verified by 2% X-gal. Plasmid DNA was then prepped for DNA 
sequencing using Qiagen Plasmid mini prep kit (Qiagen) according to 
manufacturer’s instructions. 
Plasmid DNA was sequenced by using Applied Biosystems  BigDye Terminater n3.1 
Cycle Sequencing kits. All reaction were performed on a 96 well plate and 
included included 3.5µl 5X sequencing buffer; 0.5µl Ready Reaction; 8µl 
template (100-200ng of plasmid DNA); ~3.2µl primer (2.0 µM Final); ~4.8µl H2O.  
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IPCR amplifies the unknown DNA sequences that are immediately 
adjacent to the known sequence of our transgene
Gstm1 restriction sites
Gstm1
unknown
 
Figure 4-1: Schematic of the inverse PCR (IPCR) procedure with results 
Genomic DNA were digested with a restriction enzyme and ligated. Templates 
then underwent multiple PCR reactions in order to target specific products. 
Adapted from Bessereau (271).  
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The temperature program cycle was: 96°C for 45 secs, 50°C for 25 secs, 60°C for 
4 mins. Steps 1-2 repeated 25 times.  
Sequencing was initially analyzed on Applied Biosystems SeqScape software 
version 2.1 to see if fragments aligned to the genome. Fragments that were 
aligned were then analyzed by hand and each nucleic acid was looked at in order 
to verify that the connecting sequences were novel and not erroneous transgene 
fragments. Experimental sequences were then aligned with known sequences 
derived from bioinformatic databases such as UCSC or ENSEMBL.  
4.2.5 Copy Number Variation 
Identification of the Gstm1 transgene across generations was determined in both 
transgenic lines through Taq-man analysis. Copy number variation Taqman 
probes, SNP Genotyping Assay (Applied Biosystems) and SNP Gene Expression 
Assay (Applied Biosystems), were custom synthesized to a unique portion of the 
transgene construct.  The SNP Genotyping Assay was analyzed by Taqman 
Genotyper, a specifically designed analysis package developed by Applied 
Biostand for this assay. The SNP Gene Expression Assay was compared to a unique 
single copy gene (RNase P 30) that was custom designed for the genetic 
background of rats. Using the comparative (∆∆CT) method with additional steps 
as calculated by Applied Biosystems Copy Caller Software, copy number variation 
analysis was performed on the Taqman 7900. 
4.2.6 Statistics 
All results are displayed as mean ± SEM and n represents the number of 
independent experiments performed. Data were analyzed using a one-way 
ANOVA followed by Tukey’s post hoc test for all total gene and protein 
expression experiments. For Transgene expression, data were analyzed using a 
one-way ANOVA followed by Newman-Keuls’ post hoc test.  
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4.3 Results 
4.3.1 Gstm1 Expression in Cardiovascular Relevant Tissues 
4.3.1.1.1 Kidney  
In order to fully assess changes in renal Gstm1 expression in both transgenic 
lines, transgene (or WKY form) mRNA specific expression in addition to protein 
and IHC expression profiles were measured. At 5 weeks of age, total renal Gstm1 
expression was assessed by quantitative real time PCR (qRT-PCR) in male WKY, 
SHRSP, Tran1 and Trans2 rats. Total renal Gstm1 mRNA at 5 weeks of age was 
significantly higher in Trans1, Trans2 and WKY rats compared to SHRSP (p<0.05) 
(Figure 4-2). Furthermore, while renal expression of Gstm1 in the Trans1 line was 
significantly less than that of the WKY, expression in the Trans2 line was not 
different from WKY expression. Transgene specific (or the WKY variant of 
Gstm1), renal Gstm1 mRNA was assessed by SYBR quantitative real time PCR 
(qRT-PCR) in male WKY, SHRSP, Trans1 and Trans2 rats.  Expression of transgene 
renal Gstm1 mRNA at 5 weeks of age was significantly higher in Trans1, Trans2 
and WKY rats when compared to with SHRSP (p < 0.05), (Figure 4-2). To further 
investigate the extent of the changes in Gstm1 expression, total protein Gstm1 
levels in the kidney were measure by western blot and Immunohistochemistry 
(IHC). At 5 weeks of age, total Gstm1 protein in Trans2 and WKY rat kidneys 
were significantly increased when compared to SHRSP levels. While protein levels 
in Trans1 rats were similar to that of Trans2, they were not significantly 
different from that of the WKY nor were they significantly different from that of 
the SHRSP (i.e. they were intermediate) (Figure 4-2). These expression levels 
were also confirmed with IHC where expression was found mainly in the distal 
tubules (Figure 4-2). 
At 21 weeks of age, total renal Gstm1 mRNA was significantly higher in Trans1 
and WKY rats when compared to with SHRSP (p < 0.05), (Figure 4-3). Transgene 
renal Gstm1 mRNA was significantly higher in Trans1 and WKY rats when 
compared to with SHRSP (p < 0.05), while Trans2 rats showed very little 
transgene expression (Figure 4-3). At 21 weeks of age, WKY Gstm1 protein levels 
were significantly increased compared to that of the SHRSP (Figure 3-10) 
*(p<0.01). Gstm1 protein levels in Trans1 and Trans2 rats were not significantly 
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different from that of the SHRSP (p>0.05). These expression levels were also 
confirmed with IHC, and similarly to 5 week kidneys, expression was found 
mainly in the distal tubules (Figure 4-3). 
4.3.1.1.2 Total Gstm1 expression in other cardiovascular relevant tissue   
For other cardiovascular relevant tissues, both endogenous and transgene Gstm1 
expression (otherwise referred to as total Gstm1 expression) was measured at 
both an early developmental stage (5 weeks) and after the full onset of 
hypertension (21 weeks). At 5 weeks of age, heart, brain and aorta total Gstm1 
mRNA levels were assessed by quantitative real time PCR (qRT-PCR) in male 
WKY, SHRSP, Trans1 and Trans 2 rats. Cardiac total Gstm1 expression was 
significantly increased in SHRSP compared to WKY, Trans1 and Trans2 animals 
(p<0.05) (Figure 4-4 panel A). Levels of total Gstm1 mRNA in brain showed no 
significant difference between all four strains (Figure 4-4 panel B). Vascular 
(aorta) total Gstm1 expression was slightly increased in Trans1 and WKY rats, and 
significantly increased in Trans2 rats when compared to the SHRSP (p<0.05) 
(Figure 4-4 panel C).  
At 21 weeks of age, brain, heart, aorta and liver total Gstm1 mRNA levels were 
assessed by quantitative real time PCR (qRT-PCR) in male WKY, SHRSP, Trans1 
and Trans2 rats. Cardiac total Gstm1 expression was significantly increased in 
the Trans1 line when compared to WKY and SHRSP (p < 0.05) (Figure 4-5 panel 
A). Cardiac Gstm1 expression in Trans2 rats showed a trend towards increase, 
but was not significantly different from WKY, Trans1 or SHRSP rats (Figure 4-5 
panel A). Levels of total Gstm1 mRNA in brain were significantly increased in 
Trans1 and Trans2 animals compared to SHRSP (p<0.05). There was no significant 
difference in neural Gstm1 expression between SHRSP and WKY rats (Figure 4-5 
panel B). Similar to findings in kidney, Gstm1 expression in aorta was 
significantly increased in Trans1 and WKY rats when compared to and SHRSP 
(p<0.005) (Figure 4-5 panel C), however, aortic Gstm1 expression in Trans2 rats 
showed an increased trend but was not significantly different from WKY, Trans1 
or SHRSP rats (Figure 4-5 panel C). Total Gstm1 expression in the liver was 
significantly increased in Trans1, Trans2 and WKY rats when compared to SHRSP 
(p<0.05) (Figure 4-5 panel D).      
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Figure 4-2: Changes in Renal Gstm1 expression between Trans1, Trans2 and parental 
strains at 5 weeks. 
Gstm1 expression in kidney at 5 wks of age in SHRSP (n=8), WKY (n=8), Trans1 
(n=8), and Trans2 (n=3) rats. (A)Total Gstm1 levels were significantly increased 
in WKY, Tran1 and Trans2 lines when compared to the SHRSP *(p<0.05) 
**(p<0.01). (B) WKY variant Gstm1 levels were significantly increased in the WKY, 
Trans1 and Trans2 rats when compared to the SHRSP *(p<0.05). (C) Total protein 
was extracted from kidney tissue and resolved by gel electrophoresis. Western 
blot indicated an increased Gstm1 expression in WKY, Trans1 and Trans2 rats 
when compared to SHRSP *(p<0.05). Increased Gstm1 expression was confirmed 
by densitometry with each band normalized to β-Actin (n=3 for each strain). (D) 
IHC of Gstm1 protein on whole kidney sections from WKY, SHRSP and Trans1 rats 
at 5 weeks of age. Magnification =10x. Values are presented as mean ± SEM. 
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Figure 4-3: Changes in Renal Gstm1 expression between Trans1, Trans2 and parental 
strains at 21 weeks.  
(A)Total Gstm1 expression in kidney at 21 weeks in SHRSP (n=8), WKY (n=8), 
Trans1 (n=8), and Trans2 (n=6) rats. Total Gstm1 levels were significantly 
increased in WKY, Trans1 and Trans2 rats when compared to the SHRSP *(p<0.05) 
**(p<0.01). (B) WKY form Gstm1 levels were significantly increased in WKY, 
Trans1 and Trans2 rats when compared to the SHRSP *(p<0.05). (C) Western blot 
indicated an increased Gstm1 expression in WKY when compared to SHRSP 
*(p<0.05). Increased Gstm1 expression was confirmed by densitometry with each 
band normalized to β-actin (n=3 for each strain). (D) IHC of Gstm1 protein on 
whole kidney sections from WKY, SHRSP and Trans1 rats at 21 weeks of age. 
Magnification =10x. Values are presented as mean ± SEM  
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Figure 4-4: Expression of Total Gstm1 in Cardiovascular Relevant Tissues for Trans1, 
Trans2 and Parental Strains at 5 wks of Age. 
Total Gstm1 mRNA expression in (A) heart, (B) brain and (C) aorta at 5 wks of 
age in SHRSP (n=8), WKY (n=8), Trans1 (n=8), and Trans2 (n=3) rats. Cardiac 
Gstm1 levels were significantly reduced in the animals when compared to SHRSP 
animals *(p<0.05 vs. SHRSP), +(p<0.05 vs. Trans1 rats). There were no significant 
differences in Gstm1 expression levels in the brain between the four strains. 
Aortic Gstm1 expression levels were significantly increased in Trans2 animals 
when compared to the SHRSP. Values are presented as mean ± SEM 
  
139 
 
Brain - 21 wk
SHRSP WKY Trans1 Trans2
0.0
0.5
1.0
1.5
2.0
2.5
3.0
*
*
B
RQ
Liver - 21 wks
SHRSP WKY Trans 1 Trans 2
0.0
0.5
1.0
1.5
2.0
**
*
D
RQ
Heart - 21 wks
SHRSP WKY Trans1 Trans2
0.0
0.5
1.0
1.5
2.0
2.5
*
A
RQ
No
rm
al
iz
ed
 
to
 
G
ap
dH
Aorta - 21 wks
SHRSP WKY Trans1 Trans2
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
*
*
C
RQ
 
Figure 4-5: Total Gstm1 Expression for Trans1, Trans1 and Parental Strains at 21 wks of Age 
in Cardiovascular Relevant Tissues  
Total Gstm1 mRNA expression in (A) heart, (B) brain, (C) aorta and (D) liver at 21 
wks of age in SHRSP (n=8), WKY (n=8), Trans1 (n=8) and Trans2 (n=6) rats. 
Cardiac Gstm1 levels were significantly increased in Trans1 (n=8) animals when 
compared SHRSP (n=8) animals *(p<0.05). Neural Gstm1 levels were significantly 
increased in Trans1 (n-8) and Trans2 (n=6) rats when compared to SHRSP (n=8). 
Aortic Gstm1 expression levels were significantly increased in WKY (n=8) and 
Trans1 (n=8) animals when compared to the SHRSP (n=8) *(p<0.01). Hepatic 
Gstm1 levels were significantly increased in WKY (n=8), Trans1 (n=8) and Trans2 
rats (n=6) when compared to the SHRSP *(p<0.01). Values are presented as mean 
± SEM.  
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4.3.1.1.3  WKY Variant (Transgene specific) Gstm1 expression in Cardiovascular 
Tissue   
At 5 weeks of age, brain, heart and aortic transgene specific Gstm1 mRNA levels 
were assessed by SYBR quantitative real time PCR (qRT-PCR) in male rats in the 
WKY, SHRSP, Trans1 and Trans 2 rats. Cardiac transgene Gstm1 expression was 
significantly increased in the WKY when compared to the SHRSP (p<0.05) (Figure 
4-6 panel A). Trans1 and Trans2 rats were not significantly difference from the 
SHRSP parental strain. The trend towards increased expression for the Trans2 
line did not reach significance due to large variability probably due to low n 
numbers (Figure 4-6 panel A). Neural transgene Gstm1 mRNA levels in WKY were 
significantly increased when compared to the SHRSP (p<0.05), however, while 
there was a similar increasing trend in transgene Gstm1 expression in Trans1 and 
Trans2 rats, it did not reach significance  (p>0.05) (Figure 4-6 panel B). Vascular 
transgene expression showed an increased trend in Trans1 and WKY rats and was 
significantly increased in Trans2 and (p < 0.05). Additionally, Trans2 vascular 
transgene expression was significantly increased to that of the WKY levels (p < 
0.05) (Figure 4-6 panel C).  
At 21 weeks of age, brain, heart, and liver transgene Gstm1 mRNA levels were 
assessed in male rats in the WKY, SHRSP, Trans1 and Trans 2 rats. Cardiac 
transgene Gstm1 expression was significantly increased in WKY when compared 
to SHRSP (p<0.01) (Figure 4-7 panel A). Cardiac Gstm1 expression in Trans1 and 
Trans2 rats showed increased trends but was not significantly different from 
SHRSP rats (Figure 4-7 panel A). Levels of neural transgene Gstm1 mRNA were 
significantly increased in WKY animals when compared to SHRSP (p<0.01). There 
was no significant difference in neural Gstm1 expression between Trans1 and 
Trans2 and SHRSP animals (p>0.01) (Figure 4-7 panel B). Hepatic transgene 
Gstm1 expression was significantly increased in WKY when compared to SHRSP 
(p<0.01) (Figure 4-7 panel C). Unfortunately, transgene expression in the aorta 
resulted in undefined errors where the experimentation appeared to proceed 
normally through all stages of testing but the instrument did not generate an 
analysis or provide final results at the end of the run. This lack of definite result 
was further investigated by Exiqon which could find no fault with the probe or  
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Figure 4-6: Transgene (WKY specific) Gstm1 Expression in Trans1, Trans2 and Parental 
Strains at 5 Weeks of Age. 
Transgene (WKY form) Gstm1 expression in (A) heart, (B) brain and (C) aorta at 5 
wks of age. Cardiac transgene Gstm1 levels were significantly increased in the 
WKY (n=8) animals when compared to SHRSP (n=8) animals *(p<0.01). Neural 
transgene Gstm1 levels were significantly increased in the WKY (n=8) when 
compared to the SHRSP (n=8) *(p<0.01). Aortic Gstm1 transgene expression levels 
were significantly increased in Trans2 animals (n=3) when compared to the 
SHRSP (n=8) **(p<0.001). Values are presented as mean ± SEM.  
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Figure 4-7: Transgene (WKY Specific) Gstm1 Expression in Trans1, Trans2 and Parental 
Strains at 21 Weeks of Age. 
Transgene (WKY form) Gstm1 expression in (A) heart, (B) brain, (C) liver at 21 
wks of age. Cardiac transgene Gstm1 levels were significantly increased in WKY 
(n=8) when compared to SHRSP (n=8) *(p<0.01). Cardiac expression in Trans1 
(n=8) and Trans2 (n=6) animals showed increased trends of expression when 
compared SHRSP animals. Neural transgene Gstm1 levels were significantly 
increased in WKY (n=8) when compared to the SHRSP (n=8). Hepatic Gstm1 levels 
were significantly increased in WKY (n=8) when compared to the SHRSP *(p<0.01) 
and Trans1 showed trends of increased expression. Values are presented as mean 
± SEM.  
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cDNA used and thus values for 21 week vascular expression data are not 
included.    
4.3.1.1.4 Expression of Other Gstm Family Members  
The mu family of glutathione tranfersases are highly homologous and in order to 
assess any changes to the mu family expression caused by the integration of the 
transgene, Gstm2 and Gstm3 mRNA expression was measured in a variety of 
tissues at 21 weeks of age. β-actin was used as a housekeeper for all experiments 
except for heart where GapdH was used. While brain Gstm2 expression was 
significantly increased in the WKY compared to the SHRSP *(p<0.05), there was 
no significant change in expression in neural, renal, cardiac, hepatic and vascular 
Gstm2 expression in Trans1 and Trans2 rats was when compare to the SHRSP 
(p>0.05) (Figure 4-8). There was no significant change in Gstm3 expression in the 
transgenic rats when compared to the SHRSP (p>0.05). The only significant 
differences in Gstm2\3 expression occurred between WKY and Trans2 rats in 
renal Gstm2 expression (Figure 4-8), and WKY and Trans1 rats in the liver (Figure 
4-9).  
4.3.1.2 Immunohistochemistry 
To further investigate vascular Gstm1 expression, IHC was performed on the 
aorta at 21 weeks of age. Measuring percent staining in the aorta demonstrated a 
significant increase of Gstm1 in WKY (n=4) when compared to SHRSP (n=4) 
(p<0.05) (Figure 4-10). There was a an increased trend in protein expression for 
aortas in Trans1 (n=4) and Trans2 (n=4) rats which was not significantly different 
from either parental strain, conveying an intermediate expression (Figure 4-10) 
4.3.2 Location of the Transgene Insertion Site 
Inverse PCR was used to amplify regions of DNA adjacent to the transgene in 
order to determine the insertion site of the transgene in each of the transgenic 
lines. Liver genomic DNA from each transgenic line was restricted using the 
HindIII restriction enzyme, and inverse PCR was performed. Using transgene 
specific primers for the HindIII restriction site, we obtained positive PCR 
amplification for both transgenic lines (Figure 4-11). As shown in Figure 4-11, 
multiple unique bands were identified for each of the transgenic animals. These 
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bands were gel extracted, and the fragment was cloned into Strataclone vector. 
The clones were then screen and every band was sequenced. After being aligned 
to the transgene and IPCR sequence, results indicated that there was only one 
band from Trans2 rats to have unknown, or different from the transgene, 
sequence (Figure 4-11). This sequence was then blasted to the Brown Norway, 
including non-assembled trace sequences. This led to the sequence lining up to 
the trace sequence of rt71hp27.x. Recently, a new updated Brown Norway 
sequence has been made available on Ensmbl with increased genome sequencing 
capabilities; however, unfortunately, these increases did not include the 
rt71hp27.x trace sequence. 
After sequencing, none of the sequences for Trans1 rats using the HindIII 
restriction site were unique, and were generally inter-ligated transgene 
sequences, i.e. transgene fragments that were restricted and ligated onto other 
transgene fragments. In order to further investigate this, another restriction site, 
Pst1, was used for identification of the insertion sequencing for Trans1 animals. 
As shown in Figure 3-14, where both HindIII and Pst1 restriction enzymes were 
used for restriction during inverse PCR, there are bands unique to the Trans1 rats 
when compared to the SHRSP. Unfortunately, similar to the HindIII restriction 
site, each of the PstI bands were either internal fragments or inter-ligated 
transgene fragments. 
In order to ascertain that the transgene had not identically inserted itself into 
genome for both transgenic lines (which is highly unlikely), the primers used to 
verify the insertion site of the transgene into the rt71hp27.x trace sequence in 
the Trans2 line were used as sequencing primers for the insertion of the 
transgene into the Trans1 rat genomic DNA. For Trans1 line, there were no 
transgene sequences adjacent to the rt71hp27.x trace sequence. Allowing the 
conclusion, that while the exact insertion site within the genome for Trans1 rats 
is still unknown, it differs from that of the Trans2 line insertion site.         
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Figure 4-8: Gstm2 expression in Trans1, Trans2 and parental strains at 21 weeks of age. 
Total Gstm2 expression in (A) kidney, (B) brain, (C) heart, (D) aorta, (E) liver at 
21 wks of age. Renal Gstm2 levels of WKY, Trans1 and Trans2 animals were not 
significantly different from SHRSP (p>0.05). Renal Gstm2 expression in Trans2 
rats was significantly less than WKY (*p<0.05). Neural Gstm2 levels were 
increased in WKY (n=8) when compared SHRSP (n=8) animals, but not in either 
Trans1 (n=8) or Trans2 (n=6) rats. Cardiac, aortic and hepatic Gstm2 levels were 
not significantly different across all four strains. Values are presented as mean ± 
SEM.
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 Figure 4-9: Gstm3 expression in Trans1, Trans2 and parental strains at 21 weeks of age. 
Total Gstm3 expression in (A) kidney, (B) brain (C) heart, (D) aorta, (E) liver at 
21 wks of age. Renal, neural, cardiac, vascular and hepatic Gstm3 levels in WKY 
(n=8), Trans1 (n=8) and Trans2 (n=6) animals were not significantly different 
from SHRSP (n=8) (p>0.05). The only significant difference in expression was 
hepatic Gstm3 expression between the WKY and Trans1 animals (*p<0.05). Values 
are presented as mean ± SEM. 
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4.3.3 Copy Number Variation 
Data from the custom Taqman Copy Number Assay (Applied Biosystems) conveyed 
that there were multiple copies of the transgene in Trans1 rats across multiple 
generations (Figure 4-13). While this probe was custom designed and 
manufactured to anneal to SNP variations that were specific to the WKY variant 
of Gstm1 there was, however, evidence of PCR amplification suggesting a mis-
aligning of the probe within the SHRSP genome. Further investigation of this 
finding in conjunction with Applied Biosystems determined that mis-expression of 
the WKY Gstm1 variant in the SHRSP genome was within their quality control 
parameters and was therefore an assay artefact. This caused difficulty analyzing 
transgene copy number with this probe. Because of these mis-alignment issues, 
and the delay in Trans2 rat breeding, these experiments were not repeated in 
Trans2 animals.  
In order to further investigate transgene copy number in both transgenic lines, 
internal fragments from the inverse PCR sequencing were analyzed. When 
viewed, both transgenic lines included internal fragments that contained 
segments of the transgene that sequenced from the end of one copy into the 
beginning of the next, in a head-to-tail array.    
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Figure 4-10: Localization of Gstm1 in the Aorta at 21 weeks of age.  
A: IHC of Gstm1 protein in whole kidney sections from WKY, SHRSP, Trans1 and 
Trans2 rats at 21 weeks of age. Magnification =10x. B: quantitative measurement 
of Gstm1 expression expressed as percentage staining (n=4 for all strains). 
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Gstm1 restriction sites
Gstm1
IPCR amplifies the unknown DNA 
sequences that are immediately 
adjacent to the known sequence of 
our transgene
Plasmid Vector towards PCR insert
CCGCGGAGCGGCGCTCTAGACTAGTGGATCCCCCGGGCTGCAGCCCAATGTGGAATTCGCCC
TT
Primer 3 and transgene end
TGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTAGGCTTTTGCAAAACGTT
UNKNOWN
TTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATA
ACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAAT
GACGTATGTTCCCATAGTAACACCAATAGGGACTTTCCATTGACGTCAATGGGAGGAGTATTTA
CGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACG
TCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTAC
TTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCA
ATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATG
GGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCCCGCCCCAT
TGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCTATG
Primer 4
GTGCACTCTCAGTACAATCTGCTC
Plasmid Vector
AAGGGCGAATTCCACAGTGGATATCAAGCTTATCGATACCGTCGACCTCGAGGGGGGCCCGG
TACCCAGCTTTTGTTCCCTTTAGTGAGGGTTAATGCGCGCTTGACGTAATCATGGTCATAGCTG
TTGCTGTGTGAAATGTATCCGCTCACATTCCMMACACATACGAGCGGGAGCATAAAGTGTAA
GCTGGGGTGCTATGAKTGACTAACTCMATAATTGCTTGGGCCTCATGACCGCTCAGTCAGAAC
TGTCTGCCACTCCAATAATTGATCGGCAG
unknown
B
 
Figure 4-11:  Schematic of the inverse PCR procedure with results. 
 A: Liver genomic DNA from SHRSP (n = 2), WKY (n=2), Trans1 (n=4) and Trans2 
(n=3) rats using restriction site HindIII. B: Templates underwent multiple PCR 
reactions in order to target specific products. Adapted from Bessereau (271). The 
text box is a representative sequence where the unknown/flanking region of DNA 
assembles to a trace archived sequence identified in the Trace Archives for Brown 
Norway (Trace Archive reference rt71hp27.x.) 
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Figure 4-12: Mapping the transgene insertion site by inverse PCR for Trans1 rats. 
Liver genomic DNA from SHRSP (n = 2), transgenic (n=2), WKY (n=1) rats was 
digested by HindIII and PstI. Trans1 animals showed unique bands for both 
restriction sites 
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Figure 4-13: Copy number variation between parental strains and Trans1 rats 
CNV as determined by Taq-man assay and Copy Caller analysis. Data show that 
Trans1 rats display a significant increase in wild type Gstm1 copy number when 
compared to the SHRSP parental strain *(p<0.005) across generations. Gen1 = 1st 
generation, Gen2+ = 2nd and subsequent generations. Values are presented as 
mean ± SEM. 
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4.4 Discussion 
In this chapter the molecular characterization of the Gstm1 transgenic rat has 
been investigated before onset of hypertension (5 weeks) and at maturity (21 
weeks). Both transgenic lines have demonstrated an increase in total and 
transgene specific expression of Gstm1 in kidneys at 5 weeks of age (Figure 4-2) 
as well as increased transgene expression in several other cardiovascular tissues 
(Figure 3-4). Additionally, we saw increased total Gstm1 expression in a range of 
cardiovascular tissues at 21 weeks of age (Figure 4-4) without potential changes 
of two other Gstm family members (Gstm2 and Gstm3) that could be an artefact 
from the addition of the transgene (Figures 4-8 and 4-9). Although it was not 
possible to identify the exact location of the transgene insertion site in both 
transgenic lines, data presented indicate that they are not identically inserted 
and from this it can be inferred that the decrease in blood pressure is not due to 
the insertion site alone. Furthermore, sequencing data shows that each 
transgenic line contains multiple copies of the transgene across a number of 
generations.  
Investigation at 5 wks of age, showed a significant increase in total and 
transgene (WKY) specific renal Gstm1 mRNA expression in Trans1 and Trans2 rats 
(Figure 4-2) with a similar trend in renal Gstm1 protein expression (Figure 4-2). 
While this was confirmed with IHC in whole kidney at 5 weeks of age for Trans1, 
IHC analysis for Trans2 was not feasible due to breeding difficulties which 
resulted in very low numbers of rats for this line. This general increase in renal 
Gstm1 expression (Figures 4- 2) allows us to conclude that the increase in total 
Gstm1 expression in the transgenic lines are a result of increased transgene 
specific Gstm1 expression rather than changes in endogenous Gstm1 (Figure 4-2). 
However, this increase of renal Gstm1 mRNA expression is not sustained at the 
later time point investigated (i.e. 21 weeks of age) in the Trans2 line. This 
unsustained increase of expression, or return to SHRSP levels, at 21 weeks is also 
observed for protein levels in both Trans1 and Trans2 (Figure 4-3). However, an 
age related decline in transgene expression is not unique to these animals. 
Previous reports have shown that transgene expression levels can decline with 
time both in vivo and in vitro (Lit paper and references 6,9 of paper, Uneda et 
al.). For example, EGFP expression, under the control of the ef1-α promoter, 
was found to be progressively limited during the later stages of development 
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(272),  and completely restricted in adult tissue of X. leavis (273), Medaka (274), 
and zebraﬁsh (275). While these studies have reported a decrease in expression 
levels during later stages of life, each of these studies, in line with ours, 
demonstrated phenotypic differences at a later stage as a result of early 
developmental expression (272-275).  
The over expression of Gstm1 in the kidney before the onset of hypertension, 
appears to have a preventative effect on the progression of hypertension in the 
transgenic SHRSP rat (Figure 3-1 and Figure 4-2). While Gstm1 mRNA is 
differentially expressed between the two transgenic lines (Figure 4-3) at 21 
weeks of age, both lines continue to have almost identical reductions in systolic 
blood pressure. Indeed, increased mRNA and protein levels in the kidney at 5 
weeks of age seem to be able to reduce the severity of disease in mature 
animals, at a time point when the SHRSP would have normally developed full 
hypertension. This reduced disease severity will be further examined in the 
subsequent chapter where renal and vascular pathology and function is 
investigated (ex vivo) in mature rats. Other studies have found similar results 
with early over expression of genes during development. Studies conducted by 
Perez et al. have shown the early increased expression of Trx1 not only provided 
an increased resistance to oxidative stress in the mouse but elongated the life 
span of the animal as well (242).  
While there seems to be very few phenotypic differences between the two 
transgenic lines, there are some expression differences that make each line 
unique. One factor that could potentially play a role in this variation of 
expression exhibited by the same transgene is the impact of the transgene 
insertion site (or positional effect). Often differences in expression are due to 
enhancers that regulate neighbouring genes (276). While these enhancers 
regulate their respective gene of interest, they can also affect the expression 
pattern of the transgene that is inserted near them. Identification of the exact 
transgene insertion site in our transgenic lines would have provided important 
information for the determination of these potential regulatory factors. 
However, despite concerted effort and utilization of both previous and new rat 
genome assemblies it was not possible to fully determine the exact location for 
either of the transgenic lines. The inverse PCR method used for the rapid in vitro 
amplification of unknown DNA sequences that flank a region of known sequence 
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proved to be problematic for our transgenic animals. While we did find many 
unique bands in the transgenic columns (Figures 4-11 and 4-12) that 
demonstrated additional fragments of DNA in the transgenic genomes unique to 
Trans1 and Trans2; ligation issues for both lines made it difficult to ascertain the 
insertion site. For Trans1, these ligation issues made it virtually impossible to 
determine the insertion site of the transgene. Each unique band was made up of 
various inter-ligated fragments of the transgene from internal copies. In order to 
accommodate for this, multiple restriction sites and corresponding primers were 
used. Nonetheless, there was no further insight to where the Trans1 integrated 
into the SHRSP genome. 
We were able to establish the Trans2 insertion site to be within a region of the 
genome located in the trace archived sequenced area, rt71hp27.x. The 
rt71hp27.x. genome sequence has yet to be assembled to the rat genome which 
makes it impossible to know which chromosome this trace resides on, however, 
this is an ongoing process and hopefully future advancements by the EURATRANS 
collaborative Rat consortium will make this information available in the near 
future. Since there was additional rt71hp27.x sequence in Ensembl, the 
additional sequence was used to verify Trans2 insertion into this region by 
designing primers to the additional sequence. Because rt71hp27.x sequence has 
not yet been assembled to the Brown Norway genome, it is difficult to determine 
if Trans2 was indeed undergoing expression regulation from DNA-methylation or 
by any other regulating enhancers or genes (269). Further investigations will 
elucidate where this archived sequence is within the full rat genome. 
An additional result arising from sequencing the unique bands from the 
transgenic rats has confirmed transgene integration and the incorporation of 
multiple copies numbers for both transgenic lines in a head to tail fashion. In 
addition to using sequencing as a method to confirm copy number across 
generations, copy number variation was assessed by CNV Taqman probes (Applied 
Biosystems) that were custom synthesized to a unique portion of the WKY form 
(transgene) construct (See Appendix). However, due to technical difficulties of 
unspecific primer annealing, this method was found not to be reliable (i.e. SHRSP 
animals were showing increased copy numbers when sequencing data confirm 
that no copy exists within this genome) (223). Moreover, Trans1 and Trans2 both 
had endogenous expression of Gstm1 in their genome which increased the 
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possibility and occurrence of reduced primer specificity. Because of this, the 
copy number assessment was not reliable through this method. However, since 
genotyping was carried out on every Trans2 animal and on randomly selected 
Trans1 animals, we were assured that the transgene was present through 
multiple generations.   
One of the reasons that the ef1-alpha promoter was chosen for this study was 
that the ef1-α promoter-driven transgenic animals have been widely used 
because of ubiquitous expression of the gene during development (277;278). 
However, as with all methods of genome manipulation there is always potential 
for unexpected effects in which makes each transgenic line produced unique (7). 
There are many factors that can be influenced when incorporating a new or 
different gene into the genome. Because of this, we investigated the effects of 
increased Gstm1 on other members of the Gstm family. There are eight currently 
known members of the Gstm gene family in the rat and the entire family has a 
high sequence homology (211). In this study, we also examined two family 
members; Gstm2 and Gstm3, in order assess any changes in expression of the 
Gstm family and to determine their potential to be altered as a result of 
increased Gstm1 expression in the SHRSP. Gstm2 expression was investigated 
because the sequence is the most similar to Gstm1 and many IHC antibodies bind 
to both Gstm1 and Gstm2 (211). Measuring Gstm2 expression allowed for a more 
in-depth assessment of the actual changes of Gstm1 in the transgenic rats. 
Gstm3 was then investigated in order to insure that other members of the Gstm 
family were not significantly altered with the incorporation of the transgene. 
Since there were no significant changes in Gstm2 and Gstm3 expression in the 
transgenic rats compared to the SHRSP in any of the tissues, we were able to 
conclude that increased Gstm1 expression alone was having a functional affect 
on systolic blood pressure in the transgenic rat and not a combined effort of the 
Gstm family. 
The current chapter has assessed the differences in expression levels of Gstm1 in 
the two transgenic lines and has demonstrated that there is an increase in renal 
Gstm1 prior to the onset of hypertension in both transgenic lines, which is 
maintained at 21 weeks of age in Trans1 rats. In the next chapter we follow up 
these findings by investigating whether the increased levels of Gstm1 in kidney 
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and other cardiovascular tissues, has a functional impact on intermediate 
phenotypes including renal and vascular function and oxidative stress.  
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5.1 Introduction 
In the previous chapters, it has been demonstrated that a significant increase in 
Gstm1 expression in the kidney at an early stage of development resulted in a 
significant decrease in blood pressure and cardiac hypertrophy in the transgenic 
rat lines. To fully understand the effects of increased Gstm1 expression in the 
SHRSP background, other functional aspects should be examined in order to 
determine if increased Gstm1 expression results in improved intermediate 
phenotypes and reduced end organ damage (i.e. renal and vascular function and 
pathology).  
It is well established that oxidative stress is an important pathogenic factor in 
the development of cardiovascular disease and increased production of reactive 
oxygen species (ROS) and/or reduced defences against ROS not only leads to 
endothelial dysfunction but also causes structural damage to tissue and organs 
(237;279;280). In particular, previous studies have shown that the oxidative 
stress pathways play important roles in the development of renal and vascular 
pathology (96;199). Considering the role of Gstms in the protection against 
reactive oxygen species it is anticipated that enhanced Gstm1 expression will 
improve antioxidant defences in the tissues and organs where expression has 
been improved.  
5.1.1 Renal Function 
Hypertension is a multifactorial disease which affects many cardiovascular organs 
including the heart, blood vessels and kidneys (33). It is well established that 
hypertension is associated with renal injury and dysfunction which can result in 
poor fluid maintenance and electrolyte homeostasis. The SHRSP has a marked 
susceptibility to develop renal damage while the SHR, from which the SHRSP 
strain originated, is a relatively resistant strain (281). While both strains are 
considered hypertensive, and both have relatively similar genomes, the severity 
of renal injury is marked in the SHRSP, thus allowing us to conclude that SHRSP 
harbours genetic factors that contribute to renal injury susceptibility.      
One of the main indications of renal impairment is the increased levels of 
proteinuria in the urine due to reduced glomerular filtrations or an insufficiency 
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of absorption due to the leakiness of the podocyte layer in the glomerulus (282). 
Furthermore, there is evidence for reduced renal function in SHRSP which is 
characterized by increased proteinuria, reduced glomerular filtration rate (GFR) 
and structural damage, such as glomerulosclerosis and tubulointerstitial damage 
after the onset of full hypertension and in salt-loading conditions (87;283). 
Additionally, there is increasing evidence in the literature that oxidative stress is 
central to this renal dysfunction (96;284-286).  
 
5.1.2 Vascular Function 
Endothelial dysfunction is also associated with hypertension. More specifically, 
increased blood pressure has been shown to decrease endothelium-mediated 
vasodilation and has been reported in both hypertensive patient and various 
animal models of hypertension (287;288). Vascular tone is normally regulated by 
a delicate balance between vasodilators and vasoconstrictors, whereas 
disturbance in the NO/O2
- pathways can lead to hypertension which, if reaching 
malignant levels results in end-organ damage. However, mechanisms to explain 
the observed dysfunction are conflicting and vary depending upon the model 
examined. In the SHRSP, there is a decrease in endothelium-dependent 
relaxation despite increased eNOS activity (234;289;290). Data has shown that 
free radicals such as superoxide react with and inactivate the vasodilator nitric 
oxide, reducing NO bioavailability and impairing vascular function (237;290;291). 
Since Gstm1 plays an important antioxidant role, we investigated the impact of 
increased Gstm1 expression on vascular endothelial function through assessment 
of conduit (aorta) and resistance (mesenteric) artery function. 
Additionally the mechanical properties of mesenteric resistance arteries (MRA) 
were investigated due to their fundamental importance in blood pressure 
regulation. Resistance arteries are the major site of resistance to blood flow and 
therefore play an important role in blood pressure regulation. Elevated 
peripheral resistance is a hallmark of essential hypertension; therefore, 
abnormalities in the morphology/mechanical function of resistance arteries can 
participate in mechanism that elevate blood pressure (292). It has been well 
established that vascular remodelling occurs in response to an increase in blood 
pressure.  While the underlying mechanisms leading to vascular remodelling are 
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not well understood, it has been shown that the adaptive change in the structure 
and elasticity of the vessel is characterized by a change in vessel diameter and 
stress-strain relationship (293-295). Specifically, in the SHRSP, when compared 
to normotensive rates, lumen diameter is smaller and wall thickness to lumen 
ratio is increased (296). 
5.1.3 Aims 
In the previous chapters, we have shown that a significant increase in Gstm1 
expression at an early stage of development results in a significant decrease in 
blood pressure and cardiovascular risk in our transgenic lines. From this data, we 
hypothesized that this reduction in blood pressure and end organ damage are due 
to improved vascular and kidney function through reduced oxidative stress. The 
aim of this chapter was to investigate whether increased Gstm1 gene expression 
plays a functional role in oxidative stress and end-organ damage.  The functional 
properties of Gstm1 in the transgenic SHRSP rats were examined through (1) 
oxidative stress measurements, (2) wire and pressure myography, (3) histological 
analysis and (4) renal function measurements.  
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5.2 Materials and Methods 
5.2.1 Metabolic Cages 
Telemetered animals were placed in metabolic cages for the collection of urine 
and the monitoring of water in-take for baseline and salt-loaded studies. At 16 
weeks old, the rats were housed in the metabolic cages for 24 hours and baseline 
data was collected on water intake and urine volume for WKY, SHRSP, Trans1 
and Trans2 animals. Additionally, at 21 weeks old, rats were housed in metabolic 
cages for 24 hours and additional baseline or salt-loading data (WKY, SHRSP, and 
Trans1 only was collected on water intake and urine volume. Urine was kept on 
ice and stored at -80°C, until required for biochemical analysis for chloride, 
potassium and Sodium concentrations. The analysis was carried out using a 
Beckman CoulterAU640 clinical chemistry analyser (formally known as Olympus 
AU 640) using ion selective electrodes (ISE) utilising potentiometry. The urinary 
creatinine and total protein concentrations were assessed by creatinine 
clearance kit (Section 2.2.4) and Peirce proteinuria kits (Section 2.6.2), 
respectively.    
5.2.2 Estimated Glomerular Filtration Rate 
Kidney function was examined in rats at 21 weeks of age at baseline and after 
salt-loading. Blood samples were collected during sacrifice for WKY, SHRSP, and 
transgenic animals. To extract plasma, whole blood was collected into heparin 
lined tubes and was stored on ice for a maximum of 24 hours until centrifugation 
at 2240 g for 20 mins at 4°C. Plasma was removed without disturbing red and 
white blood cells and was stored at -80°C for future experiments. Urine was 
collected for 21 hours prior to sacrifice with water intake over 24 hours 
recorded. Indirect glomerular filtration rates (GFR) were determined by a 
clinically validated automated analyzer (c311, Roche Diagnostics, Burgess Hill 
UK), using the manufacturers calibrators and quality control material. All 
calculations were normalized to kidney weight. 
5.2.3 Tissue Collection 
Animals were sacrificed after 9 weeks of telemetry monitoring at 21 weeks of 
age. Blood samples were collected and plasma extracted for functional 
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measurements. A quarter of a kidney was fixed in 10% formalin for histological 
analysis (Section 2.2.3). Kidney, brain, heart, aorta, and liver tissues were snap 
frozen for further analysis. Thoracic aorta and mesenteric resistance arteries 
(MRA) were isolated for the investigation of endothelial function by wire 
myography and tested for mechanics by pressure myography. Oxidative stress 
measurements, as previously detailed, were investigated using snap frozen 
tissue. Oxidative stress details are contained in section 2.2.5.  
5.2.4 Wire myography 
For examination of functional response and vascular reactivity, small (3rd order) 
mesenteric arteries (MRA) and thoracic aortas were harvested from animals at 21 
weeks of age. Full details of wire myography experiments are in Section 2.2.6. 
Mesenteric arteries and thoracic aortas were dissected from connected tissue, 
trimmed into sections approximately 2mm in length (4 mm for Aortas), and 
stored in overnight at 4° C before use. Contractile responses were tested by pre-
treatment with KCL (10µM), noradrenalin (phenylephrine for aortas) and 
carbachol. Vessels were left to rest for 30 mins following two Krebs’ buffer 
washes. A cumulative concentration response curve to noradrenalin for MRA and 
phenylephrine for aortas, 10 nM to 30 µM was performed first in the absence and 
again after two Krebs’ washes, in the presence of L-NAME (100 µM ). The 
increase in tension in the presence of L-NAME provided a measure of the effect 
of NO on basal tone and a measure of NO bioavailability. The percentage of 
maximal contraction was calculated compared to response at 30 µM 
noradrenalin/phenylephrine without L-NAME. Similarly for assessment of 
relaxation responses, carbachol curves from 10nM to 10 µM were performed to 
measure the percentage of relaxation from maximal contraction in response to 
stimulated NO release. AUC was calculated from the response curves.  
5.2.5 Pressure Myography 
In order to examine the structural and mechanical differences in mesenteric 
resistance arteries, the pressure-diameter relationship differences between 
SHRSP, WKY and transgenic lines, was assessed by pressure myography. Dissected 
MRA (approximately 2 mm in length) were subjected to increased intramluminal 
pressure from 10-110 mmHg at 10 and 20 mmHg intervals over a period of 
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approximately 30 mins. Measurements of internal (Di) and external (De) were 
measured and used to calculate structural parameters cross sectional areas (CSA) 
and wall to lumen ration using the equations listed in section 2.2.7.  
5.2.6 Oxidative stress 
For examination of the oxidative stress cascade, measurements on various steps 
of the oxidative stress pathway were performed in 5 week, 21 week and 21 week 
salt loaded animals (i.e. superoxide, hydrogen peroxide, nitric oxide, 
glutathione, and lipid peroxidation). Samples were homogenized using snap 
frozen tissues and all manufacturers’ recommendations for each kit were used. 
All methods are fully described in Sections 2.2.5     
5.2.7 Histology – Gross Pathology Analysis 
Full details for the preparation of tissues and histological analysis is fully 
described in Section 2.2.3. To assess renal remodelling, 3 µm renal adjacent 
sections from WKY, SHRSP and transgenic animals were stained with Harris 
haematoxylin and eosin and structures of tissues were examined by microscopic 
analysis; nuclei appeared purple and cytoplasm pink. Fibrosis was examined by 
staining with picrosirius red. Microscopic analysis and a colour threshold 
application were used to measure the average intensity of picrosirius red stain of 
fibrotic tissue (ImageProPlus 4.1, Media Cybernetics, US).  
5.2.8 Statistical Analysis 
Animal work was carried out with 6-8 animals per group. All quantification of 
histological analyses was carried out blind. Statistical analysis was done using 
commercially available packages including Prism Graphpad®. Significance was 
set P<0.05 and calculated using a one way ANOVA. Tukey post-hoc analysis was 
performed if overall ANOVA at least one p<0.05. 
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5.3 Results 
5.3.1 Effects of Gstm1 expression on oxidative stress 
5.3.1.1 Kidney 
In order to assess the changes in oxidative stress as a result of increased Gstm1 
expression after the onset of hypertension, multiple stages of the oxidative 
stress cascade was measured (i.e. superoxide, hydrogen peroxide, glutathione 
and lipid peroxidation). At 21 weeks of age there was no significant difference 
between the strains for kidney levels of  superoxide (O2
-), as measured by 
lucigenin chemiluminesence, and hydrogen peroxide, as measured by Amplex Red 
Assay (Figure 5-1) (p>0.05). Intracellular GSSG: GSH ratio levels were measured 
in kidneys at 21 weeks age. GSSG: GSH ratios, which when elevated are 
indicative of oxidative stress; show a reduced trend in the WKY and both 
transgenic lines when compared to the SHRSP at 21 weeks of age (Figure 5-1). 
Measurement of lipid peroxidation using a malondialdehyde (MDA) assay showed 
a significant reduction in renal MDA production in the WKY (n=8), Trans1 (n=8) 
and Trans2 (n=6) when compared to the SHRSP (n=8) at 21 weeks of age (p<0.05) 
(Fig. 8 Panel A).  
In order to further investigate renal oxidative stress levels during the early 
stages of development, and to determine if they correspond with the increase of 
Gstm1 expression before the onset of hypertension, we measured GSSG: GSH 
ratio levels at 5 weeks of age. There were no significant differences in GSSG: 
GSH ratio levels between the four strains (Figure 5-2). Furthermore when GSSG: 
GSH ratio levels of 5 weeks are compared to that of 21 wks, ratio levels at 5 
weeks of age were considerably reduced.  
Additionally, glutathione measurements on salt-loaded kidneys were also 
performed at 21 weeks of age. GSSG:GSH ratios were significantly reduced in 
WKY and Trans1 animals when compared to the SHRSP (Figure 5-3) (p<0.01). 
Renal MDA production in salt loaded animals was significantly decreased in the 
WKY when compared to the SHRSP (p<0.05).  
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Figure 5-1: Renal Oxidative Stress Measurements in SHRSP, WKY and Transgenic lines at 21 
weeks of age. 
Measurements of various steps in the oxidative stress pathway in kidneys from 
SHRSP (n=8), WKY (n=8), Trans1 (n=8) and Trans2 (n=6) rats. There was no 
significant difference in oxidative stress in superoxide (lucigenin 
chemiluminescence), hydrogen peroxide (Amplex Red), Nitrate and Nitrite 
(Greiss Assay) and glutathione between all for strains (p>0.05). Lipid 
peroxidation (MDA) measurements showed a significant decrease in oxidative 
stress in the WKY, Trans1 and Trans2 rats when compared to the SHRSP (p<0.05). 
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Table 5-1 Renal Oxidative stress Measurements in SHRSP, WKY, and Transgenic lines at 5 wks of 
age 
 
 GSSG:GSH ratio 
(µM) 
 Lipid peroxidation  
(MDA:Protein Ratio) 
 
 5 wks 21 wks  5 wks 21 wks  
SHRSP 0.0396±0.004 0.4291±0.08  0.00736±0.002  0.0476±0.01  
WKY 0.0769±0.013 0.2572±0.04  0.005332±0.001 *0.0241±0.005  
Trans1 0.0475±0.010 0.2666±0.04  0.01258±0.004 *0.0241±0.002  
Trans2 0.0553±0.016 0.3607±0.08  0.00776±0.0003 *0.0214±0.002  
       
The table provides oxidative stress data at 5 and 21 weeks of age for two stages 
in the oxidative stress pathway for comparison between ages. n=6-8 for SHRSP, 
WKY, and Trans1 and n=3-6 for Trans2 at 5 weeks. WKY, Trans1 and Trans2 rats 
are significantly different at 21 weeks of age when compared to the SHRSP 
*(p<0.05).  
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Figure 5-2: Renal Oxidative Stress Measurements in SHRSP, WKY and Transgenic lines at 21 
weeks of age for Salt loaded Animals 
Measurements of oxidative stress pathway parameters in SHRSP (n=8), WKY 
(n=8), and Trans1 (n=8) rats. (A) Glutathione measurements in WKY and Trans1 
rats were significantly reduced when compared to SHRSP (p<0.05). (B) WKY lipid 
peroxidation measurements were significantly reduced when compared to SHRSP 
(p<0.05).  
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5.3.1.2 Vasculature 
Intracellular GSSG: GSH ratio levels were measured in the aorta at 21 weeks age. 
While there was no significant difference in GSSG: GSH ratios between WKY 
(n=8), SHRSP (n=8), Trans1 (n=8) rats (p>0.05), GSH: GSSG ratios levels for 
Trans2 rats (n=8) were significantly increased compared to that of the SHRSP and 
WKY (p<0.001 and p<0.01, respectively) (Figure 5-4). 
Measurement of lipid peroxidation using a malondialdehyde assay showed no 
significant change in aortic MDA production in the WKY (n=8), Trans1 (n=8) and 
Trans2 rats (n=6) when compared to the SHRSP (n=8) at 21 weeks of age (p>0.05) 
(Figure 5-4).  
5.3.1.3 Other Tissues 
Intracellular GSSG: GSH ratio levels were measured in the liver at 21 weeks age. 
GSSG: GSH ratios in the WKY (n=8), SHRSP (n=8), Trans1 (n=8) and Trans2 (n=8) 
rats were not significantly different from each other (Figure 5-5). Measurement 
of lipid peroxidation using a malondialdehyde assay in the heart, brain and liver 
were not significantly different between any of the strains (p> 0.05) and were all 
within a normal range (Figure 5-5). 
5.3.2 Effects of Gstm1 on Renal Function 
5.3.2.1 Estimated GFR 
Creatinine clearance, as measured by estimated (indirect) glomelular filtration 
rate (GFR), was measured at 21 weeks immediately prior to sacrifice. While 
there was a trend towards increased GFR in Trans1 rats, there was no 
significance difference between all four strains (Figure 5-6) (p>0.05) at baseline.  
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Figure 5-3: Vascular Oxidative Stress Measurements in SHRSP, WKY and Transgenic lines 
at 21 weeks of age  
Measurements of oxidative stress parameters in the thoracic aorta for SHRSP 
(n=8), WKY (n=8), Trans1 (n=8) and Trans2 (n=6) rats. (A) While there was no 
significant difference in glutathione measurements between WKY, Trans1 and 
SHRSP (p<0.05), glutathione measurement in Trans2 rats was significantly 
increased when compared to the SHRSP and WKY (p<0.001 and p<0.01, 
respectively). (B) There was no significant difference in lipid peroxidation 
between WKY, Trans1, Trans2 and SHRSP rats.  
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Figure 5-4: Oxidative Stress Measurements in SHRSP, WKY and Transgenic lines at 21 
weeks of age in Cardiovascular Tissues  
Measurements of various steps in the oxidative stress pathway in SHRSP (n=8), 
WKY (n=8), Trans1 (n=8) and Trans2 (n=6) rats. There was no significant 
difference in hepatic glutathione and lipid peroxidation measurements between 
all four strains (p<0.05). Cardiac and brain lipid peroxidation measurements were 
not significantly different between all four strains (p>0.05).  
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5.3.2.2 Biochemical analysis of Urine 
Sodium, potassium and chloride excretion was measured at 21 wks in WKY (n=8), 
SHRSP (n-8), Trans1 (n=8) and Trans2 (n=8) rats. There was no significant 
difference between all four strains at baseline for sodium, potassium and 
chloride (Figure 5-7) 
5.3.2.3 Renal Hypertrophy 
At 21 weeks of age, kidney mass, normalized to body weight, was significantly 
lower in WKY (n=8) when compared to SHRSP (n=8) during both baseline 
conditions and after salt loading conditions (p<0.0001). Renal mass index for 
Trans1 rats (n=8) was not significantly different when compare to SHRSP at 
baseline or during salt-loading, and Trans2 (n=6) was not significantly different 
from the SHRSP at baseline (Figure 5-7). Due to breeding difficulties, salt-loading 
data could not be assessed for Trans2 rats.     
 
5.3.2.4 Proteinuria 
At 21 weeks of age during baseline measurements, levels of proteinuria in the 
WKY (n=6), Trans1 (n=6) and Trans2 (n=6) rats were significantly less than that of 
the SHRSP (n=12) (p<0.05) (Figure 5-8). During salt-loading, this significant 
difference between the parental strains was exaggerated, with WKY (n=8) salt-
loaded animals having a significantly reduced proteinuria compared to that of 
the SHRSP (n=8) (p<0.05). After salt-loading proteinuria in Trans1 (n=8) animals 
was no longer significantly reduced compared to that of the SHRSP, however, it 
was not significantly different from that of the WKY either (Figure 5-8) (p>0.05). 
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Table 5- 2 Renal Parameters in 21 week old Animals 
 
 
 
 
 
The table illustrates measurements of creatine clearance, sodium, chloride, potassium in order to determine kidney function. n=6-8 per 
group; *(p<0.05) denotes a significant difference between from the corresponding (Salt or Baseline treatment) SHRSP strain.  
 
 
                        SHRSP                 WKY                Trans1              Trans2              SHRSP Salt        WKY Salt         Trans Salt    
GFR        1.565 ± 0.206 1.642 ± 0.137 2.369 ± 0.309 1.605 ± 0.265 3.284 ± 0.56 5.296 ± 0.51 1.862 ± 0.33 
NA2+        83.98 ± 11.13 78.24 ± 8.433 59.29 ± 7.533 76.27 ± 20.70         ND         ND         ND 
K+        116.2 ± 14.02 149.1 ± 14.09 153.0 ± 23.60 115.1 ± 30.08         ND         ND         ND 
Cl-        100.1 ± 10.84 148.7 ± 30.58 99.93 ± 15.76 110.6 ± 30.99         ND         ND         ND 
RMI        4.242 ± 0.044 3.389 ± 0.049* 4.355 ± 0.366 4.115 ± 0.142 4.115 ± 0.11 2.91 ± 0.06*  4.44  ± 0.17 
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Figure 5-5: Proteinuria Measurement in Urine in 21 week old animals.  
(A)  Measurements of urine proteinuria at baseline in WKY (n=8), SHRSP (n=8), 
Trans1 (n=8) and Trans2 (n=6) rats. Proteinuria in WKY, Trans1 and Trans2 rats was 
significantly reduced when compared to the SHRSP (p<0.05). (B)  Measurements of 
urine proteinuria after salt-loading in WKY (n=8), SHRSP (n=8), Trans1 (n=8). WKY 
proteinuria was significantly reduced when compared to the SHRSP (p<0.05).  
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5.3.2.5 Renal Fibrosis and Morphology 
Histological evaluation of renal fibrosis was carried out in kidney sections from 
SHRSP (n=4), WKY (n=4), Trans1 (n=4) and Trans2 (n=4) rats at 21 weeks of age. 
Quantification of picrosirius red staining by % of integrated optical density (%IOD) 
showed no interstitial fibrosis in any of the four strains (Figure 5-10).  
Renal morphology at 21 weeks of age, using haematoxylin staining, showed normal 
arterioles in the WKY and transgenic animals. Renal arterioles in the SHRSP were 
beginning to show evidence of hyperplasia, which is a sign of accelerated 
hypertension (Figure 5-11).  
5.3.3 Effects of Gstm1 expression on the Vasculature 
5.3.3.1 Aortic Function 
Alpha-adrenergic vasoconstrictor mechanisms were tested in thoracic aortae from 
WKY (n=7), SHRSP (n=8), Trans1 (n=6), and Trans2 (n=4) animals at 21 weeks of age. 
Experiments were conducted using dose-responses to phenylephrine (PE), and were 
normalized to 0.1M KCL. There was no significant difference in maximum PE-
induced contraction in aortas between the WKY (AUC 9.012 ± 2.6), SHRSP (AUC 7.77 
± 0.75), Trans1 (AUC 6.59 ± 1.9), and Trans2 rats (AUC 6.39 ± 1.6) (Figure 5-12). 
Additionally, aortas were incubated with the NOS inhibitor L-NAME for 30 mins prior 
to constriction of phenylephrine dose-response curves (Figure 5-12). Inhibition of 
NO-mediated vasodilator responses in the vessel resulted in a great contractility in 
aortae of WKY (AUC 11.32 ± 2.6), SHRSP (AUC 12.17 ± 1.89), Trans1 (AUC 10.45 ± 
3.39), and Trans2 (AUC 11.10 ± 2.2) lines (Figure 5-12). However, there was a much 
larger response in the WKY animals than the SHRSP, Trans1 or Trans2 rats (Figure 5-
12).      
The difference in forces generated in response to PE stimulation before and after 
NOS inhibition was used to measure the bioavailability of NO in aortae. PE induced 
vasoconstriction was only significantly increased in WKY aortic rings when compared 
to SHRSP (p<0.05) (Figure 5-13). The AUC was calculated for NO bioavailability 
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curves and illustrated in Figure 5-13 panel B. There was no change in NO 
bioavailability in the transgenic lines when compared to the SHRSP.  
In order to assess stimulated NO release, carbachol response curves were 
constructed and relaxation of vessels reached a maximum of  42% for WKY, 34% for 
SHRSP, 19% for Trans1, and 65% for Trans2 (Figure 5-14). While there were no 
significant differences in relaxation between the parental stains, Trans2 relaxation 
appears more pronounced than the other three strains but variability is so large that 
more n numbers are needed (Figure 5-x). Additionally, Trans1 appears to have very 
little or no relaxation in response to carbachol. The corresponding AUC for each of 
the strains were SHRSP (420 ± 45.56), WKY (551.6 ± 31.21), Trans1 (644.5 ± 19.98) 
and Trans2 (329.5 ±139.4) showed that the only significant difference between the 
four strains was between SHRSP and Trans1 (p<0.05) 
5.3.3.2 Mesenteric resistance artery function 
Alpha-adrenergic vasoconstrictor mechanisms were assessed in mesenteric 
resistance arteries (MRA) from WKY (n=7), SHRSP (n=6), Trans1 (n=7), and Trans2 
(n=5) animals using the agonist noradrenalin. Concentration response curves before 
and after NOS inhibition with L-NAME were assessed (Figure 5-15 Panels A and B). 
Vascular reactivity was similar in all groups with noradrenalin-induced contraction. 
The slight left-ward shift suggests enhanced contractility after blocking NO synthase 
(Figure 5-15 Panel B). AUC calculations indicated that there was no significant 
difference between MRA function at a basal response level to noradrenalin and 
following NOS inhibition when comparing responses within and between relevant 
groups (Figure 5-15, Panel C).  
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Figure 5-6: Assessment of Renal Fibrosis by Picrosirius Red in 21 week old animals  
Kidney sections were stained with picrosirius red and intensities measured by 
ImageProPlus 4.1 (Media Cybernetics, US). Bar =100µM. N=4-6 per group. 
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Figure 5-7: Haematoxylin and Eosin staining in kidney sections from transgenic and parental 
strains at 21 weeks of age.  
Kidney sections from rats at were stained with haematoxylin and eosin staining and 
show no evidence of vascular pathology in WKY, Trans1 and Trans2 rats, but 
evidence of vascular hyperplasia in SHRSP. Bar =100µM. N=4-6 per group.  
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Figure 5-8: Concentration Response Curves in the presence and absence of the NOS inhibitor L-
NAME in Aorta 
SHRSP (n=7), WKY (n=7), Trans1 (n=6) and Trans2 (n=5) rat aortic rings were 
measured for contractile response from stimulation with increasing concentrations 
of phenylephrine (PE) normalized to contraction with KCL. Responses (A) in the 
presence of PE, and (B) in the presence of PE plus L-NAME where PE-induced 
contractibility was greatest in WKY animals in the presence of L-NAME.  
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Figure 5-9: Nitric oxide bioavailability in 21 week aorta 
(A) 21 week old SHRSP, WKY, Trans1 and Trans2 rat aortic nitric oxide 
bioavailability measured as the difference in the ability of aortae to respond to PE 
stimulation in the presence and absence of NOS inhibitor L-NAME (normalized to 
contraction with KCL). (B) NO bioavailability calculated as area under the curve. 
Data show a significant increase in NO bioavailability in the WKY when compared to 
the SHRSP *(p<0.05). There was no significance difference in NO availability 
inTrans1 and Trans2 rats when compared to SHRSP (p>0.05)  
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Figure 5-10: Effects on Carbachol-induced Vasorelaxation of Aortae 
Pre-contracted aortas from SHRSP, WKY, Trans1 and Trans2 rats were subjected to 
increasing concentrations of carbachol for stimulated NO release which resulted in a 
reduction of tension in all groups. (B) Calculated area under the curve showed no 
significant difference between the parental strains, however Trans1 AUC was 
significantly increased compared to SHRSP (p<0.05).   
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The function of MRA’s were also assessed by the vasodilatory response to 
carbarchol-stimulated NO release (Figure 5-15 Panel A). Carbachol dose response 
curves in pre-contracted arteries were not modified between any of the four strains 
as the vessels relaxed to similar extents in response to the addition of carbachol. 
AUC was calculated for each group and although the highest vasodilator responses 
were observed with the SHRSP and WKY (AUC SHRSP: 130±19.53; WKY: 135.5±14.19) 
there was no significant differences between the groups (Figure 5-15 Panel B).  
5.3.3.3 Mesenteric resistance artery structure and mechanics 
Structural differences of MRA from SHRSP, WKY, Trans1 and Trans2 rats were 
assessed through pressure myography where internal diameter representing the 
lumen width and external diameter representing total lumen and medial width of 
the MRA’s (Figure 5-16). While internal diameter was not significantly different, 
there were trends suggesting a larger increase in diameter in response to increased 
pressure in the WKY, Trans1 and Trans2 rats (Figure 5-16 panel A). External 
diameter exhibited similar trends for Tran1 and Trans2 animals and was significantly 
increased in the WKY when compared to the SHRSP (p<0.01) (Figure 5-16 panel C). 
Cross sectional area (CSA) was significantly increased in WKY, Trans1 and Trans2 
rats when compared to SHRSP (p<0.01) (Figure 5-16 panel C). There were no 
significant differences in wall to lumen ratio (Figure 5-16 panel D) between strains.  
The pressure-circumferential wall strain curves of MRA’s from SHRSP (n=5), WKY 
(n=7), Trans1 (n=7) and Trans2 (n=5) rats are illustrated in Figure 5-16. Values were 
calculated from internal diameter measures (as intraluminal pressure increases) in 
comparison to the initial lumen diameter measurements at 10 mmHg and, 
therefore, indirectly the artery’s ability to stretch. SHRSP had the smallest 
circumferential wall strain (AUC 1.167±0.31) which was increased in both transgenic 
lines (Trans1: 1.25±0.33 and Trans 2 1.85±0.55) and WKY has the largest 
circumferential wall strain (3.83±1.69), however, this did not reach significance. 
Circumferential wall stress, which takes into account intraluminal pressure, lumen 
diameter and wall thickness, was not significantly different between all four strains 
(Figure 5- 16).  
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Figure 5-11: Mesentaric resistance arteries contractile response to noradrenalin 
Vasoconstriction of MRA from SHRSP (n=7), WKY (n=7), Trans1 (n=8) and Trans2 
(n=5) rats using wire myography, (A) measured as a percent of their maximum 
response to 30 µM noradrenalin, and (B) following NOS inhibition with L-NAME.(C) 
AUC calculated from noradrenalin dose response curves shows similar MRA 
contractility in the absence (-) and presence (+) of L-NAME. Elisabeth Beattie 
contributed to wire myography experiments. 
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Figure 5-12: Mesentaric resistance artery function in response to carbachol-stimulated nitric 
oxide release. 
(A) Pre-contracted MRAs from SHRSP, WKY, Trans1 and Trans2 rats were stimulated 
with increasing concentrations of carbachol to cause NO-mediated relaxation. (B) 
Corresponding area under the curve calculations do not show significant differences 
between SHRSP (n=7), WKY (n=7), Trans1 (n=8) and Trans2 (n=5) rats.  
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Figure 5-13: Comparison of structural parameters of mesenteric resistance arteries over a range 
of intraluminal pressures  
21 week old SHRSP, WKY, Trans1 and Trans2 animals. (A) Internal diameter (B) 
external diameter (C) cross-sectional area (CSA), and (D) wall:lumen ratio in MRAs 
by pressure myography. WKY, Trans1 and Trans2 rats had significantly increased CSA 
when compared to the SHRSP. External diameter intraluminal pressure was also 
significantly increased in WKY when compared to SHRSP *(p<0.01).            
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Figure 5-14: Comparison of mechanical parameters of mesenteric resistance arteries 
Pressure myography analysis in SHRSP (n=5), WKY (n=6), Trans1 (n=7) and Trans2 
(n=5) rats. (A) circumferential wall strain, (B) stress-pressure relationship, and (C) 
stress-strain relationship curves in mesenteric arteries. SHRSP have the lowest 
circumferential wall strain compared to the WKY with the highest. Similarly with 
the right-ward shift in the stress-strain relationship indicative that WKY has reduced 
vessel stiffness when compared to the SHRSP.  
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Cross sectional-intraluminal pressure was significantly increased in WKY, Trans2 and 
Trans2 rats when compared to SHRSP (p<0.01) (Figure 5-16 Panel C). Assessment of 
arterial stiffness between the four strains revealed a right ward shift for WKY 
animals, but was not statistically significant between the groups (Figure 5-16).  
5.4 Discussion 
The data presented in this chapter clearly shows a reduction in renal oxidative 
stress in both transgenic lines (Figures 5-1). Furthermore, we saw evidence of 
reduced renal pathology as indicated by the absence of renal vessel hyperplasia and 
reduced proteinuria in the WKY, Trans1, and Trans2 rats at 21 weeks of age (Figure 
5-7). These improvements in oxidative stress status and renal pathology were also 
apparent in salt-loaded Trans1 rats (Figure 5-2). In addition to the blood pressure 
reductions identified in the previous chapters and the reduced renal 
pathophysiology of the transgenic lines, H&E staining showed a more similar 
morphology to the WKY in the transgenic lines with no signs of accelerated 
hypertension. Aortic and mesenteric wire myography data showed that there was no 
significant difference between SHRSP and transgenic lines for vascular function 
(Figure 5-8). Mesenteric structure and function in the transgenic lines were only 
significantly different from the SHRSP in terms of increased vessel cross sectional 
area (CSA) (Figure 5-14 Panel c), but did show trends of improved structure and 
function (Figure 5-14).      
 
Since previous studies have shown that the SHRSP is deficient in renal Gstm1 
expression (96), we hypothesised that production of transgenic lines in which Gstm1 
expression has been rescued would improve oxidative status and cardiovascular 
function. Our ex vivo studies have confirmed this, and although the reduction in 
GSH:GSSG ratio levels do not quite reach significance for Trans1 and Trans2 rats; 
there is a trend towards significance in the kidneys at 21 weeks. This reduction is 
further verified by lipid peroxidation measurements which were significantly 
reduced in Trans1, Trans2 and WKY rats when compared to SHRSP (Figure 5-1). This 
improvement of oxidative status at several steps of the oxidative stress pathway 
further validates the role of glutathione in the defence against oxidative stress (96) 
187 
 
(Figure 5-1). Given that both glutathione (Gstm1) and lipid peroxidation are 
components that occur later within the oxidative stress cascade, other earlier 
components of the oxidative stress pathway were investigated in order to more fully 
understand the mechanisms underlying the improved oxidative stress profile in 
these transgenic rats. Superoxide (O2
-) and hydrogen peroxide (H2O2) were measured 
at 21 weeks of age and data showed that there were no significant differences 
between the strains (Figure 5-14). In contrast, previous studies in 20 week old 
SHRSP have demonstrated significantly increased O2
- levels in basal and NADH 
stimulated renal cortex compared to WKY. There are several factors that may be 
responsible for this difference. Firstly, it is well recognised that measurement of 
reactive oxygen molecules in biological environments is inherently challenging due 
to their short life span and limited selectivity of detection systems (give references 
here). Secondly, there are differences in the methods of measurement between this 
and the previous study, including the use of whole kidney as opposed to renal 
cortex. However, similar to the current findings, there was no significant difference 
observed in renal H2O2 levels between SHRSP and WKY rats at 20 weeks of age. From 
the point at which glutathione acts in the ROS cascade, we observe differences in 
renal oxidative stress between the SHRSP and WKY, and significant improvements in 
the transgenic lines. Therefore, the current novel data from Trans1 and Trans2 rats, 
together with previous evidence in the literature convey that several components of 
the oxidative stress pathway are reduced in animals expressing the WKY form of 
Gstm1 in the kidney (96). 
To better understand the association between increased Gstm1 expression and 
reduced ROS levels, renal oxidative stress was also measured at an early time point 
(5 weeks of age) where Gstm1 expression is shown to be increased in both 
transgenic lines (Table 1). Data showed that at this early time point oxidative stress 
was low in all four strains when compared to kidneys from 21 week old rats. These 
low values at 5 weeks of age allow us to conclude that while there is an increase in 
Gsmt1 expression in the WKY and transgenic lines compared to the SHRSP, there is 
no elevation of oxidative stress in any of the four strains before the onset of 
hypertension. Oxidative stress measurements in other cardiovascular tissues at 21 
weeks of age, i.e. the brain, show similar results to that described in the literature. 
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For example, Kishi et al. demonstrated that lipid peroxidation, (indicated by TBARS) 
in whole brain was significantly greater in the SHRSP than that of the WKY at 18 
weeks of age (297). Results from the current study showed a trend towards a 
decrease in lipid peroxidation in the WKY, Trans1 and Trans2 rats when compared to 
the SHRSP in the whole brain at 21 weeks of age (Figure 5-4). From this data it can 
be concluded that increased (WKY) Gstm1 expression at an early age not only leads 
to significantly decreased blood pressure levels at maturity but also improves 
oxidative stress levels in several organs. In addition to oxidative stress parameters, 
other predictors of renal pathology were measured at 21 weeks of age in order to 
further investigate the effects of increased Gstm1 expression. While estimated 
glomerular filtration rate was within a normal range for all four strains (normal 
range 1.2-3.0 mls/min (298)) (Table 2), increased proteinuria levels in the SHRSP 
are predictive of  renal damage (299). Moreover, previous studies have shown that 
an increased left-ventricular mass index is correlated with early signs of renal 
failure (300), and the SHRSP strain demonstrates both of these risk factors while our 
transgenic lines do not. H&E staining further supports this reduced renal pathology 
in our transgenic animals by showing normal WKY like arterioles throughout the 
kidney (Figure 5-7),whereas  the SHRSP strain, at 21 weeks of age, shows signs of 
accelerated hypertension with the development of arteriolar hyperplasia (240). 
Renal fibrosis was also investigated, however, the SHRSP and WKY did not display 
renal fibrosis at the 21 week time point (240).  
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Figure 5-19: The roles of glutathione and other enzymes in the oxidative stress pathway 
BH4 = tetrahydrobiopterin; eNOS = endothelial nitric oxide synthase; H2O = water; 
H2O2 = hydrogen peroxide; GPx = glutathione peroxidase; GSH = glutathione; GSSG = 
oxidized glutathione; GSTs = glutathione s-transferases; LO- or LOO- = lipid radicals; 
NAD(P)H =nicotinamide adenine dinucleotide (phosphate); NO = nitric oxide; O2 = 
molecular oxygen; O2
-
 = superoxide anion; ONOO- = peroxynitrite; ROS = reactive 
oxygen species; SOD = superoxide dismutase; VSMC = vascular smooth muscle cell. 
Adapted from Ref. (146)  
190 
 
 
 
 Despite significant improvements in oxidative stress status and proteinuria, 
transgenic rats display similar levels of renal mass index (renal hypertrophy) to the 
SHRSP (Figure 5-8). This may reflect that while blood pressure is reduced in the 
transgenic animals, it is not equivalent to WKY levels and still display a degree of 
hypertension. This possibly suggests that blood pressure levels above a certain 
threshold (i.e. hypertensive levels) play a more significant role in renal mass index 
than oxidative stress (279). Furthermore, while studies consistently show a 
correlation between renal function and hypertension (4;284;285;301;302), this data 
suggests some dissociation between renal mass index and other renal pathology 
measurements (i.e. proteinuria and renal vascular hyperplasia), however further 
investigation is needed.  
So far the majority of the investigations in Trans1 and Trans2 rats have focussed on 
the kidney. This is because the original finding of reduced Gstm1 expression in the 
SHRSP was observed in the kidney. However, other organs may be contributing to 
the significant reduction in hypertension in Trans1 and Trans2 rats. In particular, 
altered contractility of the vasculature may be a contributing factor. Previous 
studies conducted by Kerr et al. have shown that the SHRSP has increased oxidative 
stress levels and decreased endothelial function in the aorta (234).Therefore it was 
important to investigate whether the increased vascular Gstm1 expression in the 
transgenic animals plays a role in reducing vascular oxidative stress and improving 
endothelial function. Furthermore, results from a study by Yang et al. (303) using 
mice with differing susceptibility to renal injury, suggested that Gstm1 is a novel 
regulator of VSMC proliferation and migration through its role in handling reactive 
oxygen species (303). In this study by Yang et al., mice that were susceptible to 
vascular injury (C57BL/6) demonstrated reduced endogenous Gstm1 expression 
when compared to injury resistant SV129 mice. Given that both transgenic rat lines 
demonstrated an increased level of expression of aortic Gstm1 compared to the 
SHRSP, it was anticipated that vascular parameters and function would be similarly 
improved in line with the study by Yang et al. However, the current study failed to 
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show a significant change in aortic GSSG: GSH ratios and lipid peroxidation in our 
transgenic lines. Moreover, aortic vascular responses to phenylephrine +/- L-NAME 
were not significantly different between the SHRSP and transgenic animals (Figure 
5-8). While these differences between the two studies can be attributed to species 
and background differences (i.e. mouse vs. rat, endogenous expression verses 
transgene), it would have been interesting to investigate if transgenic expression of 
Gstm1 impacts differently on VSMC proliferation when compared to rats with 
endogenous expression and to further examine other down-stream effects of Gstm1 
in our transgenic lines.  
 Investigation of vascular function was performed through measurement of nitric 
oxide bioavailability in the aorta where an increase in contraction after NOS 
inhibition provides a measurement of basal nitric oxide available for vasodilation. In 
previous studies (96;240), vascular endothelial function in the SHRSP was 
significantly reduced when compared to the WKY (4;87;237). The data generated in 
this study confirms these findings in the aorta where WKY animals had significantly 
increased levels of basal nitric oxide bioavailability (Figure 5-12). Evaluation of 
endothelial function in the Gstm1 transgenic lines however showed that there was 
no significant difference for either Trans1 or Trans2 animals when compared to the 
SHRSP. The lack of change in endothelial response in the transgenic lines, despite 
the increases in vascular Gstm1 expression and reduced blood pressure (Figures 4-
2), supports previous evidence suggesting that there are many factors that 
contribute to vascular  function, especially in the SHRSP (291;304-306). Studies 
published by McBride et al., have shown that increased vascular oxidative stress has 
a negative impact on vascular function (96;307). One possibility for lack of a 
significant endothelial response in the transgenic lines is the low sample size, 
especially in the Trans2 line where breeding difficulties limited the number of males 
available for investigation. Relaxation to carbachol was not significantly between 
the parental SHRSP and WKY strains, which is in direct contrast to previous studies 
by Koh-Tan et al. and  McIntyre et al. where SHRSP rats showed an attenuated 
relaxation to carbachol when compare to WKY rats (240;289).  The lack of 
significant difference in relaxation to carbachol between the parental strains and 
the wide variability observed in the Trans2 response could be due to damage of the 
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endothelial layer during experimental set up. This risk is generally greater with less 
experienced operators, and since sample size was limited for each strain these 
could be important contributing factors. In order to rectify this it would important 
to increase both the sample size and skill at vessel dissection and preparation, 
however, that was not possible within the time frame of this thesis.           
Vascular remodelling in the parental and transgenic strains was assessed in MRA’s. 
With the exception of wall to lumen ratio, basic measurements of lumen size and 
cross sectional areas were either significantly increased in the WKY, Trans1 and 
Trans2 rat MRAs (Figure 5-16) or showed trends towards significance when compared 
to the SHRSP. The proportional increase of diameter and cross-sectional area to 
increased pressure whilst maintaining similar wall to lumen ratio indicates that WKY 
and transgenic rats tend to have larger luminal diameter than SHRSP (despite all 
vessels from each of the strains being 3rd order vessels)(296;308). Mechanical 
properties of MRAs in the normotensive WKY animals have an improved MRA 
circumferential wall stain and stress-strain relationship when compared to the 
SHRSP which is in agreement with previously published data (308;309), Mechanical 
properties were not improved in the transgenic MRAs.   
As mentioned previously, that while we have observed multiple significant 
differences between the SHRSP and the transgenic lines in terms of blood pressure, 
gene expression and oxidative stress, the Gstm1 transgenic rats still remain a model 
of hypertension (Figure 3-1)  since blood pressure is not reduced to levels equivalent 
to the WKY. Therefore, it is not unexpected that many of the vascular parameters 
measured in this study are similar between SHRSP and the transgenic lines. 
However, the significant impact on blood pressure levels, improved renal oxidative 
stress and reduced renal injury do provide strong evidence for an important role of 
Gstm1 in the defence against the development of hypertension and underlying 
pathophysiological changes. Our findings in the rat provide strong evidence to 
examine the role of the GSTM family in a human population.  
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6 Characterization of the GSTM family in a human 
cohort   
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6.1 Introduction 
Essential hypertension is a complex multifactorial disease, resulting from the 
combined effects of a large number of genes, each of which explain only a small 
fraction of blood pressure variance (280;310;311). The use of traditional methods to 
discover contributing genes such as genetic linkage and candidate gene approaches 
have proven difficult and generally failed to discover reproducible associations with 
hypertension (8;311). More recently, GWAS studies have had greater success 
identifying 43 loci associated with phenotypic variance for systolic and diastolic 
blood pressure (59;311;312). However, in order to understand the functional roles 
of these genetic loci on blood pressure regulation it is essential to interrogate the 
impact of these loci in suitable rodent models. This translational approach will 
improve our knowledge and understanding of pathways, networks and gene- 
environment interaction underlying essential hypertension. An equally important, 
alternative translational strategy is to examine robust candidate genes originally 
identified in rodent models, within human hypertensive and normotensive cohorts. 
However a major limiting factor of these studies is often poor access to suitable 
human tissues. In previous chapters where the Gstm1 transgenic rat has undergone 
comprehensive phenotypic and molecular characterisation, it has been shown that 
increased renal expression of Gstm1 plays an important role in blood pressure 
regulation, cardiac and renal function the SHRSP. Gstm1 therefore represents an 
excellent candidate to be taken forward in a translational approach of human 
essential hypertension.     
In humans, the glutathione-s transferases with their closely related GST isoforms 
and their overlapping substrate specificities have presented a particular challenge 
for investigators when it comes to investigating each individual enzyme. While there 
are many variants within the GST family, the majority of these studies have been 
focused on the GSTM1 and GSTT1 deletion (null) alleles and the GSTP1 valine allele 
(Val/Val) (313). The significance of GSTM1 polymorphism in human was first 
recognized in cancer studies demonstrating that individuals carrying the GSTM1 
deletion allele were at increased risk for colon and lung cancers (314;315). Other 
consequences of the genetic polymorphisms include potential differences in 
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tolerance to toxic agents. To date, GSTM1 is the most comprehensively studied 
among all human GSTs, and has been shown to play an important role in the 
response to oxidative stress (196). Furthermore, many studies have linked GSTM1 
and GSTT1 deletions to susceptibility to a number of cancers, including colorectal, 
lung, skin, bladder and breast cancers (211;316); in addition to being associated 
with increased cardiovascular risks (301;317).    
Multiple studies have proposed the possible involvement of GST gene variants in 
human essential hypertension (8;318-320). Specifically in the study by Delles et al. 
in 2008, where they showed a significant association of the rs11807 SNP in the 3’ 
region of GSTM5 with hypertension in the MRC BRIGHT TDT cohort, with the T-allele 
being over-transmitted to hypertensive offspring. They also showed that GSTM5 
mRNA expression in renal tissue was significantly reduced in subjects homozygous 
for the T-allele compared with C-allele carriers (8), although they were unable to 
replicate the association of rs11807 SNP and hypertension in the MRC BRIGHT Study 
case-control cohort (involving n=1675 hypertensive and n=1654 normotensive 
subjects) (8).  
To date, there is uncertainty as to which human glutathione S-transferase m (GSTM) 
is the direct orthologue of Gstm1 in the rat. Although there are possibly eight 
members in the rat GSTM gene family, there are only five known members in the 
human GSTM gene family. The potential existence of several human homologues of 
the rat Gstm1 and their functional involvement in cellular antioxidant defences 
warrant further clinical investigation. Taken together, this suggests that the entire 
human GSTM gene family should be investigated as a putative candidate gene family 
for cardiovascular phenotypes. In addition to investigating the GSTM family, in order 
to more fully understand the role of oxidative stress in hypertension, it will be 
important to examine other glutathione enzymes such as the GPx family. GPx-1 and 
GPx-3 considered good candidates for this due the fact that GPx-1 is considered as 
an enzyme that protects the most against oxidative damage (185), while GPx-3 is 
found to be predominately expressed in the kidney (189).  
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Human kidney tissues from a Silesian cohort of normotensive and hypertensive 
subjects were made available through collaboration with Dr Maciej Tomaszewski, at 
the University of Leicester (321). This provided an ideal opportunity to assess the 
human GSTM family and translate our findings from a rodent model of hypertension 
to humans. The aims of this Chapter were to (1) characterize human renal GSTM2, 
GSTM3, GSTM5, GPx-1 and GPx-3 expression profiles in the Silesian Renal Tissue 
Bank samples from both hypertensive and normotensive patients, (2) genotype the 
rs11807 SNP and assess correlation it with human GSTM5 expression. 
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6.2  Materials and Methods 
6.2.1 Ethics and Demographics 
The Silesian Renal Tissue Bank is a collection of tissue from over 150 patients with 
nonmetastatic renal cancer. Each patient received an elective unilateral 
nephrectotmy at the reference centre of Urology (Medical University of Silesia, 
Silesia Poland). Phenotyping was performed in the Department of Internal Medicine, 
Dialectology and Nephrology (Medical University of Silesia, Silesia Poland) which 
included taking a clinical history (Standard coded questionnaires), physical 
examinations, weight, height and blood pressure measurements according to the 
protocol outline in (321). Samples of approximately 1cm3 of tissue were obtained 
from the healthy (unaffected by cancer) pole of the kidney immediately after 
surgery and transferred into containers with RNAlater (Ambion, Austin, Texas, USA) 
and preserved at -70C before mRNA extraction and expression analysis.  
Table 6-1 
Demographics  Hypertensive Normotensive 
Sex (male/female) 
Age (Years) 
 55/37 
63.5 ± 9.34 
25/20 
55.6 ± 11.1 
BMI (Kg/m2)  28.7 ± 4.19 25.7 ± 4.0 
Waist Circumference (cm)  97.95 ± 15.23 86.9 ± 12.9 
SBP (mmHG)  142.98 ± 12.5 125.2 ± 7.6 
DBP (mmHG)  86.4 ± 7.4 78.1 ± 6.6 
DBP, diastolic blood pressure; SBP, systolic blood pressure. Data are given as 
mean±SD.  
6.2.1.1 Ethical Approval  
All subjects provided written informed consent and the study was approved by the 
local Ethical Committee for clinical research of the University of Leicester hospital. 
6.2.2 RNA Extraction 
RNA extraction from kidney tissue was conducted using RNeasy mini kits (Qiagen, 
USA). RNeasy kits isolate RNA based on the selective binding properties of a silica-
based membrane. All steps were followed according to manufacturer’s instructions; 
however, the extraction went as follow. The homogenation apparatus and hood 
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were thoroughly cleaned using RNAase (Ambion, USA) and the experiments were 
completed on ice to prevent RNA degradation. A maximum of 20 µg of starting 
tissue was used providing a yield of ~30 µg of RNA. Tissue was suspended in lysis 
buffer (700 µl of β-mercaptoethanol [Sigma-Aldrich, UK] in 70 ml of RTL buffer) and 
homogenised using a rotor-stator homogeniser. The lysate was then centrifuged for 
3 min at full speed, removed and used in all future steps as illustrated in the 
handbook. The spin column was placed in a 1.5 ml collection tube and 40 µl of RNase-
free water was added to the spin column membrane. After incubation for 1 min (room 
temperature), the column was centrifuged for 1 min at 8,000g room temperature. The 
resultant RNA-containing liquid was stored at -80°C. 
6.2.2.1 Measurement of RNA quality and quantity  
RNA quality and quantity was assessed using NanoDrop (Labtech) spectrophotometer 
in a manner identical to that described in section 2.2.1.2. The 260 nm wavelength is 
absorbed by RNA while the 280 nm wavelength is absorbed by sample contamination 
(in particular proteins). A ratio of around 2.1 (260:280 nm) indicated a pure RNA 
sample. 
6.2.3 Reverse Transcriptase 
Reverse Transcription was performed using the Applied Biostystems Reverse 
transcription Kit (Applied Biosystems). All steps were performed according to 
manufacturer’s instructions. 1 µg of DNAse treated RNA samples were reverse 
transcribed into cDNA in a 20 µL reaction containing a final concentration of 1X RT 
buffer, 5mM MgCL2, 1mM dNTP mixture,1u/µL RNAsin (RNase inhibitor), 0.5 µg of 
random heximers, 15 u of AMV reverse transcriptase (Multiscribe) on a 96-well 
plate. For negative controls, additional reactions without reverse transcriptase were 
included.   The reaction was then placed on a thermocycler and underwent the 
following conditions 25°C for 10 min, 48°C for 30 mins, 95°C for 5 mins. The 
samples were then diluted to 100µL and stored at -20°C until use. 
199 
 
6.2.4 Relative real-time PCR 
Relative real-time PCR was used for quantitation of mRNA expression using the 
ViiA™ 7 Real-Time PCR System (Applied Biosystems, USA). Sample expression was 
determined by a two-step RT-PCR assay using the Taqman Gene Expression 
Assays from Applied Biosystems/life technologies in a multiplex reaction (if the gene 
of interest and housekeeper reacts with the same efficiency). Each reaction 
consisted of 2.5 µL Taqman Expression Fast PCR Master Mix, 1x VIC labelled β-
microglobulin (B2M) endogenous housekeeping probe, 1X FAM-labelled probe for the 
gene of interest, and 2 µL of cDNA in a final volume of 5 µL in a 384-well plate. The 
comparative eeCT method was used for relative quantification of expression, 
normalized to B2M in each sample. While there are other common choices of control 
genes (including ribosomal protein, beta actin, peptidylpropyl isomerase and 
glucuronidase β), B2M is widely accepted to have good expression levels in a number 
of tissues, including those used here 
Probes of interest were assessed for correct functioning using a serial dilution of 
cDNA input. 11 µl of TaqMan gene expression master-mix (Applied Biosystems, USA) 
was added to 1 µl probe of interest or control gene and 9 µl of cDNA (one reaction 
at each concentration of the cDNA serial dilution; 80 ng/µl, 40 ng/µl, 20 ng/µl, 10 
ng/µl, 5 ng/µl). This was incubated following the protocol: denaturing at 50°C for 2 
min, further denaturing at 95º C for 10 min, 50 cycles of 95º C for 15 sec each and 
60º C for 1 min. 
6.2.5 DNA Extraction   
 Peripheral blood was obtained from all participants by venipuncture. In all cases, DNA 
was isolated from peripheral blood mononuclear cells. 4.5 ml of red blood cell lysis 
solution (Qiagen, USA) was added to 4.5 ml of whole blood and inverted ten times 
before being incubated at room temperature for 10 min. The lysate was then 
centrifuged at 2000g for 10 min at room temperature. All but 5µl of the supernatant 
was discarded and the same volume of lysis solution (Qiagen, USA) was added and the 
pellet dislodged using a pipette tip. This mixture was incubated at 37oC for 1 hr, during 
which the tube was inverted at 10 min intervals. The solution was allowed to 
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homogenise for between 12 hrs and 72 hrs. 1 ml of protein precipitation solution 
(Qiagen, USA) was added and vortexed for 20 sec, before being centrifuged at 2000g for 
10 min at room temperature. The supernatant was subsequently poured into a tube 
containing 3 ml of isopropranol (Qiagen, USA), inverted ~50 times and centrifuged at 
2000g for 3 min at room temperature. The supernatant was poured away and the tubes 
left to drain for 10 min. Once dry, 3 ml of 70% (v/v) ethanol was added and tubes were 
inverted ten times before centrifugation at 2000g for 1 min at room temperature. 
Again, the supernatant was discarded and the tubes left to drain for 10 min. 250 µl of 
DNA hydration solution (Gentra Systems, USA) was added once dry, and incubated for 1 
hr (65oC) during which the tubes were agitated at 20 min intervals. Finally, the DNA 
solution was left to cool overnight before being centrifuged at 2000g for 1 min at room 
temperature and stored at -20º C. 
6.2.5.1 Measurement of DNA quantity and quality  
DNA quality and quantity was assessed using a Nanodrop 8-sample 
spectrophotometer ND-8000 (Fisher Scientific, UK). This technology measures DNA 
concentration between 5 and 2000 ng/µl using different wavelengths of light 
projected through the sample (depending on the absorbance of DNA compared to 
contaminants). A 260/280 ratio of 1.8 and a 260/230 ratio of 1.8-2.2 indicates a 
pure sample. The Nanodrop was blanked using 2 µl of DNA hydration solution before 
1 µl of each sample was loaded for analysis. The concentration and purity of each 
DNA sample was measured. Those with DNA concentrations <20ng/µl, a 260/280 
ratio <1.6 or >2.0, or a 260/230 ratio outside of the 1.7-2.3 range were discarded. 
The remaining samples were diluted to 15 ng/µl using DNA hydration solution before 
storage at -80ºC. 
6.2.6 Genotyping  
The Taqman genotyping assay is used to differentiate between different allelic 
states of SNPs through the use of coloured fluorophores. Commercially designed 
Taqman probe mixes (such as those used here) contain two probes, with one probe 
designed to anneal to each allelic state of a given SNP (e.g. one probe [VIC labelled] 
may anneal to the A state and one [FAM labelled] to the G state of a bi-allelic SNP). 
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Each probe is initially attached to a quencher in order to prevent its fluorescence. 
Once the probe has annealed to the DNA (SNP state allows the binding of one or 
both probes to DNA; homozygous major allele, heterozygous, homozygous minor 
allele), polymerisation and DNA amplification takes place using forward and reverse 
PCR primers provided with the probes. The process of polymerisation removes the 
quencher from the probe allowing the probes to emit fluorescence that can be 
detected. For this particular experiment, a human GSTM5-specific TaqMan gene 
expression assay (rs11807) was obtained from Applied Biosystems. A master-mix 
containing 1,200 µl of Taqman genotyping master-mix (Quanta Biosciences, USA), 
800 µl of deionised water and 10 µl of specific probe mix (Applied Biosystems, USA) 
was vortexed for 1 min. 5 µl of this master-mix was added to 1 µl of each DNA 
sample placed on a 384-well plate (one DNA sample per well). At least four negative 
controls (containing no DNA) and two positive controls (where the allelic state was 
known) were placed onto each 384-well plate. The plate was then covered with a 
film slip and centrifuged at 2000g for 1 min at room temperature. The assay 
reaction was completed on a GeneAmp PCR System 9700 (Applied Biosystems, USA) 
using the following program: 95°C 10 min then 45 cycles of 92°C for 15 sec each, and 
60°C for 1 min, 72°C for 10 min. Depending on the SNP analysed, optimisation of the 
reaction consisted of either the alteration of the cycle number or annealing 
temperature. Fluorescence was detected using a ViiA™ 7 Real-Time PCR System 
(Applied Biosystems, USA), where genotype calls were automatically called and 
checked by two independent, experienced scientists. Figure 6-1 illustrates an 
example of a cluster plot showing differentiation between SNP states by genotyping. 
6.2.7 Statistical Analysis 
Initial SNP quality checking included estimation of allele frequencies using the 
Hardy-Weinberg equilibrium. Gene expression was analyzed using Prism graph pad 
using student’s t-test or 1-way ANOVA as appropriate.  
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Figure 6-1: Allelic discrimination of SNPs. 
SNP detection is achieved with 5' nuclease chemistry by means of exonuclease 
cleavage of an allele-specific 5' dye label, which generates the permanent assay 
signal. The Applied Biosystems SDS software uses an advanced multicomponent 
algorithm to calculate the distinct signal contribution of each allele of a marker 
from the fluorescence measurements of each sample well during the assay plate. 
Figure is modified from Applied Biosystems website (www.lifetechnologies.com).  
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6.3 Results 
6.3.1.1 Genotyping 
We investigated SNP rs11807, in the full Silesian Renal Tissue Bank (~200 samples). 
When genotyped for rs11807 ~3% (7 of 131) of the sample was homozygous for TT, 
28% (54 of 131) was heterozygote for CT, and 53% (70 of 131) was homozygote for 
CC (Figure 6-2) (8). In the subgroup of hypertensive patients (n=56), the rs11807 SNP 
showed a borderline significance with increased blood pressure (p=0.054).        
6.3.1.2 Gene Expression 
Renal expression levels of GSTM2, GSTM3, and GSTM5 were measured in renal tissue 
samples from both hypertensive and normotensive subjects. GSTM5 and GSTM3 
expression was not significantly different between renal tissues from normotensive 
and hypertensive subjects. Renal GSTM2 expression was significantly increased in 
hypertensive subjects when compared to normotensive samples (p<0.05) (Figure 6-3 
Panel A). In addition to the glutathione s-transferases, renal glutathione peroxidises 
(GPx) were measured. There were no significant differences in GPx-1 and GPx-3 
expression between normotensive and hypertensive patients (Figure 6-3 Panel B).   
6.3.1.3 Genotype-Phenotype Association 
In order to assess a genotype phenotype association, we examined how the rs11807 
genotype affects GSTM5 expression in the kidney. Renal GSTM5 expression showed 
borderline significance, with lower expression in subjects homozygous for the T 
allele compared to subjects carrying the C allele (CC, n=47; CT n=63; TT, n=5) 
(p=0.054) (Figure 6-4).   
6.3.1.4 Gene expression correlations  
To determine whether gene expression patterns exists that describe or predict the 
differences between blood pressure, the expression patterns of the GSTM and GPx 
families were analyzed. Correlation between gene expression patterns were 
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significant between GSTM5 and GPx-1 (p>0.001) and GSTM5 and GPx-3 (p>0.01) 
(Figure 6-5).  
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Figure 6-2: Cluster Plot of the rs11807 gene  
An allelic discrimination plot showing the amplification of Allele 1 (T) on the X axis 
and the amplification of Allele 2 (C) on the Y axis. Samples homozygous for the T 
allele are identified by the red circle, and samples homozygous for the C nucleotide 
are identified by the blue circle. Heterozygous samples are identified by the green 
circles. The no template controls are indicated by the cross    
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Figure 6-3: Human Glutathione s-transferase and Glutathione peroxidise expression  
GSTM family renal mRNA expression was assessed in 105 subjects. Data are 
displayed as delta CT values. Expression of (A) GSTM family members, and (B) GPx 
family members. GSTM2 expression was significantly different between 
normotensive (NT) and hypertensive (HT) subjects *(p<0.05). There was no 
significant difference in expression of GSTM3, GSTM5, GPx-1 or GPx-3 (p>0.05) 
between hypertensive and normotensive subjects. Data represented as mean ± SEM.  
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Figure 6-4: Genotype-phenotype association between GSTM5 and rs11807. 
GSTM5 renal mRNA expression was assessed in 105 subjects. Subjects were 
genotyped for the rs11807 polymorphism in the 3’ region of GSTM5. Data are 
displayed as Delta CT values. Reduced expression in subjects homozygous for the T 
allele demonstrated borderline significance. Data represented as mean ± SEM.  
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Figure 6-5: Gene expression correlation as depicted by scatter plots  
The relative change of gene expression (RQ) from qRT-PCR of (A) GSTM5 and GPx-3 
and (B) GSTM5 and GPx-1 were correlated. The correlations between GSTM5/GPx-3 
and GSTM5/GPx-1 were significant at p<0.01 and p<0.001, respectively.   
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6.4 Discussion 
The aim of this chapter was to translate findings from a rodent model of 
hypertension into humans and expand on the study carried out previously by Delles 
et al. (8). Expanding this investigation to include a larger number of subjects and 
assessment of several other members of the GSTM gene family has provided 
additional evidence to confirm a relationship between the GSTM family and 
hypertension. While there was no significant difference in renal expression in 
GSTM5, GSTM3, GPx-1 and GPx-3 between normotensive and hypertensive patients 
(Figure 6-3), GSTM2 expression was significantly increased in hypertensive subjects 
when compared to normotensive subjects (Figure 6-3). Moreover, we identified a 
borderline significance (p=0.054) between the rs11802 SNP genotype and GSTM5 
expression. Further investigation between gene expression correlations showed 
there was a significant linear correlation between GSTM5 and GPx-1 expression 
levels (Figure 6-5).  
The previous study carried out by Delles et al. used a small cohort of 45 subjects, 
and only examined GSTM5 expression, as a potential ortholog of rat Gstm1. In this 
previous study it was concluded that although Gstm1 was a robust candidate gene 
for hypertension in the SHRSP, it did not successfully translate to human 
hypertension (8). However, since a direct human ortholog of rat Gstm1 is not 
apparent, in the present study the decision was made to broaden the investigation 
to incorporate multiple members of the GSTM family and also to include GPxs. 
Significant correlation between GPx-1 and GSTM5 was not unexpected because 
GSTM5 and GPx-1 both play a role against oxidative stress. In plants, synchronized 
increases in expression have been shown to routinely appear between GSTMs and 
GPxs (183;186). The GPxs have been shown to have correlated expression patterns 
to the GSTM family, and more specifically, GPx-1 is known for its reduction of 
oxidative stress and GPx-3 is found predominately in the kidney (186). 
Determination of unique expression profiles of the GSTM and GPx families in 
hypertensive patients would help to elucidate their potential role in blood pressure 
control and hypertension.  
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 In humans, it is known that the GSTMs share a high sequence homology, because of 
this we hypothesized that since there is no individual ortholog, the GSTM family 
may possibly function as a combined homologue to the rat Gstm1 gene. 
Unfortunately, the expression analysis carried out in this study does not support this 
hypothesis so far. However, there are additional GSTM family members (GSMT1 and 
GSTM4) in the human genome that need to be examined, but this was not possible 
in the timeframe of the visit to the University of Leicester. In contrast, another 
possible reason why there were no firm expression profile conclusions is that, as a 
family, the GST enzymes are highly redundant and to some degree other members 
of this family are able to compensate for the absence and or polymorphism of one 
isoenzyme. This has been evidenced by the recent meta-analysis of Benhamou et al. 
showed the GSTM1 deletion carries only a small risk of lung cancer (322). 
Furthermore, a recent study done by Bhattacharjee et al. have shown that in the 
absence of GSTM1, GSTM2 is shown to be over expressed as a compensatory 
mechanism in humans (323).While our study did not have the means to incorporate 
GSTM1 expression patterns and compare them to GSTM2 expression patterns within 
our cohort, it is interesting to know that there are compensatory mechanism in 
place within the GSTM family. This explains part of the difficulty of trying to 
correlate expression patterns of the GSTMs within a diseased state.  
We were able to show a borderline significant association of rs11807 with GSTM5 
(p=0.054) in the Silesian cohort; GSTM5 mRNA expression in renal tissue was 
reduced in subjects homozygous for the T-allele compared with C-allele carriers, 
which is in concordance to the findings of Delles et al. (8) . Nevertheless, this does 
not provide strong evidence to indicate that rs11807 is the functional SNP 
associated with hypertension. There are a number of promotor variants that have 
been shown to affect GSTM5 transcription (324). Given the strong linkage 
disequilibrium between markers within GSTM5, Delles et al. states that it is possible 
that rs11807 is in linkage disequilibrium with a functional variant upstream of this 
SNP regulating GSTM5 transcription (8).  
Delles et al. has shown through detailed synthany, that human GSTM2 and GSTM5 
are genetically related to rat GSTM1 (8), and thus possibly play similar roles in the 
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reduction of oxidative stress and blood pressure. Data from the current study 
supports a role for both GSTM2 and GSTM5, however despite these significant 
relationships the results should be viewed with a certain degree of caution. Firstly, 
while the subjects within the Silesian cohort are considered hypertensive, each 
patient has been undergoing hypertension management through drug and lifestyle 
therapy so it is difficult to ascertain if any potential effects of GSTM are being 
confounded or masked by this treatment. Secondly, due to time and sample 
limitations we were unable to fully investigate oxidative stress parameters within 
the human cohort.  
In conclusion, the translation of rat Gstm1 findings into a human cohort 
demonstrated limited success. While Gstm1 is known as a functional candidate gene 
for hypertension in the SHRSP, it is difficult to directly translate this into humans. 
This study re-confirmed the relationship between GSTM5 mRNA expression and the T 
allele, and showed a correlation between GSTM2 and hypertension. These findings 
should be taken forward in future studies to better identify the role GSTM2 plays in 
hypertension in humans.  
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7 General Discussion 
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The aims of this study were to establish definitive proof through a transgenic rat 
model that reduced Gstm1 expression in the SHRSP plays a causative role in the 
development of hypertension and oxidative stress. Here we provide evidence to 
confirm that reduced Gstm1 expression affects blood pressure regulation and 
oxidative stress utilizing two independent transgenic rat lines. Gstm1 deficiency was 
rescued in the SHRSP by incorporation of a normal (or WKY type) Gstm1 gene into 
the SHRSP genome and this led to a significant reduction in SBP, DPB, and pulse 
pressure. Furthermore, oxidative stress as indicated by MDA:protein ratio and 
GSH:GSSG levels were significantly reduced in both transgenic lines when compared 
to SHRSP. Renal pathology was also reduced in both transgenic lines.  
While genetic modification by random transgene insertion has proved to be a 
reliable and effective method to examine gene causality (7;121) recently much 
effort has been invested into improving techniques for gene knock out or 
incorporation of new genes into the rat genome. These novel advanced technologies 
include zinc-finger nucleases and transcription activator-like effector nucleases 
(TALENs) that allow for gene knockout or knock in by targeted genome editing 
(130;141;325). At the time of the production of our Trans1 and Trans2 rat lines, ZFN 
and TALEN technologies were still at a very early stage of development and were 
considerably more expensive e.g. around $35,000 (£18,000) per transgenic rat in 
2009, and were therefore not viable options for our transgenic rescue study. 
Although now considerably cheaper (approximately £5,000 per transgenic rat) it is 
still not possible to knockout or knock in certain genes on particular genetic 
backgrounds with ZFN or TALEN technology. Another recently developed genome 
engineering technology based on the CRISPR-Cas system (Clustered Regularly 
Interspaced Short Palindromic Repeats) developed from Streptococcus pyogenes is a 
relatively easy, and inexpensive alternative method for genome modification. The 
system consists of two components, namely a Cas9 endonuclease and gRNAs. The 
target specificity of the system relies on a 20-nucleotide  variable region at the 5 
prime end of  the gRNAs and thus rapid, multiplexed construction of gRNA 
expression  vectors targeting various genomic sites is possible (326). In a study by 
Mashimo et al., CRISPR technology has been applied to the rat genome in embryos 
where the CRISPR method, in tandem with single strand DNA oligonucleotides as 
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donor templates, efficiently generated knock in mutation in rats (327). There are 
many advantages to this new method of transgenic production, such as a generation 
time of 4-6 months with a >20% efficiency and gene targeting nucleases are not 
strain dependent and can be used on any rodent strain (328). Furthermore, artificial 
nuclease can be used to induce a variety of allelic change, which was previously 
only available in mouse due to ES cell lines restrictions. Also, through these 
methods it may be possible to adapt this to other mammalian species, which would 
aid in the translational aspects from rodent models to humans. 
When using random transgene insertion to generate transgenic rodent models, 
researchers can face several theoretical and technical challenges 
(130;141;194;329;330) some of which were faced with the Gstm1 transgenic SHRSP 
rat lines. For example although both Trans1 and Trans2 lines demonstrated overall 
reductions in oxidative stress, BP and end organ damage, each line showed some 
unique molecular and phenotypic expression patterns. However, phenotypic 
variability within independently generated lines (despite the use of the same 
transgene construct and promoter) is not unique to our study. Variability has been 
observed by Pravenec et al. in the development of CD-36 transgenic rat lines in an 
analogous ‘transgenic rescue’ study using the ef1-α promoter (7;121). In  2001, two 
transgenic lines were generated, SHR-TG10, which carried 6-8 transgenic copies of 
CD-36 but did not show kidney transgene expression, and SHR-TG19, which carried a 
single transgene which was expressed at low levels in the kidney and a blood 
pressure reduction (121). In 2003, more transgenic lines were produced (SHR-TG93 
and SHR-TG106) which showed variability regarding glucose tolerance and insulin 
sensitivity (7). Other limitations of gene knock-in or knockdown studies in rodent 
models include the intrinsic complexity of living organisms and/or the redundancy 
of some metabolic pathways, which prevents definitive conclusions to be made 
regarding the direct impact of gene modification (121;130). While transgenic 
animals have proven to be a powerful tool when assessing the complex mechanisms 
of gene-gene interaction (327), it is clear that transgenes often do not behave as 
independent units, but rather are significantly and variably influenced by factors 
such as the site of integration, the number of transgene copies in an array, 
expression during development and many other factors (242;260). These influences 
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sometimes lead to marked variations in expression patterns between different 
transgenic lines carrying the same construct, which appears to be the case with the 
Gstm1 transgenic SHRSP. However, despite the unique characteristics of each of the 
transgenic lines, when investigating the role of Gstm1 in the transgenic rat as a 
whole, we can conclude that increased Gstm1 expression during developmental 
periods plays a role in blood pressure regulation in the SHRSP at later stages of the 
animal’s life. 
If additional time had been available, it would have been important to more fully 
analyze the molecular aspects of the differences in gene expression and the 
subsequent changes that occurred after maturation by generating additional animals 
from the second transgenic line (Trans2). There are many potential factors that 
could impact on the level of transgene expression. One of these factors could be 
age-related increases in DNA-methylation (275). For example two early studies in 
rodents, one in mouse tissues and another in rat germline competent ES and liver 
cells, revealed consistent age-related increases in DNA-methylation of ribosomal 
genes that correlated with inhibition of gene expression (241;331). A second factor 
that could potentially lead to variation in expression levels exhibited by insertion of 
identical transgenes is position effect. Often differences in expression are due to 
enhancers that regulate neighbouring genes (332). Future studies would be 
important to investigate if any of these factors play a role in the unique expression 
profiles between the two transgenic lines.  
Furthermore, the creation of a third transgenic line would prove invaluable in 
clarifying the role of the WKY Gstm1 plays in the defence against oxidative stress 
and the prevention of hypertension. The use of Zinc Finger Nuclease, TALEN or 
CRISPR technology would provide distinct benefits such as being less susceptible to 
transcriptional effects from the genome, an increased likelihood of physiologically 
faithful gene expression patterns in the transgenic lines, and a >20% efficiency 
(333). The production of a WKY transgenic rat in which Gstm1 expression is knocked 
out or reduced could provide important confirmatory evidence for a role of Gstm1 
in the defence against the development of hypertension, if it was to show elevated 
blood pressure, oxidative stress and end-organ damage. Alternatively, the use of 
cre-lox technology (334) to produce a conditional knock-in in the SHRSP strain would 
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provide opportunity for more in-depth investigation. The ability to switch a gene on 
or off at defined times during development and maturity would allow a much 
clearer assessment of the roles of Gstm1 in the development of oxidative stress in 
this model. Moreover, cre-lox technology could be used to generate a tissue (e.g. 
kidney) specific model that would further elucidate how renal oxidative stress 
affects blood pressure regulation. Broadening the research scope by the generation 
of various types of transgenic lines, would provide further evidence of the role 
oxidative stress plays in the development of hypertension and cardiovascular 
disease.  
The kidney is highly vulnerable to the damage caused by ROS, and as such it is of 
interest to researchers due to the role it plays in blood pressure regulation (335). In 
this study, we have shown that in addition to the beneficial reduction of blood 
pressure, increased renal Gstm1 expression during early stages of development also 
plays an important role in the reduction of oxidative stress and retention of optimal 
renal function throughout the life of the animal. Specifically, Gstm1 transgenic rats 
show reduced renal pathology as indicated by the absence of renal vessel 
hyperplasia and reduced proteinuria when compared to the SHRSP. Furthermore, we 
have seen a reduction of renal oxidative stress in the transgenic lines. In certain 
pathological conditions, the increased generation of oxidative stress and/or the 
decrease in the antioxidant system leads to tissue damage (335). Moreover, lipid 
peroxidation is one of the many mechanisms in the oxidative stress pathway that 
can cause tissue damage, including within the kidney (335). These processes have 
been implicated in the pathogenesis of several systemic diseases such as 
hypertension, diabetes mellitus and hypercholesterolemia. In line with these 
previous findings, our study of the Gstm1 transgenic rat has shown a significantly 
reduced renal lipid peroxidation and reduced blood pressure. Thus providing 
evidence that increasing Gstm1 expression in SHRSP rats plays a role in the 
prevention of hypertension and renal pathology.         
In terms of translation of our Gstm1 findings in the rat, we were fortunate to gain 
access to the Silesian Renal Tissue bank, which has more than quadrupled in size 
since previously studied by Delles et al. (2008), which allowed for a more 
comprehensive investigation of human kidney samples from normotensive and 
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hypertensive subjects (8). Detailed syntenic analysis has shown that both GSTM5 
and GSTM2 are functionally and genetically related to rat Gstm1 and therefore 
worthy of further investigation. We found a borderline significant (p=0.054) 
association between the rs11802 SNP genotype and GSTM5 expression and 
significantly increased GSTM2 expression in hypertensive patients when compared to 
normotensive patients. Although the importance of GSTMs in human hypertension is 
still speculative, our results do indicate a potential link which requires further 
investigation.   
While time and budget limitations in the present study prevented a more in-depth 
investigation of protein expression within the Silesian Renal tissue bank, our group 
as part of the Glasgow Biobank, has started collecting kidney biopsy tissue from 
normotensive and hypertensive subjects in Glasgow. These renal tissue samples are 
taken from the healthy pole of kidneys removed during nephrectomy due to non-
metastatic renal tumor. The collection of these human samples would allow us to 
assess GSTM protein levels in the kidney along with analysis of renal oxidative stress 
levels in order to investigate the correlation between oxidative stress, kidney 
pathology and GSTM genotypes. It is anticipated that these studies will provide a 
better understanding of the role that the GSTM gene family plays in the defence 
against oxidative stress in the kidneys.  
Numerous studies have shown that antioxidant and reactive oxygen species 
scavengers are effective in animal models for protecting against cardiovascular 
disease but it has been difficult to translate these findings to humans (335;336). 
Chronic treatment of individuals at a high risk for cardiovascular disease with 
varying doses of antioxidants such as vitamin C, E and β-carotene either alone or in 
combination have failed to reduce blood pressure, improve cardiovascular risk or 
reduce mortality rates(337;337-339). One example of this was shown in a study by 
Shao et al. where dietary supplementation of nitrate, in amounts resembling a rich 
intake of vegetables in humans, prevented the development of hypertension in 
young SHR rats (340). However, it is known that prolonged exposure to organic 
nitrates induces tolerance and endothelial dysfunction in patients with 
cardiovascular disease (341). It is suggested that these difficulties in translation 
could be due to a multiplicity of reasons, such as short duration of animal studies 
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(compared to a lifetime of exposure to risk factors in humans), therapeutic dose 
differences between animals and humans, and different pathophysiologic processes 
between animals and humans (335). Other reasons for antioxidant therapy failure in 
humans include cellular compartmentalization of antioxidants, such that potential 
therapeutics, do not reach appropriate targets (e.g. mitochondria). In addition, 
recruited patients may have advanced cardiovascular disease which is not amenable 
to intervention (342). Therefore, despite studies showing that patients with 
hypertension and oxidative damaged have an excess of ROS biomarkers, indicating 
the importance of oxidative stress molecular mechanisms and cardiovascular disease 
(336), large scale antioxidant trials have had limited success. It is possible that a 
stratified medicine approach, whereby the individual genetic basis of disease is 
taken into consideration in order to deliver personalized therapy (343), may be a 
more appropriate strategy for combating disease resulting from oxidative stress 
injury. The use of resources such as Generation Scotland (344), which is an ethically 
sound family- and population based biobank set up to identify the genetic basis of 
common complex diseases, could prove to be extremely useful in the investigation 
of novel prevention or therapeutic strategies, including stratified medicine 
approaches. Generation Scotland provides a unique opportunity to carry out health 
research with a highly stratified patient population could significantly improve 
therapeutic effectiveness or allow preventative measures before the full onset of 
oxidative stress injury and disease. Importantly these studies will improve our 
understanding of how sources of ROS and NOS are regulated, how they specifically 
interact with their targets, and how they modulate cardiovascular pathophysiology. 
 
Finally, in order to more fully understand the molecular mechanisms and pathways 
underlying altered Gstm1 activity and oxidative stress within the SHRSP, renal 
tubular epithelial cells derived from transgenic and parental rat strains could be 
investigated. Assessment of Gstm1 catalytic activity could be carried out by using 
total GST activity assays and the proposed GSTM1-specific substrate 1,2-dichloro-4-
nitrobenzene (DCNB) (345). This could be further investigated by analysis of the 
changes in renal cell oxidative stress levels and various intracellular interactions 
(such as cell proliferation and migration) as shown in Yang et al. (303). It would also 
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be interesting to investigate the effects of increased or decreased Gstm1 expression 
in SHRSP and WKY specific vascular smooth muscle cells and the subsequent effects 
on oxidative stress levels within these cells in order to better understand the role of 
Gstm1 on the vasculature.  
In summary, multiple in vivo, ex vivo and molecular techniques have been applied 
in the characterisation of the Gstm1 transgenic SHRSP rat. This model demonstrates 
significantly reduced blood pressure, reduced oxidative stress and improved levels 
of renal Gstm1 expression. This data supports the hypothesis that reduced renal 
Gstm1 plays a causative role in the development of hypertension in the SHRSP rat. 
Furthermore, because of these novel findings, we can apply this knowledge of the 
oxidative stress pathway, specifically the GSTs, to a better understanding of the 
cardiovascular system.  
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Appendices 
Microsatellite Markers 
D2Rat18  
D2Wox13  
D2Wox5  
D2Mit3  
D2Rat14  
D2Wox3  
D2Mit5  
D2Mit6  
D2Rat167  
D2Wox15  
D2Rat28  
D2Mit18  
D2Wox9  
D2Wox19  
D2Mit21  
D2Mit14  
D2Rat49  
D2Arb18  
D2Mgh12  
D2Rat58 
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Transgene Sequence 
>pEF1/Myc-His A 
AATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTT
AGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCGACG
GATCGGGAGATCTCCCGATCCCCTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATA
GTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAAT
TTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCG
TTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGGCT
TTTGCAAAAAGCTTTGCAAAGATGGATAAAGTTTTAAACAGAGAGGAATCTTTGCAGCTAATG
GACCTTCTAGGTCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCAC
ATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAG
GTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGC
CAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCC
TTGCGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGT
TGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGT
TGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCT
CGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTT
CTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGC
CGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGC
GCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCT
CGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTG
AGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTC
GGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGC
TTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTG
GAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTG
GGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTT
TGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATT
TCAGGTGTCGTGAGGAATTAGCTTGGTACTAATACGACTCACTATAGGGAGACCCAAGCTGGC
TAGGTAAGCTTGGTACCGTTTAAACTCGAGGTCGACGGTATCGATAAGCTTCAAATTGAGAAG
ACCACAGCGCCAGAACCATGCCTATGATACTGGGATACTGGAACGTCCGCGGGCTGACACACC
CGATCCGCCTGCTCCTGGAATACACAGACTCAAGCTATGAGGAGAAGAGATACGCCATGGGCG
ACGCTCCCGACTATGACAGAAGCCAGTGGCTGAATGAGAAGTTCAAACTGGGCCTGGACTTCC
CCAATCTGCCCTACTTAATTGATGGATCGCGCAAGATTACCCAGAGCAATGCCATAATGCGCT
ACCTTGCCCGCAAGCACCACCTGTGTGGAGAGACAGAGGAGGAGCGGATTCGTGCAGACATTG
TGGAGAACCAGGTCATGGACAACCGCATGCAGCTCATCATGCTTTGTTACAACCCCGACTTTG
AGAAGCAGAAGCCAGAGTTCTTGAAGACCATCCCTGAGAAGATGAAGCTCTACTCTGAGTTCC
TGGGCAAGCGACCATGGTTTGCAGGGGACAAGGTCACCTATGTGGATTTCCTTGCTTATGACA
TTCTTGACCAGTACCACATTTTTGAGCCCAAGTGCCTGGACGCCTTCCCAAACCTGAAGGACT
TCCTGGCCCGCTTCGAGGGCCTGAAGAAGATCTCTGCCTACATGAAGAGCAGCCACTACCTCT
CAACACCTATATTTTCGAAGTTGGCCCAATGGAGTAACAAGTAGGCCCTTGCTACACTGGCAC
TCACAGGGAGGACCTATCCACATTGGATCCTGCAGGTCTAGAGGGCCCTTCGAACAAAAACTC
ATCTCAGAAGAGGATCTGAATATGCATACCGGTCATCATCACCATCACCATTGAGTTTAAACC
CGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTG
CCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCA
TCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGG
GAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCG
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GAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAAGCGCG
GCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCT
TTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGG
GGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAG
GGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAG
TCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTC
TATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATT
TAACAAAAATTTAACGCGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCC
CAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTG
GAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAA
CCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTC
CGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGC
TATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGAG
CTTGTATATCCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAAC
AAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGG
CACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGG
TTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGC
TATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGG
GAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTC
CTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTA
CCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCG
GTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCG
CCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCT
TGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTG
TGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCG
AATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCT
TCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGCGAAATGACCGACCAA
GCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGC
TTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAG
TTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATC
ACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATC
AATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCA
TAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGC
ATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCA
CTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCG
GGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCG
GTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAA
TCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTT
GCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCA
GAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGT
GCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAG
CGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAA
GCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCG
TCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGAT
TAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTA
CACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGT
TGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCA
GCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGA
CGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTT
CACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAAC
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TTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCG
TTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATC
TGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAAT
AAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCA
GTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGT
TGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTC
CGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTC
CTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGC
AGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTA
CTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAAT
ACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTC
GGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGC
ACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAG
GCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCT
TTTTC 
 
GREEN = EF1 promoter 
UNDERLINED = polyA HisA 
YELLOW = polyA Myc-His 
BOLD ITALIC = pvuII site 
BOLD = Start of f1 Ori 
GREY = Sequence quoted in Goodwin EC, Rottman FM. The 3'-flanking 
sequence of the bovine growth hormone gene contains novel elements required for 
efficient and accurate polyadenylation. J Biol Chem. 1992 Aug 15;267(23):16330-4. 
PMID: 1644817 
 
BGH RVS PRIMER: TAGAAGGCACAGTCGAGG 
Binding sequence: CCTCGACTGTGCCTTCTA 
 
T7 Primer: TAATACGACTCACTATAGGG 
 
AatII: GACGTC - One Cut Site: 6872bp 
PvuII: CAGCTG – 3 sites. Fragments: 1096bp;1071bp;4705bp 
 
AatII/PvuII fragment: 2725bp 
 
Cut with PvuII 1st, extract 4705bp fragment. Cut with AatII, 
extract 2725bp fragment (leaving 1980bp fragment). 
 
KpnI: GGTAC/C 
Xho1: T/CTAGA 
 
SLUDGE = GSTM1+GSTM4a primers 
 
BOLD UNDERLINED = MCS of pAD5 K-NpA 
 
UNDERLINED = 5’ and 3’ UTR (NB – not entire UTR sequences, only 
those bound by GSTM1 and GSTM4 primers. 
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RED = SNPs found between SP and WKY sequences 
 
BLUE = Confirmed BGH polyA reference sequence from Invitrogen  
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